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Using “Omics” to Discover Predictive Biomarkers in Women at High Risk of 
Spontaneous Preterm Birth 
Angharad Care 
 
Spontaneous preterm birth (sPTB) is a complex pregnancy syndrome that remains 
poorly understood and is associated with significant perinatal morbidity and 
mortality worldwide. Current research suggests that there are multiple disordered 
physiological processes that trigger a final common pathway of early labour, rather 
than a single specific cause. It is this heterogeneity that has hindered the discovery of 
a single predictive biomarker and existing screening methods for sPTB prediction are 
insufficient to detect all women at risk. Consequently, our inability to identify 
women at risk inhibits efforts of prevention, which cannot be achieved without better 
understanding of causation or a more robust way of accurately discriminating those 
at high risk. 
 
The development in “omics” technology has led to exciting breakthroughs in other 
areas of medicine and offers new avenues of investigation for sPTB prediction. The 
primary aim of the thesis was to establish a way of combining different types of 
‘omics’ analysis from the same individual in a pilot study to identify candidate 
biomarker predictors or pathways.  
 
Three different “omic” methodologies; genomics, transcriptomics and metabolomics, 
were used to analyse blood taken from asymptomatic women high-risk for sPTB at 
16 and 20 weeks of pregnancy. Lastly, I investigated if there are distinct differences 
in biomarkers between PPROM and sPTB subgroups of spontaneous preterm birth.  
On an individual omics level only transcriptomics showed an association with sPTB. 
Gene set enrichment in this population demonstrates that the selenoamino acid 
pathway differentiates asymptomatic high-risk women. Hierarchical clustering in a 
non-linear distance matrix differentiated all but one of the sPTB and PPROM cases. 
More studies are required to validate the findings from our analysis. 
 
Data from each omics discipline was combined together in a single data matrix and 
machine learning analyses applied. The area under the curve (AUC) of receiver 
operating characteristic (ROC) values for Linear discriminant analysis (0.90), 
Genetic expression programming (0.70), K-Means (1.00), Linear support vector 
machine (0.96), Support vector machine with a Gaussian Kernel (0.96), Probabilistic 
neural network (1.00) and Random Forest (0.96) demonstrate that most machine 
learning methods perform well on our dataset. Sample sizes needed to reach 
excellent (AUC = 0.9) vs. moderate (AUC = 0.7) prediction performance were found 
to be within realistic ranges.  
 
This study provides a conceptual analytical framework for the prediction of sPTB. 
For a larger cohort prediction power is excellent, making individualized preterm 
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1.1 Epidemiology of Preterm Birth 
Definition 
Preterm birth (PTB) is usually defined as delivery at any gestation before 37 
completed weeks of pregnancy (<37+0 weeks, <259 days) (Spong et al. 2013). The 
lower limit of preterm birth and upper limit of late spontaneous miscarriage are 
blurred as the limit of viability varies with differences in healthcare settings. The 
World Health Organisation recommends using 28 weeks completed gestation as a cut 
off for viability, whereas neonates reaching 23 completed weeks have been 
successfully resuscitated in the UK. If the baby is born before compatibility with life, 
spontaneous delivery is termed “miscarriage”. Despite the difference in semantics, 
both late spontaneous miscarriage and early spontaneous birth are considered to 
share the same pathophysiological triggers.  
Incidence 
Worldwide, an estimated 15 million babies are born before 37 completed weeks 
of pregnancy (Howson et al. 2012). Across 184 countries, the rate of PTB ranges 
from 5% to 18% and in nearly all countries reporting reliable data, the rates of 
prematurity are increasing (Blencowe et al. 2013, Chawanpaiboon et al. 2019).  
Being born preterm results in insufficient time in utero for complete organ 
maturation and three quarters of all perinatal mortality and over half of long-term 
morbidity is attributable to PTB (Goldenberg et al. 2008). Many survivors face a 
lifetime of disability, including cognitive impairment, motor disability, poor 
respiratory health, behavioural disturbance and visual and hearing deficiency. The 




Complications of prematurity are the leading cause of death among children 
under five years of age and were responsible for nearly one million deaths 
worldwide in 2013 (Blencowe et al. 2013). The emotional and economic 
implications of PTB remain a burden to healthcare systems and societies. Parents 
of neurologically disabled children report social exclusion from parents with 
normal children, anxiety, relationship breakdown, reduced quality of life and 
ending careers to become carers (McCormick. 1985).  One UK study (Mangham 
et al. 2009) estimated the total cost to the public sector for the care of children 




Figure 1.1 Percentage of infant deaths and number of live births per week of gestation in England 
and Wales. Data from Office of National Statistics. Pregnancy and ethnic factors influencing births 




As neonatal morbidity and mortality are inversely proportional to the gestational 
age of birth, preterm birth is often sub classified into: 
• Late preterm (34+0 to 36+6 weeks) 
• Moderate preterm (32+0 to <34+0 weeks)  
• Very preterm (28+0 to <32+0weeks)  
• Extremely preterm (<28+0 weeks) 
This type of classification groups neonates by gestation specific morbidity and 
mortality risks, helping us to discuss prognosis in general terms.  However, a 
classification based on gestation tells us little about the phenotype or cause of these 
births. Preterm birth is the only pathology defined by a specific time point rather than 
a common collection of signs and symptoms.  There are multiple causes and 
pathologies under this umbrella term, therefore preterm birth can also be classified 
based on phenotype:  
1. Medically indicated or “iatrogenic” preterm birth (30%)  
2. Spontaneous preterm labour with intact membranes (sPTL-IM) (45%) 
3. Premature prelabour rupture of the membranes (PPROM) (25%)  
followed by either i) medically indicated delivery or ii) spontaneous labour  
Medically indicated, iatrogenic or elective preterm births aim to prevent 
severe maternal or fetal morbidity and mortality from conditions such as pre-
eclampsia, intrauterine growth restriction, fetal distress, placental abruption or 
maternal medical disease. The remaining 70% are due to a spontaneous onset of 
labour with regular uterine contractions and progressive dilatation of the cervix or 
secondary to spontaneous rupture of the membranes that is not immediately followed 
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by regular uterine contractions and labour (Goldenberg et al. 2008). Pregnancies 
affected by PPROM frequently labour spontaneously, but it is difficult to predict at 
what gestation in the future labour will occur; from hours to months later. If there are 
concerns regarding infection or fetal wellbeing, labour may be induced before it can 
begin spontaneously. In studies of preventative treatment sPTL-IM and PPROM 
have frequently been lumped together as “spontaneous preterm birth”. Spontaneous 
PTB (sPTB) is currently viewed as a “syndrome” rather than a disease entity 
encompassing multiple disease mechanisms into a final common pathway of delivery 
(Villar et al. 2012). 
Clinically, PPROM is generally defined as the onset of amniotic fluid (AF) 
leakage from the vagina prior to the onset of labour at less than 37 weeks of 
gestation. However, there is no universally accepted classification of PPROM for use 
in the research studies. Difficulty arises trying to ascertain a timepoint at which 
labour commences that is measurable and objective, particularly as women can 
report irregular symptoms of labour prior to membrane rupture. Therefore, a 
challenge arises in appropriately classifying women with PPROM from those 
classified as spontaneous preterm labour (sPTL). Delivery of the baby is an objective 
event and better recorded than the onset of labour. Some studies assign an arbitrary 
time from rupture of membranes to birth beyond which a spontaneous preterm birth 
would be classified as PPROM and not sPTL-IM. Definitions from several published 
studies of PPROM are shown in Table 1.1. There is a range of inclusion criteria and 
time specifications depending on what is being studied. Only one study listed here 
(Hadley et al. 2017) has included criteria for indicated or sPTB classification. 
Additionally, the diagnosis of ruptured membranes can in itself be challenging for 
clinicians. Additional bedside testing for the presence of AF in the posterior fornix of 
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the vagina can assist in making the diagnosis if the clinical history is unclear, but like 
all clinical tests can be subject to false positives and negatives. 
Table 1.1 Inclusion criteria for PPROM cases in research studies published in 2017/8 
  














Sak et al.  2017 ✓  ✓  NS NS  
Zhang et al  2017 NS NS NS NS  
Sung et al 2017 ✓  ✓  48 
hours 
NS  
Dundar et al 2017 ✓  ✓  NS NS  
Vanderbroucke 
et al 
2017 ✓  ✓  NS 72 hours  
Hadley et al 2017 ✓  ✓  NS >2 hours Did not meet 
criteria for 
indicated PTB 
or PTL (6 
contractions an 
hour or equal 
to 4cm dilated) 
Toprak et al 2017 ✓  ✓  NS NS  
Musilova et al 2017 ✓  ✓  NS NS  





Shree et al 2017 NS NS NS >12 hours  
Hromadnikova 
et al 
2017 ✓  ✓  2 hours NS  
Radochova et 
al 
2017 ✓  ✓  NS NS  
Patel et al 2017 ✓  ✓  NS NS  
Pharande et al 2017 NS NS NS >24 hours Clinical 
diagnosis 






Risk Factors  
The triggers of spontaneous labour, both at term and preterm, are still poorly 
understood – and a precise mechanism is not established in most cases. Therefore, 
factors associated with preterm birth have been sought to try and identify the most at-
risk populations. Women with a previous preterm birth have a recurrence risk of 15% 
to 50% depending on the number, gestational age and characteristics of previous 
deliveries (Goldenberg et al. 2008). The risk of a recurrent preterm birth is inversely 
related to the gestational age at the first delivery (Kazamier et al. 2014). Most risk 
factors cannot be altered between pregnancies such as genetic influences or uterine 
abnormalities. Even modifiable risk factors such as social status and body mass index 
(BMI) are difficult to change. Identifying at-risk women for spontaneous preterm 
birth in their first pregnancy is particularly challenging. Table 1.2 lists some of the 




Table 1.2 Risk factors for spontaneous preterm birth 
Risk Factors for Spontaneous Preterm Birth 
Medical/Obstetric 
History 
Previous Preterm Birth 
 Anatomical abnormalities of the uterus 
 Conceiving through In Vitro Fertilisation (IVF) 
 Thrombophilia 
Chronic medical conditions such as diabetes and high blood pressure 
 Excisional cervical surgery (e.g. knife cone biopsy, 
LLETZ) 
Other cervical damage – in previous delivery, recurrent second trimester surgical 
terminations 
 Family history of spontaneous PTB (maternal side only) 
  
Maternal Extremely Low (<19) Body Mass Index (BMI) 
 Short Inter Pregnancy Interval (<6 months) 
 Higher social deprivation 
 Smoking 
 Increasing age 
 Domestic Violence 
  
Fetal Congenital Abnormality 
 Chromosomal Abnormality 
  
Current Pregnancy  Short cervical length for gestational age 
 Positive fetal fibronectin between 22 and 34 weeks 
 Certain congenital abnormalities of the fetus 
 Vaginal bleeding in pregnancy 
Infections – urinary tract, sexually transmitted, bacterial vaginosis, periodontal 
disease 
Overdistension of the uterus – multiple pregnancy, polyhydramnios, macrosomia 
 Recurrent Antepartum haemorrhage 
 Pre-eclampsia, uteroplacental insufficiency 
 
 
Neonatal Outcomes following Preterm Birth 
Two UK cohort studies comparing outcomes of babies born between 22 and 
26 weeks in 1995 and 2006 show survival rates of extremely premature infants have 
been improving (40% to 53%) (Costeloe et al. 2012). Overall, more babies are now  
being admitted for care at earlier gestations, although healthy survivor numbers are 
increasing so are the total number of neonates with moderate or severe disability. 
The Epicure 2 study showed that in infants born before 26 weeks in 2006 
approximately 44% will survive to three years of age and of those 15% will have a 
severe disability. Neonatal clinical networks have now increased centralisation of 
care for babies born less than 26 weeks as survival is greatest in hospitals that can 
provide neonatal intensive care (Level 1 service) (Marlow et al. 2014). 
Short Term Morbidity 
Cells in the lung alveoli (Type 2 pneumocytes) begin to produce surfactant 
from 30 weeks of gestational age decreasing the surface tension within the alveoli. 
Babies born below this gestation are at highest risk of respiratory distress syndrome 
(RDS). Although rates of RDS have decreased over the last few decades due to the 
use of antenatal corticosteroids, increased use of surfactant and improvements in 
lung ventilation, some preterm neonates treated with oxygen and positive-pressure 
ventilation will ultimately develop bronchopulmonary dysplasia (BPD), a chronic 
lung injury.  
Preterm neonates are particularly susceptible to intraventricular haemorrhage 
(IVH) due to the high levels of vascularisation that is occurring during brain 
development before 34 weeks. Severe haemorrhage predisposes the child to 
impairment of cognitive, motor and visual functions. Periventricular leukomalacia 
(PVL) is a white matter brain injury that has long term sequelae including cerebral 
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palsy and a low IQ (Back et al. 2007). Even in the late preterm birth group between 
32-36 weeks there are increased levels of autism, attention deficit hyperactivity 
disorder (ADHD) and school difficulties when compared with children born at term 
(Guy et al. 2015). 
The pathogenesis leading to necrotising enterocolitis (NEC) remains 
unknown. It is a gastrointestinal disorder leading to ischemic injury and abnormal 
bacterial colonisation. In preterm infants NEC usually presents after the 
commencement of feeds and may appear after two to three weeks of life once 
preterm babies have survived the early neonatal period. The mortality for NEC can 
be as high as 50% and operative intervention is necessary in almost 20% to 40% of 
cases (Yee et al. 2015). 
Long Term Morbidity 
Studies examining long term outcomes for preterm babies show the same inverse 
relationship with gestational age for both morbidity and mortality. In the UK, 39% of 
deaths under the age of five years are directly caused by prematurity (WHO. 2015). 
A risk of ill health during childhood exponentially increases for very preterm and 
moderately pre-term (32 to 36 weeks) neonates when compared to term counterparts 
(Boyle et al. 2012). Long term adverse outcomes include delayed behavioural 
development at six years of age, decreased lung function at eight to nine years of age, 
increased hospitalisation, lower exercise capacity into early adulthood and increased 
risk of poor metabolic and cardiovascular health (Bartha et al. 2012, Lapillonne et al. 




1.2 Causes of Spontaneous Preterm Labour 
 
The mechanisms that lead to human term labour, let alone preterm parturition are 
not yet fully understood. It is, therefore, unsurprising that effective strategies to 
prevent preterm birth remain inadequate on an individual level. Better identification 
of the cause may help focus use of the correct preventative interventions or lead to 
development of more effective treatments. Various pathological processes linked to 
preterm birth include inflammation triggered by infection, pathological uterine 
distension (multifetal pregnancy, polyhydramnios, uterine anomalies), cervical 
insufficiency and fetal and maternal stress.  
Inflammation and Infection 
The role of inflammation and infection in preterm birth has been recognised 
for many decades. Infection is frequently associated with preterm labour (PTL) in 
both humans and animal models. In pregnant mammals, systemic administration of a 
microbial load can induce PTL (McDuffie et al. 1992). In humans, 25%- 40% of 
sPTB have evidence of intrauterine infection, particularly in PPROM (Agarwal and 
Hirsch. 2012). However, in these cases it can be difficult to elucidate if intrauterine 
infection preceded ruptured membranes or occurred following the loss of the 
protective membrane barrier. Ascending infection from the genital tract causing 
inflammation of the lower uterine segment and triggering cervical shortening and 
labour has been proposed as one mechanism of PTL.  
The AF cavity is a sterile environment, therefore positive cultures of AF are 
considered pathological. The reported rates of positive culture of AF detected in 
women presenting in PTL with intact membranes is 13%, this is higher than rates of 
non-labouring preterm patients and term labourers (Goncalves et al. 2002). In women 
with PPROM this rises to 32% and again to 75% by the time these women 
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subsequently labour, demonstrating colonisation of microbes both before and during 
the latent period (Goncalves et al. 2002). A third mechanism of infection unrelated to 
the cervix is haematological spread through the placenta causing microbial invasion 
of the amniotic cavity (MIAC) (Goncalves et al. 2002). This route of infection is 
supported by the fact that extrauterine infection such as asymptomatic bacteriuria and 
pyelonephritis (Wing et al. 2014), periodontal infection (Parthiban and Mahendra. 
2015) and malaria (McDonald et al. 2015) are all associated with an increased risk of 
preterm birth.  
Changes in cervical ripening during labour have been associated with 
increased production of inflammatory cytokines such as interleukins-1, -6, -8, tumour 
necrosis factor (TNF) and prostaglandins (Chandiramani et al. 2012, MacIntyre et al. 
2012).  Influx of inflammatory cells into the cervix release matrix metalloproteins 
contributing to collagen breakdown and ultimately a softening or ripening of the 
cervix.  
Uterine Stretch  
Overdistension over the uterus as a PTB risk has been exemplified clinically 
by the decrease in the mean age of spontaneous delivery to 35 weeks in twins and 30 
weeks in quadruplets. Additionally, women diagnosed with polyhydramnios and 
unicornuate uterus are also at increased risk of spontaneous PTB. In vitro, induced 
mechanical stretch of uterine myometrium causes increases in gap junction proteins 
such as CX 26 and CX 43 (Xu et al. 2013), IL-8 and oxytocin receptor (OTR) 
expression leading to MAPK pathway activation (Kim et al. 2015), and upregulating 
COX-2 activity (Sooranna et al. 2004) ultimately terminating with local 
prostaglandin release causing increased contractility of the uterine muscle. 
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Additionally, stretch also upregulates calcium signalling in the myometrium leading 
to muscle contraction (Li et al. 2009). 
Maternal / Fetal Stress   
Stress can be difficult to quantify and disassociate from other risk factors 
such as smoking, poor nutrition and low socioeconomic status. Stress in the fetus is 
thought to arise secondary to abnormal placentation, may present with growth 
restriction and lead to maturation and activation of the fetal hypothalamic-pituitary-
adrenal (HPA) axis. How the HPA axis is exactly activated is not yet understood, but 
placental corticotrophin-releasing hormone (CRH) is currently thought to play an 
important role (Gravett et al. 2010). Moreover, maternal stress increases biological 
effectors, including cortisol and adrenaline which have been postulated to activate 
placental CRH gene expression (Sandman and Davis. 2012).  CRH is a neuropeptide 
of predominantly hypothalamic origin, it is also expressed in human placenta and 
membranes and released in increasing amounts over the course of pregnancy 
(Gravett et al. 2010). The exponential rise of CRH has been associated with the 
length of gestation (McLean and Smith. 1999). These findings have led some 
researchers to suggest that placental CRH may act as a "placental clock" and regulate 
the length of gestation (McLean and Smith. 1999).  Therefore, one current theory 
behind preterm labour is the premature senescence of the placenta leading to an 
earlier trigger for birth or PPROM. There is some suggestion this may be mediated 
by imbalances in reactive oxygen species (ROS) causing damage mediated by p38 
mitogen activated kinase (p38MAPK) pathways (Polettini et al. 2015). 
Cervical Function  
Gradual softening and effacement of the cervix occur in the weeks before 
labour. Cervical ripening involves a breakdown of collagen, changes in proteoglycan 
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concentration and increase in water content that occur in response to increased local 
prostaglandin release or partial antagonism to progesterone receptors (i.e. action of 
mifepristone) (Bennett. 2007). 
The role of the cervix in maintaining pregnancy remains undefined and is 
probably multifactorial, with two key roles i) prevention of ascending infection and 
ii) physical support to keep the pregnancy in utero.  
Maintenance of a healthy mucus plug and adequate length to the cervix may 
act to prevent ascending infection that triggers production of local inflammatory 
cytokines and prostaglandin release. 
The quality of strength of the cervix to support the pregnancy in situ against 
gravitational pressure is required to prevent premature cervical dilatation. 
Recognised cervical weakness also called ‘cervical insufficiency’, causes women to 
suffer recurrent mid trimester loss usually with a history of painless dilatation of the 
cervix. Funnelling is a feature associated with cervical weakness and can be seen on 
transvaginal ultrasound (TVUSS) as the membranes prolapsing through the 
endocervical canal of the cervix. Women who have excisional cervical surgery for 
cervical intraepithelial neoplasia (CIN) or cervical cancer also have an increased risk 
of spontaneous PTB. This contributes to the argument for the function of the cervix 
being related to its length. In the treatment of CIN the proportions of the 
volume/length excised at large loop excision vary substantially, and the latter has 
been shown to correlate with the pregnancy duration (Kyrgiou et al. 2015).   
Vaginal Microbiome  
Micro-organisms, particularly pathogenic microbes have long been 
hypothesised to play a role in the onset of early labour. The recent advances of 
sequencing approaches have allowed for broad unbiased surveys of bacterial 
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communities and the discoveries of new bacterial species and different taxa. In a 
seminal paper by Ravel et al. (2011) a study of women of reproductive age showed 
that individuals could be categorised by the dominant species of lactobacillus within 
their vaginal microbiome. Lactobacillus species typically dominated more than 90% 
of their entire community and were divided into “community state types” (CST). The 
most common species of lactobacilli were L.crispatus (CST I), L.gasseri (CST II),  
L.iners (CST III) and L.jensenii (CST V) (Ravel J et al. 2011). Some women were 
also found to have microbiomes with low levels of lactobacilli and increased 
diversity of other species such as Atopobium, Gardnerella, Prevotella and 
Megasphera (CST IV – diverse group). 
In pregnancy, the vaginal microbiome is characterised by a stable, low 
richness, low diversity community and is generally dominated by Lactobacillus 
species (Aagaard et al. 2012. McIntyre et al. 2015. Romero et al. 2014). L.species are 
thought to be protective against pathogenic organisms (Reid et al. 2011) and prevent 
inflammatory shifts in the vaginal environment. Preterm birth has been shown to 
correlate with a Lactobacillus-poor, high-diversity vaginal community (DiGiulio et 
al. 2015) with bacterial vaginosis (BV)-taxa such as Gardnerella and Ureaplasma 
implicated as causative agents. Empiric treatment of BV to try and prevent sPTB has 
failed to show benefit across multiple studies and is not currently recommended 
(Brocklehurst et al. 2013). 
As methods to look at individual types of lactobacillus has developed, more 
recently there is evidence to show that vaginal microbiota dominated specifically by 
L.iners are a risk factor for preterm birth (Petricevic et al. 2014, Kindinger et al. 
2017). This has only been consistently demonstrated in Caucasian populations. 
Studies including predominantly African American and Hispanic pregnancy 
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populations could not replicate the same findings, as these populations tend 
towards a normal vaginal microbiome that is lactobacillus-poor and more diverse 
(Fetweiss et al., 2014, Ravel et al., 2011). Stability of a diverse vaginal microbiome is 
associated with term delivery whilst a significant decrease of community richness 
and diversity particularly between the first and second trimesters is associated with 
preterm birth (Stout et al. 2017). When Caucasian and African American 
populations have been compared, very few taxa associated with preterm birth were 
found in both Caucasian and African American populations (Callahan et al. 2017). 
Only the predominance of L.crispatus may be protective and increased proportions 
of Prevotella species may confer risk for sPTB across populations (Callahan et al. 
2017).  
Interestingly, dominance of L.crispatus has also been shown in other studies 
to be protective against sPTB and reduce early onset neonatal sepsis (Verstraelen et 
al. 2009, Brown et al. 2018). Brown et al. (2018) took temporal samples through 
pregnancy of the vaginal microbiome in women experiencing PPROM. Only one-
third of women with PPROM demonstrated a dysbiotic vaginal microbiome 
associated with subsequent chorioamnionitis or funisitis, suggesting two-thirds of 
women with PPROM are likely to have a non-infective cause.  
This is a promising area of research in the understanding of sPTB. However, 
more research needs to be done to understand the differences seen in “normal” 
vaginal microbiome populations in pregnancy before this knowledge can be made 
clinically useful in the prevention of sPTB. Exploration is required of the interplay 
between the vaginal microbiome and genetics to elicit racial population differences 




Genetics is estimated to play a role in up to 40% of PTB (Clausson et al. 2000). 
In singletons, genetic susceptibility to PTB is based on the evidence of familial 
aggregation, identification of disease-susceptibility genes and racial disparity in PTB 
rate that may be related to differences in risk-predisposing allele frequencies. PTB 
rates are higher in sisters of women with a history of PTB compared to their sisters-
in-law (16% vs. 9%). Mothers who were born preterm are more likely to deliver 
preterm by almost 20% (Porter et al. 1997). This suggests that PTB is inherited in a 
matrilineal manner across generations and is unlikely to be affected by patterns of 
PTB in the father’s family (Boyd et al. 2009). Several studies have confirmed a two-
fold increase in risk of sPTB for black American women compared to white 
American women, even after controlling for socio-economic factors associated with 
PTB.  
The most commonly studied pathways for potential candidate genes are those 
involved in infection and inflammation. A recent pathway analysis of published 
studies of different polymorphisms in 274 genes suggested that there may be 
different gene pathways for women presenting with sPTB and PPROM (Capece et al. 
2014). An autoimmune or hormonal regulation axis may exist for sPTB, whilst 
pathways implicated in the etiology of PPROM include hematologic/coagulation 
function disorder, collagen metabolism, matrix degradation and local inflammation 
(Capece et al. 2014). This topic will be discussed in greater depth in the next chapter 




1.3 Prediction of Spontaneous Preterm Birth 
Obstetric History 
There is particular difficulty identifying women at risk of sPTB in their first 
pregnancy. Amongst singletons a history of sPTB remains the most powerful 
predictor, whilst twin pregnancies are at 40% risk of delivering spontaneously before 
37 weeks.  A meta-analysis quantifying the risk of recurrence of sPTB based on 
different subtypes of subsequent pregnancy is summarised in Table 1.3. 
Women with a previous PTB at <37 weeks of gestation are at an increased 
risk for recurrent PTB compared with women who have a previous term birth (OR 
5.43, 95% CI 4.03-7.31). Risk of subsequent PTB is increasing with decreasing 
gestational age in the previous pregnancy (Kazemier et al. 2014). This data is taken 
from 13 relevant studies from 9104 identified publications, including n = 760, 937 
women. 
Table 1.3. Effect of past obstetric history upon absolute risk of PTB. Adapted from Kazemier 
et al. 2014.  
 
Ultrasound Measurement of Cervical Length  
Transvaginal ultrasound (TVUSS) measurements of cervical length (CL) are 
used for prediction of PTB in two broad populations; 1) women with symptoms of 
preterm labour and 2) asymptomatic populations. The asymptomatic populations can 
be further subdivided into high-risk (women with known risk factors for sPTB) and 
First Delivery Second Delivery Absolute Risk of PTL 
Term Singleton Preterm Singleton 4.0% (95% CI 3.9-4.0) 
Term Twin Preterm Singleton 1.3% (95% CI 0.7-2.0) 
Preterm Singleton  Preterm Singleton 20.2% (95% CI 19.9-
20.6) 
Preterm Twin <30 weeks Preterm Singleton 10.0% (95% CI 8.0-12.1) 




low-risk (no risk factors for sPTB). Transvaginal imaging shown in Figure 1.2 is 
more accurate than transabdominal USS measurement, with clearer images of the 
cervix obtained in this view.  
There is an increased likelihood of sPTB as the CL decreases. When using a 
short CL for risk prediction in an asymptomatic cohort, prediction is improved when 
screening a predefined high-risk population. For a 10% false-positive rate, the 
detection rate of spontaneous delivery before 32 weeks was 38% for maternal factors 
(obstetric history, smoking etc.), 55% for CL measurement alone and 69% for 
combined testing (To et al. 2006). A systematic review of TVUSS measurement 
during the second trimester found that, using ROC curves, the test performs best 
when a cut off of ≤20 mm at ≤24 weeks is used and PTB is defined as <35 weeks 
gestation.  
CL can also be plotted on a nomogram of cervical length in pregnancy as 
shown in Figure 1.3 (Salomon et al. 2009). This allows for temporal or serial plotting 
to ensure cervical length centiles are being maintained and there is no acute or rapid 
shortening. However, population centiles should be designed specifically for local 
populations as there is significant variation in the prevalence of women with a short 
cervix when screening low risk cohorts.  
In women who present with threatened preterm labour (PTL) using a CL cut-
off of ≤15 mm appears most accurate in predicting spontaneous delivery within 7 
days with a sensitivity and specificity of 74% (95% CI, 58%–85%) and 89% (95% 







Figure 1.2. Transvaginal Ultrasound Image of Cervical Length measurement. Yellow crosses 
represent callipers placed at the internal and external cervical ostia. The dashed yellow line 
between these points represents the distance measured shown in mm at the bottom right 
of the image. 41 mm is considered to be a ‘long’ cervix and the true cervical measurement 
is likely to be longer as the cervical canal curves below the straight line measurement on 
the image. 
 




Cervico-vaginal biomarkers of preterm birth 
Biological fluids such as amniotic fluid (Menon et al. 2014, Baraldi et al. 
2016), blood (Saade et al. 2016) and saliva (Lachelin et al. 2009) are a rich source of 
biomarkers. Researchers have looked for hundreds of predictive markers, but early 
significant results are not often reproducible in validation studies. Measurement of 
two serum proteins, insulin-like growth factor – binding protein 4 (IBP4) and sex 
hormone binding globulin (SHBG), have shown to have some prediction of preterm 
birth (Saade et al. 2016). A private American company (Sera Prognostics®) currently 
offer measurement by mass spectrometry but this service is not currently used in the 
UK. More success has been obtained with biomarkers in cervico-vaginal fluid, with 
three biomarker bedside tests currently used in clinical practice in the UK for women 
symptomatic of preterm labour. 
Detection of fetal fibronectin (fFN), phosphorylated insulin-like growth 
factor binding protein-1 (IGFBP1) and placental alpha microglobulin 1 (PAMG-1) in 
cervicovaginal fluid are all used as predictive tests of spontaneous PTL (Care et al. 
2018). 
   Lockwood et al. (1991) were the first to report an association between fFN 
and PTB. fFN is a glycoprotein that has been described as a biological “glue” that 
binds chorion with maternal decidua in the extracellular matrix. After complete 
fusion of the chorion and decidua at 20 weeks, fFN levels are low (<50 ng/ml) in 
cervicovaginal secretions and are thought to be released through mechanical or 
inflammatory mediated damage to the membranes before birth (Lockwood et al. 
1991). Lockwood et al. (1991) used an enzyme linked immunosorbent assay 
(ELISA) test against the monoclonal antibody FDC-6 (originally discovered by 
Matsuura H and Hakomori. (1985)) to detect fFN, with increasing concentrations 
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associated with increased likelihood of PTB. Although fFN has been recognized as 
the best predictor for spontaneous PTB <32 weeks, even when compared to a short 
CL (<25 mm) in the asymptomatic population (Goldenberg et al. 1996), it has had 
limited impact as a screening tool. Unlike a short cervix, there are currently no 
preventative treatments tested in clinical trials that have known benefit once a high 
fetal fibronectin is detected. More recent systematic reviews have challenged its use 
in the asymptomatic high risk and low risk population at all. It has been suggested 
that fFN may only be a clinically useful test in symptomatic patients where the 
biggest difference can be seen between pre and posttest probabilities of PTL. 
However, in all clinical settings considered within this review, none resulted in a 
positive summary likelihood ratio (sLR) above 10 and a negative sLR of less 
than 0.1, indicating, at best, a moderate predictive performance regardless of 
reference outcomes considered, clinical conditions, or the type of population tested 
(Faron et al. 2018). 
 In symptomatic populations, the most advantageous feature of qualitative fFN 
is its high negative predictive value (NPV) (0.93, CI 95% 0.92 – 0.95) which helps 
prevent overtreatment with unnecessary antenatal corticosteroids, reduces anxiety 
and returns women to normal care pathways (Melchor et al. 2018). The positive 
predictive value (PPV) is low (19.7%) using a qualitative test (any result above >50 
ng/ml is considered a positive result), this can be increased to 37.0% or 46.2% using 
a quantitative test, and thresholds of 200 ng/ml or 500 ng/ml respectively (Abbott et 
al. 2013). 
 A systematic review demonstrated that the test is most accurate in predicting 
sPTB within 7-10 days among women with threatened PTB before advanced cervical 
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dilatation, with median likelihood ratios of 5.4 (95% CI 4.4-6.7) (De Franco et al. 
2013).  
The ability to predict sPTB using transvaginal USS and fetal fibronectin 
together is improved by concurrent usage (Gomez et al. 2005). In a symptomatic 
population, women with a CL of at least 30 mm or with a CL between 15 and 30 mm 
with a negative fibronectin result are at low risk (<5%) of spontaneous delivery 
within 7 days (Van Baaren et al. 2014).    
IGFBP1 is a 25kDa protein that is secreted by maternal decidual cells as a 
highly phosphorylated isoform, phIGFBP1 (Martina et al. 1997). Similar to FFN, 
detection of phIGFBP1 in the cervicovaginal fluid of the posterior fornix indicates a 
disruption of the choriodecidual interface. The phIGFBP1 test has a comparable 
NPV to the test in predicting spontaneous PTB within 7 days in symptomatic women 
(phIGFBP1 92% vs. fFN 97%) (Ting et al. 2007), and a more recently published 
meta-analysis suggests it is in fact better (NPV phIGFBP1 0.99 vs. fFN  0.93) 
(Melchor et al. 2018). The advantage of this test is that it can be used in women who 
have had recent sexual activity or bleeding, which is a contraindication to fFN use. 
Unfortunately, it has poor performance in the asymptomatic population. 
PAMG-1 is a glycoprotein discovered in 1976 that is produced by the 
decidua. It exists in high concentrations in amniotic fluid, but low concentrations in 
the cervicovaginal discharge (Petrunin et al. 1976). Originally, PAMG-1 was used to 
develop a bedside test for PPROM called Amnisure ROM® test. However, false 
positive findings in women with intact membranes led to the discovery that it also 
had predictive ability for PTL within 7 days. Based on this finding, the PartoSure® 
bedside test was later developed by the same company. Two potential theories have 
been established by Lee et al. (2009) for this additional ability to predict PTL. Firstly 
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imminent onset of PTL may result in the transudation of PAMG-1 through 
chorioamniotic pores in fetal membranes during uterine contractions and/or 
secondly, through the degradation of the extracellular matrix of fetal membranes due 
to the inflammatory process of labour and/or infection allowing PAMG-1 to 
permeate.  
Comparison of these tests has been complicated by changing prevalence of 
PTL between study populations affecting positive and negative predictive values 
despite stable sensitivities and specificities. A direct comparison of PAMG-1 and 
phIGFBP1 independently and in combination with the gold standard cervical length 
measurement in 383 patients across three hospitals demonstrated that PAMG-1 has a 
significantly higher PPV and specificity compared with phIGFBP1 for the prediction 
of sPTB at 7days (P<.01). Both tests had comparable sensitivity and negative 
predictive value (Nikolova et al. 2018).   
Risk Stratification – QUIPP app 
Predictions of imminent PTL in symptomatic and asymptomatic women is reliant 
on picking up end stage physiological processes to allow for appropriate 
management. It does not aid with prevention of preterm birth by identifying an at-
risk population early enough to benefit from preventative treatment strategies. The 
app does not recommend treatment types or thresholds, but alerts users to those most 
at risk. This makes for a difficult screening tool as no treatment is available in the 
identified populations unless a short cervix is identified. 
In view of the multiple pathophysiology of PTB, it is unrealistic to expect a 
single biomarker to be able to predict sPTB in early gestation. The ideal biomarker 
test or predictive model should try to incorporate the fewest numbers of biomarkers 
to be measured, be highly sensitive and specific, exist in a biological fluid that is 
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without risk to obtain, and be detectable early enough in pregnancy to allow for 
preventative measures to be taken.  
Currently the development of the “QUIPP” electronic application that can be 
used on mobile phones gives a risk prediction in either asymptomatic or symptomatic 
populations (Watson et al. 2020, Carter et al. 2020). A screenshot of the application 
is shown in Figure 1.4. This application requires input of obstetric history, current 
gestation, cervical length and fetal fibronectin to give a risk prediction score for PTL 
within 1, 2 and 4weeks and also, risk of delivery before 30, 34 and 37 weeks. This 
app has started to be used in preterm birth prevention clinics in the UK (Care et al. 
2019), but risk thresholds for treatment remain unclear. Unpublished data from the 
Liverpool Harris-Wellbeing Preterm Birth prevention clinic retrospectively applied 
the app data to the cohort of 119 women recruited to a biomarker study. Clinicians 
were blinded at the time of taking fetal fibronectin. Using a treatment threshold of a 
QUIPP risk of PTB < 34 weeks >10% (referred to as “QUIPP positive”) would more 
than double treatment rates from 20% (24/119 treated CL alone) to 42% (51/119 
women treated) and 43 of 51 QUIPP positive women were still pregnant at 34 weeks 
(false positive rate) (Goodfellow et al. 2019). Fifteen of the 119 women (13%) had 
PPROM or sPTB <34 weeks with 8/15 women (53%) identified using the QUiPP 
app. This 10% treatment threshold gave a positive likelihood ratio (LR) of 1.3 (95% 
CI 0.76-2.18), and negative LR of 0.8 (95% CI 0.45-1.40). Modification of the 
treatment threshold could not improve on this. Existing publication suggests that 
clinicians are comfortable with a risk threshold of 5% (Carter et al. 2020, Carter et al.  
2016), if this was used clinically as a treatment threshold for preterm birth 
preventative therapy then it would result in many more women being treated with an 





The QUiPP algorithm, as a concept, is a positive advance in the field of 
preterm birth prevention. However, in women with a previous preterm birth or 
PPROM the pre-test probability of a recurrent event is often too high to reassure the 
clinician or patient and use of this risk prediction score may result in over treatment 




Figure 1.1 a) Screenshot of QUIPP app which requires data on previous obstetric history, 
cervical length and fFN result b) Screenshot of resulting risk prediction scores. 
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1.4 Prevention of Spontaneous Preterm Birth in Singleton Pregnancies 
Although prediction is key, prevention remains the ultimate goal. Prevention can 
be classified into primary and secondary preventative strategies. The aim of primary 
prevention is to lower the incidence of PTB by improving physical and mental 
wellbeing and avoiding modifiable behavioural factors associated with PTB. For 
example, smoking cessation lowers the risk of sPTB by 16% (OR 84%, 95% CI 
72%-98%) (Vanderhoeven and Tolosa. 2010). 
Secondary preventions are interventions targeted to an at-risk population 
identified from the general population. A recently published Cochrane review 
summarised all evidence for interventions relevant to the prevention of PTB as 
reported in Cochrane systematic reviews (SRs) (Medley et al. 2018b). Four 
systematic reviews reported clear evidence of benefit from: 1) midwife‐led 
continuity models of care versus other models of care for all women; 2) screening for 
lower genital tract infections for pregnant women less than 37 weeks' gestation and 
without signs of labour, bleeding or infection; and 3) zinc supplementation for all 
pregnant women without systemic illness. The fourth showed that cervical cerclage 
showed clear benefit for women with singleton pregnancy and high risk of PTB only. 
At present there are only effective preventative treatments for women 
identified with a short cervix. As a result, screening clinics have been set up across 
the UK to perform transvaginal USS women at high risk of preterm labour (Sharp & 
Alfirevic. 2014, Care et al. 2018, NHS England 2019).   
Omega 3  
A recent Cochrane review showed omega 3 supplementation to be associated 
with a reduction in PTB <37 weeks (13.4% versus 11.9%; risk ratio (RR) 0.89, 95% 
CI 0.81 to 0.97; 26 RCTs, 10,304 participants; high‐quality evidence) and early 
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preterm birth <34 weeks (4.6% versus 2.7%; RR 0.58, 95% CI 0.44 to 0.77; 9 RCTs, 
5204 participants; high‐quality evidence). This evidence was consistent across 
participants with a range of baseline risks for preterm birth (Middleton et al. 2018). 
However, it probably increases the risk of post term pregnancies.  Prolonged 
gestation > 42 weeks was increased from 1.6% to 2.6% in women who received 
omega-3 long chain polyunsaturated fatty acids (LCPUFA) compared with no 
omega-3 (RR 1.61 95% CI 1.11 to 2.33; 5141 participants; 6 RCTs; moderate-quality 
evidence).  
Although the exact mechanism by which omega-3 reduces sPTB is not 
exactly certain, it is known to have anti-inflammatory properties. Regulatory 
signalling by omega-3 polyunsaturated fatty acids (n-3 PUFAs) has been reported 
via, among others, the selective FFAR4/GPR120 (free fatty acid receptor 4) protein 
leading to reduced activity of the NFKB (nuclear factor kappa B) complex and the 
inflammasome (Oh et al. 2010, Liu et al. 2014). It may therefore play a role in 
increasing the threshold to transition into the inflammatory labouring state.   
It remains unclear whether omega supplements to the general obstetric 
population may reduce sPTB rates without increasing the complications of post term 
pregnancies, particularly increased risk of stillbirth. 
 
Antibiotics 
Although the role of inflammation in sPTB pathophysiology is well 
documented, and antibiotics are recommended in some PTB guidelines (Medley et 
al. 2018a), there is no evidence to show that the use of antibiotics in the management 
of patients in threatened preterm labour reduces the incidence of preterm birth. The 
ORACLE II trial randomised women (n = 6295) in PTL with intact membranes to 
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one of three antibiotic groups or a placebo group taken four times a day. Although 
the antibiotics were associated with a lower risk of maternal infection, none of the 
regimes associated with a lower risk of sPTB (Kenyon et al. 2001). These findings 
were also echoed in a meta-analysis of fourteen trials (n = 7837 women) although 
predominantly consisting of ORACLE II data (Flenady et al. 2013).  
 The Cochrane systematic review of systematic reviews to highlight areas for 
further investigation and development found no effect for antibiotic prophylaxis in 
the second and third trimester (Medley et al. 2018b). However, antibiotics for women 
with asymptomatic bacteriuria shows a possible benefit in reduction of preterm birth 
(Medley et al. 2018b).   
Probiotics 
 With interest increasing in the effect of the vaginal microbiome on preterm 
labour physiology, probiotics are a topic of discussion for preterm birth preventions. 
Unfortunately, at present there is insufficient data to recommend probiotics due to 
small trial numbers (Othman et al. 2007). A Cochrane systematic review evaluated 
only three trials, and the effect of probiotics on vaginal infection was assessed in 
only two trials with 88 women. Although there was an 81% reduction in the risk of 
genital infection with the use of probiotics (RR 0.19; 95% CI 0.08 to 0.48), effects on 
preterm birth could not be supported as confidence intervals were very wide and 
included no effect. Effect on PTB <37 weeks (one trial; 238 women) had a relative 
risk of 3.95 (95% CI 0.36 to 42.91) (Othman et al. 2007). 
 With the advancement in the assessment of the vaginal microbiome, targeted 
probiotics for high risk women or women with dysbiotic vaginal microbiomes may 




Prevention Therapies for Women with Short Cervix and/or History of sPTB 
 In singleton pregnancies, if asymptomatic women are identified to have a 
short cervix preventative therapy can be offered to reduce risk of sPTB. Vaginal 
progesterone (Fonseca et al. 2007, Hassan et al. 2011, Dodd et al. 2013) and, to a 
lesser extent, Arabin pessary (Goya et al. 2012) have demonstrated a reduction in 
risk of sPTB risk in an unselected obstetric population with a short cervix (<25 mm). 
However, doubts about the feasibility of adequate quality control have prevented 
universal screening programmes being introduced for an obstetric population. 
In women with a previous sPTB and a short cervix (<25 mm before 24 
weeks) a meta-analysis of five trials of cervical cerclage (n=504) has shown a 
reduction in risk of sPTB risk <37 weeks by 36% (Berghella et al. 2011) but no trial 
has shown benefit in an unselected population with short cervix (Rust et al., 2000. To 
et al. 2004). There is also supportive data for vaginal progesterone in this same 
population (Romero et al. 2018). A meta-analysis of five trials showed a risk 
reduction of PTB ≤ 34 weeks of gestation or fetal death compared to placebo 
(18.1% vs 27.5%; RR, 0.66 (95% CI, 0.52–0.83); P = 0.0005; five studies; 974 
women) (Romero et al., 2018) and based on indirect comparison meta-analysis is 
considered as effective as cerclage. Clinical trials to directly compare available 
treatments in a high-risk population with a short cervix are currently ongoing 
(Hezelgrave et al. 2016, Pacagnella et al. 2019).  
 IM progesterone or 17ɑ hydroxyprogesterone caproate (17-OHP) is a 
synthetic progesterone which has shown reduction of PTB < 35 weeks (RR 66%; 
95% CI 54%-81%) in a trial of 463 women with a history of sPTB. (Meis et al. 2003) 
It is currently given routinely to women with a history of sPTB in the United States.  
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In view of cervical length screening and multiple available treatments for 
high risk populations with a short cervix; PTB prevention clinics have been set up 
throughout the UK. A recent survey of clinics found that a combination of treatments 
are currently being used in practice, but no predictive tests are used to tailor 
treatments individually or decide between treatment combinations (Care et al. 2018). 
 
 
1.5 Rationale for Thesis 
Preterm birth prevention antenatal clinics are the current UK screening model 
which combines predictive factors of previous obstetric history of sPTB and short 
cervix on transvaginal ultrasound (Care et al. 2018). However, the majority of sPTB 
will occur in the low risk population and there is currently no good screening service 
for these women. The introduction of cervical length screening across the whole 
population has been considered, but there are still reservations as to the number of 
women with short cervix that will be detected and ultimately the number of preterm 
births prevented. This has to be weighed up against the cost and feasibility of training 
for ultra-sonographers across the UK. Even in a high-risk population there remains a 
proportion of women who have recurrent sPTB but do not present with a short cervix 
<25 mm prior to 24 weeks. In our study 9% of women with a short cervix between 
20-24 weeks will still deliver before 34 weeks despite screening (Care et al. 2014).  
There is a need for a screening test that is acceptable to the population and 
can be used in both the high and low risk populations. Lack of understanding of the 
natural history of the disease is hindering progress in this field as multiple 
pathophysiological pathways to the same endpoint of preterm labour are in existence. 
Novel high throughout technologies now mean that we are able to obtain huge 
amounts of information from a single woman. Millions of data points about genes, 
transcripts and metabolites can be combined with clinical data to establish activity at 
a cellular level.  
This thesis will address using these novel high throughput techniques in an 
exploratory pilot study to combine multiple layers of omics data from the same 
individual to identify candidate biomarker predictors or pathways. Figure 1.5 details 




1. The primary aim of the thesis was to establish a method of combining three 
‘omics’ analysis used in this pilot study for the prediction of sPTB. This 
study’s results will require replication in a larger validation study as this will 
not be performed as part of this thesis.  
2. To use three different “omic” methodologies; genomics, transcriptomics and 
metabolomics, to analyse blood taken at 16+0 and 20+0 from women at high-
risk of sPTB based on a previous history of sPTB or PPROM between 16+0-
33+6. 
3. Lastly, I aim to establish if there are distinct differences in biomarkers 
between PPROM and sPTB subgroups of spontaneous preterm birth.  
Objectives  
1. To review published studies examining genomic, transcriptomic and 
metabolomics analysis of women with sPTB or PPROM to establish existing 
biomarkers and/or biomarkers requiring validation. 
2. Perform genome wide association study (GWAS) to investigate genetic 
factors that may correlate with spontaneous PTL in women who experience 
multiple spontaneous preterm birth and provide genomic data for combined 
omic analysis. 
3. Perform transcriptomic analysis on extracted RNA to investigate gene 
expression correlating with sPTB or PPROM.   
4. Perform nuclear magnetic resonance (NMR) analysis to establish correlation 
with known metabolites to be used as part of a combined ‘omic’ analysis.  











Chapter 2: Using “Omics” for spontaneous 






Chapter 1 highlights that our ability to predict sPTB is poor and mechanisms 
of this syndrome remain poorly understood. Current screening methods for 
prediction are insufficient to detect all women at risk (Care et al. 2014). Women 
identified as at risk do not always receive a treatment that is effective in preventing 
sPTB. The sequelae of preterm birth can lead to significant mortality and morbidity 
(Costeloe et al. 2012). There is a clear need for improvements in prevention, which 
cannot be achieved without a better understanding of causation or a more robust way 
of accurately discriminating those at high risk.  
One promising area that has revolutionized personalised medicine is the use 
of “omics” in healthcare. At present they have contributed to medical advances on 
individual omic levels, such as exome and genome sequencing have improved 
diagnosis of rare disease (Worthey et al. 2011, Waggoner et al. 2018).  In this chapter 
I will review the literature and various approaches taken related to the use of “omics” 
in the context of sPTB and discuss the progress of combining omics platforms as 
well as the limitations of these methodologies.  
The suffix -omic, derived from the ancient Greek, refers to in-depth 
knowledge.  Currently, we have over 30 such disciplines with the -omics suffix 
(Figure 2.1) (Kumar, D. 2015). Omics aims to characterize and quantify biological 
molecules that combined provide the knowledge of the structure, function, and 
behavioral phenotype of an organism. The topic is too vast to consider all omics 
platforms and therefore my thesis will be focused around the discussion of genomics, 
transcriptomics and metabolomics in the prediction of sPTB; this reflects my study 





































































Genomics is the science of understanding the genomes of any given organism 
or species. The genome refers to the complete genetic code of a unique individual 
and is comprised of two complimentary strands of deoxyribonucleic acid (DNA) 
(Watson and Crick. 1953). The backbone of these strands consist of a phosphate and 
a sugar molecule attached to one of four bases: adenine (A), guanine (G), cytosine 
(C) and thymine (T). Due to the specific chemical structure of each base; A always 
pairs with T and C pairs with G. The length of the human genome is approximately 3 
billion base pairs (Mattick. 2003). This DNA strand is tightly coiled and along its 
length surround proteins called histones which help define its structure and level of 
activity. A single histone cluster surrounded by DNA is called a nucleosome. Several 
nucleosomes together form chromatin and tightly coiled chromatin form larger 
structures called chromosomes. (Annunziato. 2008)  
In humans there are 46 chromosomes arranged into 23 pairs, with one of each 
pair inherited from each parent. Twenty-two pairs are called autosomes with one pair 
called sex chromosomes consisting of the X and Y chromosome which determine 
gender. A female will have two X chromosomes (46, XX) and a male with have an X 
and Y (46, XY).  
Interestingly the average human genome contains around 5-10 million genetic 
variants including 20,000 “coding” variants which are located within transcribed 
genes. A genetic variant refers to an alteration of the most common genetic 
sequences. Clearly not all these variants are clinically significant (Levy et al. 2007). 
Single nucleotide polymorphisms (SNPs) are the most common variation in the 
genome with an estimated 10 million SNPs occurring in the human population 




at a particular location (locus) of the genome. Interestingly humans only differ from 
one another by 0.1% of their genetic make-up (Dolan and Christiaens. 2013) but this 
0.1% may determine a given individual’s disease susceptibility.   
There is a good body of evidence that supports the premise that genetic 
factors residing in the maternal genome contribute up to 40% of the variation in birth 
timing and preterm birth. Evidence supporting this claim comes from 
epidemiological studies, twin studies and segregation analysis of pedigrees (Clausson 
et al. 2000, Kristka et al. 2008, Boyd et al. 2009, Plunkett et al. 2009). See section 
2.1. Here I will explore the different techniques and study designs available to 
analyse the genome and its expression and review recent literature related to sPTB 
prediction in “omic” studies.  
Candidate Gene Studies 
Candidate gene studies have been at the very forefront of genetic association 
studies. They involve the selection of genes that are biologically plausible candidates 
for a condition such as sPTB. Therefore, require some prior knowledge about gene 
function and probable mechanisms of disease. Once genes are identified, assessment 
and selection of polymorphisms occur. The detection of genetic variants is usually 
assessed by selecting single nucleotide polymorphisms (SNPs) within that gene 
(Figure 2.2). The gene variant is then tested for its occurrence in a population with 
the disease or trait of interest (cases) and participants without the condition 
(controls).  If the case and control cohorts are adequate based on a sample size 
calculation it can show statistically different polymorphisms in relevant genes. 
Detection of these associations can then lead to evaluation of the effectiveness in 




A key limitation to these studies is that they are biased to current theories or 
presumed knowledge and cannot identify novel genes. However, these studies are 
relatively quick and cheap to perform and do not require studies of large families 
with a combination of unaffected and affected members.  
 
Figure 2.2 Single Nucleotide Polymorphisms refer to one base pair change and may fall 
within coding regions of the gene (exons; blue SNP), non-coding regions of genes, or the 
intergenic regions (introns; red SNP). (Image from Strauss et al. 2018.) 
 
For sPTB candidate gene studies have shown that some polymorphisms in 
genes coding for components of the innate immune system (Table 2.1) are 
significantly associated with PTB, but most positive results have not been replicated 




Table 2.1. List of genes that have been studied for single nucleotide polymorphisms 
associated with the risk for preterm birth. (Adapted from Sheikh et al. 2016) The genes 
highlighted in bold have been identified in more than one. 




Corticotropin receptor 1 (CRHR1) 
Follicle stimulating hormone 
receptor (FSHR) 
Glucocorticoid receptor (NR3C1) 
Insulin-like growth factor 2 (IGF2) 





Oxytocin receptor (OXTR) 
……………………. 






Prostaglandin E receptor (PTGR3) 
……….. 
Prostaglandin E synthase 2 
(PTGES2) 
Prostaglandin G/H synthase 1 
(PTGS1) 
Prostanoid DP receptor (PTGDR) 
Relaxin 2 gene (RLN2)   
Bream et al. 2013 
Plunkett et al. 2011. Chun et al. 2013 
…….. 
Bream et al. 2013 
Romero et al. 2010a, Romero et al. 
2010b  
Hataaja et al. 2011, Bream et al. 2013 
……… 
Kim et al. 2013 
Kim et al. 2013 
Bream et al. 2013, Kim et al. 2013, 
Kuessel et al. 2013. 
Ehn et al. 2007, Guoyang et al. 2008, 
Manuck et al. 2010, Oliveira et al. 
2011, Bream et al. 2013, Mann et al 
2013.  
Ryckman KK et al. 2010, Jeffcoat 
MK et al. 2014. 
Liu et al. 2012 
Bream et al. 2013 
Grisaru-Granovsky et al. 2010. 






Collagen type I (COL1A2) 
…………………………….. 
………….. ………………………… 
Collagen type IV (COL4A2)              
Collagen type IV (COL4A3)             
Collagen type IV (COL4A4)              
Collagen type IV (COL4A5)                
Collagen type IV (COL4A6)           
Collagen type V (COL5A2) alpha-2             
Intercellular adhesion molecule-1 
(ICAM1)              
Matrix Metalloproteinase 1 (MMP-
1),                                    
Matrix Metalloproteinase 8 (MMP-
8),  
Matrix Metalloproteinase 9 (MMP-
9),  
Matrix Metalloproteinase 10 
(MMP-10), 
Manuck et al. 2011. Romero et al. 
2010. Romero et al. 2012. Ryckmann 
et al. 2010. Myking et al. 2011. 
Romero et al. 2010. Romero et al. 
2012. 
Romero et al. 2010. Romero et al. 
2012. 
Romero et al. 2010. Romero et al. 
2012.  
Romero et al. 2010. Romero et al. 
2012.  
Romero et al. 2010. Romero et al. 
2012.  
Myking et al. 2011. 
Kwon et al. 2009. 
....................................... 
Pereza et al. 2014 
Ryckmann et al. 2010. 




Matrix Metalloproteinase 16 
(MMP-16),  
Tenascin-R (TNR),                                    
TIMP metallopeptidase inhibitor 2 
(TIMP2) 
Romero et al. 2010. Romero et al. 
2012.  
Romero et al. 2010. Romero et al. 
2012.  
Romero et al. 2010. Romero et al. 
2012.  




related genes  
Alpha adducing (ADD1) 
Angiopoietin 1 (ANGPT1)  
Angiotensin converting enzyme .... 
(ACE) 
Angiotensin II receptor type 1 (AT1)  
Angiotensinogen (AGT) 
.......................................................... 
Beta-2 adrenergic receptor 
(ADBR2) 
Complement receptor 1 (CR1) 
Cyclin-dependent kinase 4 inhibitor 
(CDKN2) 
Endothelial nitric oxide synthase 
(NOS3) 
Endothelin 1 (EDN1) 
Factor V (F5) 
Inducible nitric oxide synthases 
(NOS2) 
Kinase insert domain receptor (KDR) 
Peroxisome proliferator- activated 
receptor gamma (PPARG) 
Plasminogen activator inhibitor-1 
(SERPINE) 
Renin (REN) 
Small conductance calcium activated 
potassium channel 3 (KCNN3) 
Thrombomodulin (THBD) 
Vascular endothelial growth factor 
(VEGFA) 
Gibson et al. 2007 
Andraweera et al. 2012 
Valdez-Velazquez et al. 2007, Uma 
et al. 2008. 
Valdez-Velazquez et al. 2007. 
Valdez-Velazquez et al. 2007, 
Gargano et al. 2009 
Gibson et al. 2007, Suh et al. 2013. 
McElroy et al. 2013 
Falah et al. 2013 
 
Gibson et al. 2007. Suh et al. 2013. 
Romero et al. 2010. Romero et al. 
2012.  
Yu et al. 2009. Gargano et al. 2009 
Gibson et al. 2007. Suh et al. 2013. 
Andraweera et al. 2012. 
Meirhaeghe et al. 2007. 
............................. 
Gibson et al. 2007, Chen et al. 2007. 
..............  
Valdez-Velazquez et al. 2007. 
Mann et al. 2013. Bream et al. 2013. 
Day et al. 2011.  
Gibson et al. 2007. Andraweera et al. 
2012. 
Andraweera et al. 2012. 
Metabolism 
related genes 
Apolipoprotein A-I (APOA1) 
Apolipoprotein C (APOC) 
Apolipoprotein E (APOE) 
ATP-binding cassette transporter 
(ABCA1) 
Cholesteryl ester transfer protein 
(CETP) 
Cytochrome P4501A1 (CYP1A1) 
Dehydrocholesterol reductase 
(DHCR24) 
FC alpha receptor (FCɑR) 
Glutathione S-transferase mu 1 
(GSTM1) 
Steffen et al. 2007 
Steffen et al. 2007 
Steffen et al. 2007 
Steffen et al. 2007 
 
Steffen et al. 2007 
Lewinska et al. 2013, 78, 81-85 
Steffen et al. 2007 
Sugita et al. 2012 
Suh et al. 2008, Lee et al. 2010, 






Glutathione S-transferase theta 1 
(GSST1)  
 
Glutathione S-transferase theta 2 
(GSST2)   
Glutathione S-transferase theta 
pseudogene (GSTTP1) 
Hepatic lipase (LIPC) 
Hydroxy methyl glutaryl CoA 
reductase (HMGCR) 
Lipoprotein lipase (LPL) 
Mannose binding lactin (MBL) 
Methionine synthase (MTR) 
Methionine synthase reductase 
(MTRR) 
Methylene tetrahydrofolate reductase 
(MTHFR) 
Methylenetetrahydrofolate 
dehydrogenase 1 (MTHFD1) 
Serine hydroxy methyltransferase 1 
(SHMT1) 
Serum paraoxonase/arylesterase 1 
(PON1) 
Vitamin D receptor (VDR) 
Suh et al. 2008, Tsai et al. 2008, 
Zhang et al. 2008. Luo et al. 2012. 
Zheng et al. 2013 
Zheng et al. 2013 
 
Zheng et al. 2013 
 
Steffen et al. 2007 
Steffen et al. 2007 
 
Falah et al. 2013 
Falah et al. 2013 
Gargano et al. 2009 
Gargano et al. 2009  
Gargano et al. 2009, Engel et al. 
2006.  
 
Christensen et al. 2014.  
 
 
Gargano et al. 2009 
  
Ryckman et al. 2010, Myking et al. 
2011, Harley et al. 2011 





Colony-stimulating factor 2 (CSF2) 
Defensin alpha 5 (DEFA5) 
Fms-like tyrosine kinase 1 (FLT1) 
HLA class II histocompatibility 
antigen, DR alpha chain (HLA-DRA) 
HLA class II histocompatibility 
antigen, DRB1-9 beta chain 
Interferon ɣ (IFN-ɣ) 
Interferon ɣ receptor 2 
Interleukin 1 alpha (IL1α) 
 
Interleukin 1 beta (IL1β)      
                        
Interleukin 1 receptor 2 (IL1R2) 
Interleukin 1 receptor antagonist 
(IL1RN)  
Interleukin 1 receptor-associated 
kinase 1 (IRAK1) 
Interleukin 2 (IL2) 
Interleukin 2 (IL2) Interleukin 2 
receptor beta (IL2Rβ) 
Interleukin 4 (IL4) 
 
Interleukin 6 (IL6)   
Harmon et al. 2013  
Romero et al. 2010. Romero et al. 
2010b.  
Gomez et al. 2010 
Falah et al. 2013 
Falah et al. 2013 
Moura et al. 2009, Devi et al. 2014  
Harmon et al. 2013 
Ryckman et al. 2010. Sata et al. 
2009, Yilmaz et al. 2012. 
Jones et al. 2010, Hollegaard et al. 
2008, Yilmaz et al. 2012, Schmid et 
al. 2012  
 
Ryckman et al. 2010. 
Chaves et al. 2008, Kalinka et al. 
2009, Jones et al. 2012.  






Interleukin 6 receptor (IL6R)  
 
Interleukin 10 (IL10)  
Interleukin 12 (IL12)  
Interleukin 12 receptor (IL12Rβ)  
Interleukin 12 alpha (IL12α) 
Interleukin 13 (IL13) 
Interleukin 15 (IL15) 
Interleukin 23 receptor (IL23R) 
Killer cell immunoglobulin-like 
receptor three domain long 
cytoplasmic tail 2 (KIR3DL2) 
Lactotransferrin (LTF) 
Low-affinity receptor for 
immunoglobulin G (FcγRIIB) 
Major histocompatibility complex, 
class II (HL-DQA1) 
Nuclear factor-kappa B1 (NFkB1) 
Protein kinase C alpha (PRKCA) 
Selenoprotein S (SEPS1) 
Surfactant, pulmonary associated 
protein D (SFTPD) 
TIR domain receptor associated 
protein (TIRAP) 





Tumour necrosis factor receptor 2 
(TNFR2) 
TNF receptor associated factor 2 
(TRAF2) 
Toll-like receptor 2 (TLR2) 
Toll-like receptor 4 (TLR4) 
Toll-like receptor 5 (TLR5) 
Toll-like receptor 9 (TLR9) 
Toll-like receptor 10 (TLR10) 
Transforming growth factor beta1 
(TGF-β1) 
Romero et al. 2010. Romero et al. 
2010b. 
Velez et al. 2009  
 
Ryckman et al. 2010, Heinzmann et 
al. 2009, Karjalainen et al. 2012 
Moura et al. 2009, Kalinka et al. 
2009, Velez et al. 2007  Velez et al 
2008a 
Romero et al. 2010. Romero et al. 
2010b. Ryckman et al. 2010. Velez et 
al. 2007  
Stonek et al. 2008.  
Heinzmann et al. 2009.  
Velez et al. 2009 
Karjalainen et al. 2012 
Heinzmann et al. 2009. Karjalainen et 
al. 2012 
Velez et al. 2009 
Falah et al. 2013 
Harmon et al. 2013 
 
 
Romero et al. 2010. Romero et al. 
2010b. 
Iwanaga et al. 2011  
 
Falah et al. 2013 
 
Karody et al. 2013  
Gomez et al. 2010 
Wang et al. 2013  
Karjalainen et al. 2012 
 
Karody et al. 2013 
 
Moura et al. 2009, Jones et al. 2010, 
Jones et al. 2012, Pu et al. 2007, 
Hollegaard et al. 2008, Liang et al. 
2010, Harper et al. 2011, Yilmaz et 
al. 2012, Drews-Plasecka et al. 2014., 
Jafarzadeh et al. 2013.  
 
Jones et al. 2012, Pu et al. 2007. 
 
Bream et al. 2013.  




Rey et al. 2008, Bitner et al. 2013, 
Karody et al. 2013 
Karody et al. 2013 
Karody et al. 2013 
Heinzmann et al. 2009 





Early growth response 1 (EGR1) 
FERM domain containing protein 7 
(FRMD7) 
Mitochondrial genome variants  
Transcription factor AP2A 
(TFAP2A) 
Specificity protein 3 (SP3) 
Thota et al. 2012  
Enquobahrie et al. 2009  
Myking et al. 2013 
 
Velez et al. 2008b  
Enquobahrie et al. 2009 
Enquobahrie et al. 2009 
 
Family Based Linkage Studies 
Families have been used in the design of genetic studies dating as far back to 
Mendel’s study to examine the concept of inheritance of traits in plants.  They use 
designs based on related individuals, which could be sibling pairs, parents and 
offspring, or more complex family trees. Historically, they have been well suited to 
investigate conditions that have genes of major effect. For linkage studies, this is a 
family-based approach to identifying susceptibility genes. Linkage refers to the 
tendency for alleles at certain chromosome positions (loci) that are close together to 
be also transmitted/inherited together. The further apart genes are from each other, 
the more likely they are to be split apart by a recombination event during meiosis. 
Using known genetic markers that define the inheritance of the same chromosomal 
region among different family members, the approximate location of the region of 
causation is identified.  Two studies of Finnish families identified three markers with 
the highest linkage on 15q26.3 with insulin-like growth factor 1 (IGF1R) using 
autosomal chromosomal markers (Haataja R et al. 2011). When the same families 




receptor gene at Xq12 and interleukin-2 receptor gamma subunit (IL2RG) located on 
Xq13, were implicated with preterm birth (Karjalainen et al. 2012). 
Genome Wide Association Study (GWAS) 
Unlike candidate gene studies, GWAS aims to identify common genetic 
variation (>5% frequency) in hundreds of thousands of SNPs across the entire 
genome without bias of pre-existing knowledge. Complex or multifactorial diseases, 
such as sPTB, are thought to be polygenic, in contrast to highly penetrant single gene 
disorders. As GWAS is looking to identify common genetic variation with small 
effect sizes, GWAS requires a large study sample for the discovery of statistically 
significant contribution to a trait.  
Recently, a GWAS examining a large population of >40,000 women of 
European ancestry and a replication cohort of >8,000 women from a Nordic dataset 
have identified several maternal loci (EEFSEC, EBF1 and AGTR2) that may 
contribute to the length of gestation and preterm birth in Caucasian women (Zhang et 
al. 2017). EEFSEC encodes a protein involved in the production of selenoproteins, 
EBF1 encodes a protein implicated in B-cell development and AGTR2 encodes the 
type 2 angiotensin II receptor.  The study provided new lines of investigation away 
from the increasing evidence for inflammation and innate immunity. Until this study, 
other individual GWAS of sPTB had not replicated loci with genome wide 
significance (Monangi et al. 2015). The possible reasons for this include:  
• variation in definitions of preterm birth across studies (i.e. not strictly 
spontaneous preterm birth inclusion and variation in gestational age 
definitions),  
• insufficient study numbers to detect small-effect sizes across the entire allele 




• sPTB is caused by rare variants which had not been tagged by conventional 
genome wide arrays.  
• Paternal genes not considered in this method of analysis or their contribution 
to fetal genetic effect and may play more significant role.  
Additionally, the complexity of the sPTB phenotype suggests that there may be a 
genetic predisposition to different phenotypes of sPTB. There may be a small genetic 
contribution to each pathophysiology or phenotype and a combination of genetic, 
transcriptomic and environmental interaction analysis is required to examine 
biological pathways tracing back to the key genes.  
Apart from just conducting a GWAS, researchers are now interested in 
identifying SNPs that may significantly interact with environmental influences such 
as pre-pregnancy body mass index (BMI). Hong et al. (2017) identified and 
replicated a significant interaction between maternal genotype rs11161721 in the 
COL24A1 gene and pre-pregnancy BMI category on overall PTB risk in an 
African American population (n=1733; 698 mothers of PTB, 1035 term birth) 
from the Boston Birth Cohort (BBC) and in independent GWAS data sets 
deposited in the database of Genotypes and Phenotypes (dbGaP), respectively 
(African American n=780, Caucasian n=683). Although three other SNPs were 
found to be significantly associated with different PTB outcomes in the BBC, the 
associations were not confirmed in either of the two independent data sets (Hong 





Following the positive results from maternal GWAS data the risk of preterm 
birth may be associated with the maternal genome, a logical possibility is that this 
may occur through maternal transmission of the mitochondrial genome via 
mitochondrial DNA (mtDNA). The mtDNA is of interest in sPTB because oxidative 
stress is likely to play an important role in labour. (Velez et al., 2008b). Additionally, 
there is good evidence that mitochondria represent a major source of reactive oxygen 
species in aging tissues (Cadenas et al. 2000), and mitochondria have a protective 
role against inflammation. Inflammation itself may also have a role in the mediation 
of aging; a process called inflammaging, with both processes sharing many of the 
same pathways including oxidative stress and DNA damage (Salminen et al. 2012). 
In one study of preterm birth, Velez et al. (2008) used previously established mtDNA 
variants and intersected them with smoking, a known risk variable for PTB which 
increases oxidative stress. Marginal significance was shown for two of the mutations, 
A4917G and T4216C, however this has not been validated.(Velez et al. 2008b) 
Contrary to this, Alleman et al., (2012) examined the association between 
mitochondrial genotypes and preterm delivery using a meta-analysis to combine two 
large GWAS studies and tested for associated 135 mitochondrial genome SNPs 
(mtSNP). No single mtSNP reached genome wide significance and they did not 
support the theory that mitochondrial genetics contributes to maternal transmission 
of PTL and related outcomes. (Alleman et al. 2012) More recently, Crawford et al., 
(2018) discovered that infants with increasingly divergent mitochondrial and nuclear 
genome were more at risk of sPTB. This might go some way to explaining the higher 
rates of sPTB in the African American population when compared to a Caucasian 




interest that requires further study to elicit the role of mtDNA and the interaction 
with nuclear DNA leading to this phenomenon.  
A study of fetal membranes examining the mRNA expression of 
mitochondrial enzyme manganese superoxide dismutase (Mn SOD), that scavenges 
ROS and is upregulated in sites of inflammation, found upregulation in term labour 
and in preterm labour only in the presence of histological chorioamnionitis (Than et 
al. 2009). Therefore, there is inconclusive evidence regarding the involvement of 
mitochondrial genetics, but this remains a promising area for future work.   
Whole Exome Sequencing (WES)/Whole Genome Sequencing (WGS) 
GWAS, using microarray technology, has only very recently made better 
progress in PTB genetics. The lack of reproducible results is potentially explained by 
the possibility of sPTB being caused by rare rather than common variants. With high 
throughput technologies becoming increasingly affordable and accessible, it has 
become easier to perform whole exome and whole genome sequencing using next-
generation sequencing (NGS) strategies searching for new or rare variants. NGS is 
the catch all term to describe several different modern sequencing technologies 
capable of interrogating the entire genome or transcriptome, not depending on pre-
chosen targets like microarray. NGS is based on synthesis, i.e. the incorporation of 
nucleotides by a DNA polymerase while microarrays are based on hybridization to 
strands of complimentary mRNA probe stored in wells of a chip. Even for the newest 
genome-wide microarrays, it is virtually impossible to include probes against every 
single nucleotide position. 
Although the exome refers to less than 2% of the genome as a whole, it 
contains approximately 85% of known disease-causing variants. A whole exome 




whose pregnancies were complicated by PPROM (n=76) compared to normal term 
pregnancies (N=43) identified rare heterogenous nonsense and frameshift mutations 
only present in PPROM cases in several candidate genes (CARD6, DEFB1, FUT2, 
MBL2, NLRP10, NOD2) involved in dampening the innate immune response (Modi 
et al. 2017). These results suggest that PPROM may be caused by infrequent genetic 
variants that modulate fetal membrane strength leading to weakening of the 
membranes and ultimately ending in premature rupture. 
However, limitations of whole exome sequencing (WES) include missing 
structural variants. WES cannot detect important intragenic variation including areas 
of regulatory elements responsible for gene expression and it can miss some exons. 
The efficacy of the capture of exons depends on the percentage GC nucleotide 
composition of the targeted sequence (or GC capture bias). For exons with especially 
high GC content, exome sequencing can fail to produce enough coverage for 
accurate variant detection and calling. For these purposes whole genome sequencing 
(WGS) is better as it will also identify the less common mutations such as frame shift 
mutations (insertion/deletion of nucleotides that is not divisible by 3 and changes the 
reading frame order) and point mutations (single substitution / insertion / deletion of 
single nucleotide). Achieving only a low coverage may miss many variants, whilst 
cost increases for a deeper coverage makes it a prohibitively expensive technique for 





2.3 Transcriptomics  
The transcriptome is the collection of all RNA (ribonucleic acid) molecules in 
a cell, tissue or organism. Transcription is the first step in gene expression in which 
information is taken from the gene for creating proteins or transcripts used to 
regulate gene function. RNA molecules mirror the sequence of the DNA bases to 
transcribe the code. This process is controlled separately for each gene in the genome 
(Figure 2.3). A single strand of the DNA helix is used as a template and RNA creates 
a copy of the same base information as the non-coding strand, except the base uracil 
(U) is used instead of thymine (T). The enzyme RNA polymerase is used to link 
nucleotides to create a chain of nucleotides. RNA is then processed by splicing with 
a 5' cap and poly-A tail put on either ends of the read and is subsequently called 
messenger RNA (mRNA). A stretch of three bases (codon) in the mRNA determines 
the position of an amino acid in a growing protein molecule (Figure 2.3).  
By analysing the mRNA it is possible to determine which genes are being transcribed 
in all available cells present in a sample at that specific time point. However, the 
measurement of mRNA levels provides an imperfect reflection of protein levels and 
activity. The concentration of a protein is controlled not only by the level of its 
mRNA, but also by the rate of mRNA translation into protein and protein 
degradation. Other protein modifications, such as phosphorylation, are also important 
determinants of activity. With these limitations in mind, measurement of global 
mRNA expression gives insight into the overall level of gene and protein expression 
(Sealfon and Chu. 2010). Similar to genomics there are two common methods to 



























































































































































































































Microarray technology was first introduced in 1995 by Patrick Brown and 
colleagues (Schena et al., 1995). RNA microarrays have been widely used to identify 
regulated genes, pathways, or gene networks in a variety of cells and tissues when 
two or more related biological conditions are compared.   
Figure 2.4 shows a schematic of microarray. cDNAs are amplified from 
individual clones in a library. Each cDNA fragment representing an individual gene 
of interest is immobilized on a glass slide that has been coated with nucleotide-
binding chemicals. These slide arrays can be printed as whole genome microarrays 
or with a focused selection of genes of interest (Sealfon and Chu. 2011). Because 
of their shorter turnaround time, ease of analysis and cost-effectiveness microarrays 
remain the most popular approach in transcriptomic profiling. Microarray also still 
yields higher throughput than RNA Seq which has significant advantages when 
working on projects with large numbers of samples. However, as microarray is 
based on these hybridization probes that are designed from prior sequence 
knowledge, they cannot detect structural variations or discover novel transcripts. 
This also limits their sensitivity as they cannot detect differences in very similar 










































































































RNA Seq (RNA Sequencing) 
The development of novel high throughput DNA sequencing has also 
provided a new method for both mapping and quantifying transcriptomes. This 
method termed RNA sequencing improved on its forerunners of Sanger sequencing 
and tag-based methods. 
A population of RNA is converted into a library of complimentary DNA 
fragments with adaptors attached to one or both ends (Figure 2.5. Step a4). Each 
molecule is then sequenced in a high throughput manner to obtain short sequences 
from one end (single-end sequencing) to both ends (paired-end sequencing). The 
reads are typically 30-400 bp depending on the sequencing technology used. 
Following sequencing the resulting reads are aligned to a reference genome or 
reference transcripts or assembled de novo (Wang et al. 2009). One advantage that it 
offers over hybridisation methods is that it is not limited to detecting transcripts that 
correspond to existing genomic sequences. This is useful when the reference genome 
remains to be determined.  
Another advantage is that the background signal compared to microarray is 
very low because sequences can be unambiguously mapped to unique regions of the 
genome. RNA Seq. is also highly accurate in quantifying levels of expression 
(Nagalakshmi et al. 2008).  
RNA Seq. is the first sequencing-based method that allows the entire 
transcriptome to be surveyed in a very high throughput and quantitative manner. 
Unfortunately, it remains expensive for large numbers of samples or complex 
genomes. The sequence coverage, or the percentage of transcripts surveyed, has 




transcriptome, or to detect rare variants a greater sequencing depth is required for 






Figure 2.5 The data generation and analysis steps of a typical RNA-seq experiment. Image 
was obtained with permissions from “next generation transcriptome assembly” Jeffrey A. 




Transcriptomics for spontaneous PTB 
A systematic review of transcriptomics as applied to preterm birth (Eidem et 
al. 2015) showed that even though there have been at least 134 genome-wide 
transcriptomic studies of pregnancy and PTB, spontaneous PTB was only 
investigated in 7% of all studies and 18% of preterm birth studies. The majority, 76% 
of studies focussed on medically indicated PTB and specifically, pre-eclampsia.  
Placental tissue was analysed in 61% of studies which has limited utility in a 
predictive setting as it is unavailable for testing without risk to the pregnancy (Eidem 
et al. 2015). Obtaining a placenta post-partum may give key information about the 
pathophysiology of preterm and term labour, however, there is a risk that the genes 
expressed once the placenta is no longer required for its biological function are likely 
to be different to those expressed in utero and may provide misleading biological 
information. Additionally, the other most frequent tissues to be studied include 
myometrium and fetal membranes, which are also usually only accessible at delivery. 
The advantage of studying these tissues are that they are directly involved with the 
pregnancy and labour, however, like the placenta, the gene expression at or following 
delivery may give useful knowledge about the process of labour but limited insight to 
predictive markers of labour.   
The evidence for treating PPROM as a separate clinical entity to sPTL is 
growing as differences in gene expression are identified between these conditions. 
The most well replicated genes in the phenotype of PPROM (i.e. at least 2 gene 
expression studies) are listed in Table 2.2 below adapted from Eidem et al. (2015). In 
the following section, some of the most recent transcriptomic studies using different 




Table 2.2 List of genes found in two or more gene expression studies  
Entrez Gene 
ID 
Gene Function Number of studies 
972 CD74 
molecule 
Regulates antigen presentation for 
immune response 
2 
6280 S100A9 Calcium binding protein; cell cycle 
progression and differentiation 
2 
3576 CXCL8 C-X-C motif chemokine ligand 8 
(IL8); mediator of inflammatory 
response  
2 
7805 LAPTM5 Transmembrane receptor 
associated with lysosomes 
2 
23574 PRG1 P53 responsive gene 1 2 
1117 CH13L2 Chitinase 3 like 2 protein is 
involved in cartilage biogenesis, 




The first study to examine RNA sequencing data (Chan et al. 2014) in human 
myometrium samples obtained at term caesarean section following labour (n=5) and 
non-labouring term caesarean sections (n=5) demonstrated that transcriptomics 
separated these groups on differentially expressed genes (DEGs). However, the 
numbers used in this study were very small. Reassuringly, the identified genes were 
broadly concordant to those differentially expressed genes identified in previous 
microarray experiments (Havelock et al. 2005; Bukowski et al. 2006; Mittal et al. 
2010). This study by Chan et al. (2014) added information on transcript abundance, 
microRNAs, splice variants, and transcript isoforms. A decrease in progesterone 
receptor transcripts concomitant with a decrease in FOXO1 mRNA was observed. 
FOXO1 regulates PGR signalling by altering PGR target genes during transcription 
in human endometrial stromal cells (Takano et al. 2007). Overall, the data shows that 
labour is associated with an inflammatory signal and genes or pathways related to 




human sequencing data to compare orthologous genes to the expression of mouse 
genes from murine models. The three models used were a term gestational model, a 
sPTB model induced by injection of Escherichia coli LPS serotype O111:B4 (i.e. 
induced by inflammation) and a model that induced sPTB by the injection of RU486 
(induced by progesterone withdrawal). Interestingly, they found that the changes in 
human myometrial transcriptome at term most closely resembled transcriptome 
changes of the preterm mouse model induced by inflammation, which suggests a 
dominant role of inflammation in human labour irrespective of gestation.  
It must be taken into consideration that the human myometrial samples are 
taken at the point of artificial trauma to the uterus at CS and may be a transcriptomic 
reflection of an acute inflammatory reaction in the myometrium at the site of the 
incision.  However, in support of the theory that human labour is an inflammatory 
state, similar findings of inflammatory signatures are being detected in other studies 
of term and preterm placenta (Sharp et al. 2016) and in alternative tissue samples 
such as maternal decidua (Rinaldi et al. 2017).  
To identify the core genes and regulatory networks facilitating the transition 
of the myometrium from a quiescent to active labouring state Stanfield et al. (2019) 
performed an integrated analysis using two existing transcriptomic datasets (Mittal et 
al. 2010; Chan et al. 2014) and a dataset from RNA Seq analysis of myometrium 
from CS before and after the onset of labour (NCBI Gene Expression Omnibus; 
GSE80172). One hundred and twenty-six genes were significant across all databases 
and machine learning models exhibited high reproducibility between studies. This is 
demonstrating better classification and characterisation of myometrial activation 




expression data for non-labouring, early labour and active labour again, attesting to 
the importance of inflammation in the onset of labour. (Stanfield et al. 2019) 
Placental transcriptomics 
A major issue in the transcriptomic studies of sPTB in humans is the inability 
to collect healthy control placental tissue sampled at the same gestational age as 
placental tissue from actual preterm births. Therefore, gene expression differences 
identified after the standard comparison of sPTB and term placental tissue may 
reflect differences in both sPTB pathology and gestational age, and it is difficult to 
tease these two factors apart. To try and tackle this problem Eidem et al. (2016) 
matched gestational age of human placental sampling to a closely related species; 
macaque monkeys. They identified 29 sPTB specific candidate genes not thought to 
be related to gestational age. Selected genes overlapped with previously identified 
pregnancy-pathology related genes including serine peptidase, CD163 and VSIG4 
that have been characterized as maternal biomarkers of pre-eclampsia. PDE2A is a 
gene containing a SNP associated with recurrent miscarriage and ADORA3 
modulates secretion of matrix metalloproteinases and is important in the PPROM 
signaling pathway (Kim et al. 2008). 
Human decidua transcriptomics 
The maternal – fetal interface (decidua basalis and decidua parietalis) may 
play a key role in the onset of labour both at term or preterm. It is the anatomical site 
of contact between maternal and fetal tissues.   
Rinaldi et al. (2017) removed decidua from fetal membranes sampled at birth 
from four groups; term and preterm, non-labouring and labouring women. The 
decidual lymphocytes were isolated, RNA bead chip microarray was used to evaluate 




previous findings, term and preterm birth were associated with widespread gene 
expression changes related to inflammatory signalling pathway. However, no change 
in lymphocyte subpopulations were seen between the groups and no functional data 
of cell populations were available. There was elevated expression of CDID in PTL 
decidua which may suggest activation of invariant natural killer cells (iNKT) in PTL 
samples.  
Bukowski et al. (2017) attempted to solve issues of reduced power of small 
sampling numbers by increasing the number of samples taken from the same 
individual. They collected maternal and fetal blood, chorion, amnion, decidua, 
placenta and myometrium and identified expression profiles uniquely identifying 
four phenotypes.  A ten by ten samples cross validation was performed to predict 
how well their model could correctly classify samples into the four groups; term non-
labour, term labour, preterm non-labour and preterm labour. Forty-two percent of 
samples could be correctly classified, and this was an improvement on 25% of 
correctly classified samples using a random classifier. The largest differences in gene 
expression were observed in decidual samples with the proportion of genes with 
expression differences at least 1 or 2 standard deviations approximately six times 
greater than those seen in maternal blood. Results showed that regulation of immune 
pathways and immunological processes occur at the maternal-fetal interface; mainly 
in the decidua, chorion and amnion. Although the authors agreed to some degree 
with previous work stating that expression profiles of the ‘term not in labour’ group 
show local suppression of chemokines with simultaneous suppression of the NFkB 
inflammatory pathway; they disagreed that term labour is heavily related to 
inflammation. Instead they attributed the labour process to immune suppression. 




cells, such as effector T cells, from trafficking into gestational tissues such as the 
decidua, thus preventing the onset of labour (Bukowski et al. 2017). 
Fetal membrane transcriptomics 
Although the use of fetal membranes role in prediction of sPTB remains 
limited, transcriptomic studies of fetal membranes have been used to try and predict 
the neurocognitive status of the infant at 18-24 months (Pappas et al. 2015). A 
retrospective case-control study was conducted to examine the chorioamniotic 
membranes of 66 very preterm neonates (22-32 weeks) with and without 
neurocognitive impairment using RNA microarray. One hundred and seventeen 
genes were differentially expressed among neonates with and without subsequent 
neurocognitive impairment (p<0.05 and fold change >1.5). Differentially expressed 
genes were input into to a multi-gene model, developed to predict 18–24-month 
neurocognitive impairment (using the ratios of OSR1/VWF and HAND1/VWF at 
birth) (sensitivity = 74%, specificity = 83%) and validated on an independent dataset 
(n=19) (Pappas et al. 2015) 
Cervical transcriptomics 
The first study to examine the differences between sPTL (n=6) and PPROM 
(n=5) by collecting cervical biopsy samples up to 30 minutes following PTL showed 
distinct differences in the microarray gene expression and clear clustering effects 
between groups (Makieva et al. 2017). Four novel proteins with the potential to cause 
cervical remodelling leading to ruptured membranes were identified (PRAM1, 
CEACAM3, FGD3, and NDRG2) and the activity of MMP9 was found to be higher 
in the PPROM cervix. Prior to this study only 4% of all transcriptomic studies in 
term and pre-term human pregnancies utilized cervical tissue and did not look at 




Small non-coding RNA molecules called microRNA’s (miRNA) have been 
differentially expressed in gestational tissue such as cervix at two time points; 20-23 
weeks and 24-27 weeks (Elovitz et al. 2014) and placenta collected at delivery from 
patients with pre-eclampsia, sPTB < 35 weeks and a term elective CS control 
(Mayor-Lynn et al. 2011), but several researchers have found that these differences 
do not extend to peripheral maternal whole blood (Elovitz et al. 2015, Knijnenburg et 
al. 2019).  
Maternal blood transcriptomics 
Heng et al. (2016) collected maternal blood samples at two separate time 
points 17–23 and 27–33 weeks of gestation in a low risk pregnant population. 
Interestingly, when they examined differential gene expression at both time points 
between the women who went on to have sPTB and PPROM (n=51) there were no 
differentially expressed genes. Therefore data were combined and analysed as one 
single group and compared to 114 term matched controls. At timepoint 1 (17-23 
weeks; n = 51) there was no differentially expressed genes at a false discovery rate 
(FDR) <0.05 or at FDR<0.10, but at 27-33 weeks (n=47) and a FDR <0.10 there 
were 26 differentially expressed genes at between women who had SPTB and term 
delivery. It is important to note that the mean gestational age at delivery in the sPTB 
group was 33 weeks and 6 days, almost immediately following timepoint 2. Some of 
these gene changes may reflect early labour which may limit their usefulness as an 
early predictive biomarker.  
In the same study by Heng et al. (2016) no significant change in any gene 
was detected between SPTB and term delivery. Paired data and gene set enrichment 
analyses provided additional evidence that inflammatory genes were consistently 




with sPTBs compared to women with term deliveries.  Significantly enriched 
inflammatory pathways included leukocyte migration, lysosomes, NF-kB activation, 
pathways involving cytokines and their receptors (e.g. IL1, IL2, IL6, IFN, IL1R, 
TNFR2, CCR3, CXCR4 and CD40) as well as toll-like and NOD-like receptor 
signalling. In contrast, women with SPTBs had lower RNA metabolism, RNA 
processing and T cell activation (including CTLA4 pathway) compared to women 
who had term deliveries (n = 163 downregulated gene sets at T1, n = 100 at T2; 77 
common gene sets). Therefore, despite not observing any significant gene at 
FDR<0.05, numerous gene sets were significantly associated with sPTB. This team 
hypothesized that circulating maternal leukocytes respond to ‘signals’ from 
gestational tissues and alter their gene expression. The most striking gene set 
enrichment result was that women who had SPTBs have increased interleukin 
signalling, mainly driven by IL1 and IL6, and leukocyte migration into gestational 
tissues as early as 18 weeks compared to women who had term deliveries. This in 
theory could accelerate cervical ripening by increasing local oxytocin and 
prostaglandin production, weakening the fetal membranes and causing early 
contractions. Unfortunately, this study did not obtain cervical length measurements 
or fetal fibronectin and the prediction models could not be compared to current 
clinical tools. 
This study by Heng et al. (2016) was one of three (Bukowski et al. 2017, 
Heng et al. 2014) included in a recent meta-analysis of transcriptomic studies of gene 
expression profiling to identify gene expression differences detectable in maternal 
whole blood (Vora et al. 2018). Spontaneous preterm birth was defined as delivery 
less than 37 weeks’ gestation.  Combining the studies provided additional power and 




mediated pathways. Interestingly, 18 of these 210 genes also demonstrated 
differential expression in the second trimester, suggesting a possibility for early 
identification of patients who might deliver preterm. IL-1R1 and TFPI, both of which 
encode immune-related proteins, were found to be differentially expressed and 
secreted longitudinally. Perhaps the most interesting finding of all was that preterm 
maternal whole blood showed upregulation of innate immunity and downregulation 





The study of metabolomics is the large-scale study of small molecules known 
collectively as metabolites. Metabolites are typically small molecules that are the 
intermediate products of metabolic reactions occurring within cells or biological 
systems, and the end-product of the interaction of the system's genome with its 
environment. (Rochfort. 2005) By undergoing catabolism in a complex metabolic 
network, metabolites can also be components of higher order biological structures 
(DNA, transcripts, proteins) and cell structures energy, or ATP (Dunn et al. 2011). 
Although the study of metabolite profiling has a long history that started in 
the 1950’s (Rochfort. 2005), the phrase “metabolomics” was coined by Oliver S.G. 
et al. in 1998 who identified metabolites as part of a functional analysis of the yeast 
genome (Olivier et al. 1998). The Metabolomics Society defines metabolomics as; 
‘the comprehensive characterization of the small-molecule metabolites in biological 
systems, which can provide an overview of the metabolic status and global 
biochemical events associated with a cellular or biological system’ (Metabolomics 
Society. 2019). There has been some overlap with the term ‘metabonomics’ defined 
as the “quantitative measurement of time-related multiparametric metabolic 
responses of multicellular systems to pathophysiological stimuli or genetic 
modification” (Nicholson et al. 1999). Due to similar analysis techniques, 
‘metabolomics’ and ‘metabonomics’ are frequently used interchangeably, however 
the all-encompassing term ‘metabolomics’ remains the most popular in the literature 
(Rochfort. 2005, Dunn et al. 2011., Smolinska et al. 2012.) and will be used from 
here onwards in this thesis. 
Untargeted metabolomics studies are characterised by the simultaneous 




known as a top-down approach and avoids the need for a priori specific hypothesis 
on a set of metabolites, and instead analyses the global metabolomics profile (Alonso 
et al. 2015). Recent advances in the technologies used to extract and analyse this type 
of data have revolutionised its wide range of application including biomarker 
discovery (Meyer et al. 2013, Armitage and Barbas. 2014, Julia et al. 2014) and the 
analysis of complex disease. Of note, metabolomics has been successfully used to 
investigate complex pregnancy conditions such as gestational diabetes, fetal growth 
restriction and pre-eclampsia (Horgan. 2009, Sulek. 2014, He. 2015). 
Metabolites are the downstream products of gene transcription and 
translation, and metabolomics can give a clearer picture of a phenotype than 
genomics or transcriptomics. However, this layer of omics data increases in 
complexity as there are currently 114,100 metabolite entries on the Human 
Metabolome Database (HDMB) including both water soluble and lipid soluble 
metabolites (Wishart. 2018). Due to this complexity there is not one method that can 
capture all the known metabolites and to do this would require multiple techniques 
and instruments.  
The most widely used technologies in metabolomics are nuclear magnetic 
resonance (NMR) due to its high precision and mass spectrometry (MS) with 
excellent reproducibility. Fourier transform infrared (FT-IR) is also becoming more 
popular in diagnostics. It has a rapid high throughput and is relatively inexpensive, 
but with low chemical specificity.  
A chromatographic separation technique is often coupled with mass 
spectrometry such as liquid chromatography (LC) or gas chromatography (GC) to 
enhance resolution. An overview of data processing for metabolomics studies is 




In this section of the chapter I will review metabolomic publications that have 
attempted to elucidate mechanistic pathways, or predictive metabolites of sPTB 
using either NMR or MS using different biological fluids for analysis. A summary 














































































































































































Amniotic Fluid  
Two studies have looked exclusively at AF for the prediction of sPTB using 
two different mass spectroscopy techniques (Menon et al. 2014, Baraldi et al. 2016). 
One used 24 samples obtained at amniocentesis from an asymptomatic group of 
women between 21- and 28-weeks pregnancy and compared metabolic signalling to 
8 samples obtained at term caesarean section (Baraldi et al. 2016). The other 
obtained AF samples during labour from 25 women <34 weeks in labour and 
compared metabolomic signalling to 25 term controls (Menon et al. 2014). These 
studies faced challenges in their study designs as AF is not an easily accessible 
biological fluid and gestational matched controls were not available. Samples had to 
be regrouped based on detection of paracetamol metabolites but both studies revealed 
different metabolites either raised or lowered in the preterm birth group. This lack of 
concordance is possibly due to the different analytical techniques used and the 
differences in metabolites present during labour versus asymptomatic women. 
Orczyk-Pawilowicz et al. (2016) using NMR and Virgiliou et al. (2016) using 
mass spectrometry combined analysis of AF metabolites with the metabolites in 
maternal plasma and serum respectively in an untargeted approach. Their aim was to 
identify if the metabolite signatures of AF were correlated in maternal blood, which 
is a much easier and more accessible biological fluid to study. In the study conducted 
by Orczyk-Pawilowicz et al.(2016) the metabolomic profiles of plasma and AF 
samples of healthy women with normal pregnancies in the second trimester and three 
timepoints in the third trimester were studied. The highest correlation was observed 
between AF and plasma in the transition from the second to third trimester. However 
only 8 samples of plasma and 7 samples of AF were available for the second 




Interestingly, Virgiliou et al.(2016) only sampled in the second trimester but 
observed no correlation between maternal serum and AF based on the most 
commonly detected metabolites. Maternal serum was recommended for future 
metabolomic profiling studies due to ease of access and repeatability of sampling. 
The Virgiliou et al. (2016) study included 35 women delivering between 29 weeks 
and 36 weeks and compared metabolite profiles to 35 women delivering at term. 
Using partial least square discriminant analysis (PLS-DA) there was good separation 
between the groups, which was attributed to 13 lipid features. Despite a well 
conducted study, the author did not attempt to validate the results. The groups were 
also close in gestational age and there was only one week between the latest preterm 
delivery and the earliest term delivery; and four weeks between the average 
gestations of labour (35 weeks cf. 39 weeks).  This tells us little about clinically 
important preterm births (<34 weeks) but suggests that lipids may be an area of 
interest for further research. Samples were obtained from healthy patients requiring 
amniocentesis or blood tests to rule out other pathology. Unsurprisingly the resulting 
populations used in the study are heterogenous, with varying number of samples 
taken from different trimesters in the study with only a small subset with paired 
plasma and AF samples from the same woman (n=50; T2=1, T3=15, term=26, 
prolonged pregnancy=8). The AF was obtained through both transabdominal 
amniocentesis and transvaginal amniotomy. These two different collection methods 
would be subject to different contamination risks, particularly transvaginal 
amniotomy occurring at term delivery.  
From these studies different trends were observed in the two different 
biofluids of serum and plasma. Very early pregnancy elevations in total cholesterol 




birth before 34 weeks and a 2-fold increase risk for PTB between 34 and 37 weeks. 
Pyroglutamic acid and tryptophan were found to be in lower levels in the maternal 
serum of women with preterm labour.  
Pyroglutamic acid is derived from glutathione and decreased levels suggest a 
potential glutathione deficiency.  A deficiency could result in a reduced ability to 
neutralise toxins and defend against oxidative stress.  
Tryptophan is an important precursor for production of bioactive metabolites 
such as serotonin. Serotonin and tryptophan levels have been linked to depression in 
pregnancy and preterm delivery (Waters K. 2010). Tryptophan may also be a marker 
of inflammation through activation of the kynurenine pathway. Metabolism is 
catalysed by the IDO enzyme (indoleamine 2,3-dioxygenase) and acts as an 
endogenous regulator of T-cell proliferation. Inflammation leads to more IDO 
activity and expression and increased metabolism of tryptophan resulting in lower 
levels in maternal serum.  
Urine 
NMR was the method employed to examine a nested case-control group from 
the Rhea mother-child cohort (Maitre et al, 2014). Samples of urine were obtained 
between 10-14 weeks, from 1317 women in Crete, Greece. Eighty-eight women had 
sPTB and 26 women had medically induced preterm births (IPB), all defined as birth 
less than 37 weeks gestation. Samples from 288 healthy controls were also collected.  
Thirty-four urinary metabolites were identified from spectra and two methods 
of univariate analysis was performed to select likely candidate metabolites to subject 
to multivariate regression analysis. The analysis of PTB < 37-week outcomes was 
conducted both on the combined clinical subtypes (PB) and separately on each 




glycine, TMAO, lysine and the singlet at 0.63 ppm (a steroid conjugate) significantly 
varied between sPTB and control groups (p<0.05). However, only three of the six 
candidate metabolites for sPTB; formate, lysine and the singlet at 0.63 ppm, showed 
a significant trend (p<0.05) when the trend of these metabolites in the proportion of 
women with PTBs was examined (dataset split in quartiles of metabolite levels to 
investigate dose-response and sPTB). When a logistic regression model was used to 
account for other factors such as maternal age, education, parity and smoking habits, 
high lysine and low formate levels were significantly associated with a higher risk of 
sPTB. (Maitre et al. 2014) 
High levels of tyrosine, acetate, trimethylamine and formate were also 
significantly associated with a decreased incidence of fetal growth restriction 
(birthweight below 10th centile) (IORs between 0.27 and 0.14). Whereas, high levels 
of N-acetyl glycoproteins were associated with an increased risk of iatrogenic PTB.  
It is very difficult to compare or validate these findings with other 
metabolomic studies due to the differences in analytical platform and biofluid 
chosen. One other group looked at both maternal urine and plasma in different 
trimesters of healthy pregnancy and compared this to the non-pregnant state (Pinto et 
al. 2015) but no cases of sPTB were examined. As expected, levels of some amino 
acids required by the fetus decreased in the first trimester, but novel findings 
included early changes in citrate, lactate, and dimethyl sulfone levels. This is 
possibly due to a metabolic energy shift in the first trimester. Alteration in creatine 
levels was also noted, along with creatinine changes. Plasma high density 
lipoproteins (HDL) and low and very low-density lipoproteins (LDL + VLDL) levels 




accompanied by increases in fatty acid chain length with increase in lipolysis in the 
third trimester.  
Metabolites in Maternal Blood  
Plasma metabolites were examined using mass spectrometry from women 
who had preterm labour between 24 and 37 weeks of gestation (n = 57), threatened 
preterm labour but delivered at term (n=49) and samples collected at normal term 
delivery between 38 and 41 weeks (n=25) (Lizewska et al. 2018). PLS-DA models 
differentiated preterm and term births based on metabolomic profiles alone. This 
may be partly due to differences in gestational age across groups, but this was 
somewhat mitigated by including a threatened preterm labour group that were 
sampled at a similar gestation as the preterm labourers but when on to deliver at 
term. Fatty acids were found to be the group most significantly different but based on 
the results of the study by Pinto et al. (2015) this may not be wholly unexpected in 
view of the fact that there are significant gestational age changes with this group. In a 
study that took samples from women at delivery, higher levels of omega-3 fatty acid, 
docosahexaenoic acid (DHA), were seen in the preterm group when compared with a 
threatened preterm group (who went on to deliver at term) with no difference 
between preterm and term groups suggesting that detection of this fatty acid 
metabolite may occur with initiation of labour. Lower levels of amino acids were 
seen in women with preterm labour compared to threatened preterm labour possibly 
associated with a source of energy or a link to oxidative stress. Lower tryptophan in 
the PTB group had the highest statistical significance of change compared to 
threatened PTB (delivered at term) and term labour groups and has been associated 
as an inducer of oxidative stress (Elisia et al. 2011). However, it is difficult for this 




as the preterm birth group on average were sampled at 30 weeks and the threatened 
PTB group were sampled at 32 weeks. 
Souza et al. (2019) did not have this challenge with their study design as they 
analysed samples stored from the “SCOPE” cohort, an international pregnancy 
biobank serving to predict novel biomarkers for complications of pregnancy. 
Samples taken at 15 weeks and 20 weeks of pregnancy were analysed by GC-MS for 
164 nulliparous women from Cork, Ireland (sPTB <37 wks., n=55) and 157 
nulliparous women from Auckland, New Zealand. Decane, undecane and dodecane, 
belonging to a class called alkanes, were significantly associated with sPTB (FDR 
<0.05) at 20 weeks in the Cork subset but not in the Auckland cohort. The 
observation of elevated alkanes in the maternal serum of women who had sPTB was 
also linked by the authors to a possible oxidative stress response. However, this 
association was not seen in the most clinically important sPTB <34 weeks nor 
confirmed in the Auckland cohort, therefore their confidence remains limited in this 
finding. (Souza et al. 2019) 
A nested case-control study of samples collected prospectively from 305 
women attending with reduced fetal movements (RFM) in the third trimester of 
pregnancy examined the serum from 40 women with poor pregnancy outcomes using 
ultra performance liquid chromatography mass spectrometry (UPLC-MS) (Heazell et 
al. 2012). This was made from a composite of sPTB with normal weight centiles 
(n=3), preterm SGA (n=8), term SGA (28) and unexpected admissions to SCBU 
(n=1). The controls were taken from the same cohort and included women that had a 
normal birthweight infant with no perinatal complications (n=40). Principal 
component analysis (PCA) could not separate cases and controls. Univariate analysis 




fatty acids/organic acids and vitamin D metabolites) showed a trend towards 
decreased concentrations in the poor pregnancy outcome individuals. Two 
progesterone metabolites were significantly downregulated in the poor pregnancy 
outcome group; 17 hydroxy pregnenolone sulphate and pregnanediol-3-glucuronide, 
intermediates of progesterone production. It is possible that there is downregulation 
of the entire progesterone pathway in poor pregnancy outcomes. This study is largely 
biased by a fetal growth restriction population and it is unclear how to apply these 
results to sPTB, particularly as samples have been collected in the third trimester.  
The previously mentioned study by Virgiliou et al. (2016), took plasma 
samples from 35 women delivering at a mean of 35 (29 − 36 + 5) weeks in labour 
and compared them to 35 term controls, however all patients underwent 
amniocentesis. This group used lipid profiling and discovered that 13 lipid features 
contributed significantly to group separation, but the features could not be identified 
with their methodology. Using targeted profiling 54 metabolites were detected in 
maternal serum samples, using Orthogonal projections to latent structures-
discriminant analysis (OPLS-DA) the term and preterm groups showed separation 
based on their metabolomic profiles and 8 metabolites in the serum showed 
significance following unpaired t tests (p < 0.05). Pyroglutamic acid was found to be 
higher, while hypoxanthine and tryptophan were found to be lower in PTB samples. 
Using a second set of samples to confirm performance of serum predictors the results 
were found to be the same with the addition of choline, contributing to the 
classification of the two study groups in serum. This is the first study of maternal 
blood biomarkers that have collected blood prospectively between 14 and 23 weeks.  
Table 2.3 has summarised all significant metabolites when comparing 




a PTB cohort irrespective of whether the metabolite was increased or decreased 
relative to the control group and irrespective of the methodology; NMR or MS based 
techniques. The only study that achieves sampling at the same gestation in both the 
case and control groups is Virigliou et al (2016), and many of the top metabolites 




Table 2.3. Summary of metabolites identified in metabolomic studies of preterm labour. 
Metabolites that have been identified in four or more studies are in bold. 
Author Baraldi  Heazall  Lizewska  Maitre Menon  Romero Souza Virigliou 
Samples (total) n=31 n=80 n=131 n=363 n = 50 n=168 n=109 n=70 
PTB samples n=21 n=11 n=57 n=88 n = 25 n=112 n=55 n=35 
Mass Spec. ✓ ✓ ✓  ✓  ✓ ✓ 
NMR     ✓     
Amniotic Fluid ✓    ✓ ✓  ✓ 
Maternal Blood  ✓ ✓    ✓ ✓ 
Maternal Urine    ✓     

















Alpha sorbopyranose      ✓   
Amino acid chain ✓        
Acetate    ✓     
Acetaminophen metabolites     ✓ 
(7) 
   
Alanine    ✓     
Beta hydroxyl 
phenylethylamine 
     ✓   
Biliverdin     ✓    
Catechol      ✓   
Cholesterol      ✓   
Citrate    ✓     
Decane       ✓  
Dodecane       ✓  
Eicosanoic acid      ✓   
Fatty acids ✓ ✓ ✓(11)  ✓(18)    
Formate    ✓     
Fructose      ✓   
Galactose      ✓   
Glutamine      ✓  ✓ 
Glycerol      ✓   
Glycerolipids  ✓       
Glycerophospholipids  ✓       
Glycine    ✓  ✓   
Heptanedioic acid      ✓   
Hexose cluster       ✓(3,5,6)   
Histidine   ✓  ✓    
Hydropyridine ✓        
Hypoxanthine        ✓ 
Inositol      ✓  ✓ 
Isoleucine      ✓   
Lactate     ✓     
Leucine    ✓  ✓   
Lysine   ✓ ✓     
Mannose      ✓   
Methionine      ✓   
Methyladenine      ✓   
Muconic dialdehyde ✓        
N-acetyl glutamine      ✓   
N-methyl-2-pyridone-5-
carboxamide 
   ✓     
Phenylalanine      ✓   
Phenylacetylglutamine    ✓     
Phosphatidylcholine ✓        
Prostaglandin  ✓       
Progesterone     ✓    




Pyruvate        ✓ 
Salicylamide      ✓   
Succinate      ✓   
Steroid conjugate – 0.63    ✓     
Theophylline     ✓    
Trimethylamine    ✓     
Trimethylamine-N-oxide    ✓     
Tryptophan  ✓ ✓   ✓  ✓ 
Tyrosine    ✓     
Undecane       ✓   





       
4-hydroxynonenal alkyne ✓ 
 
       
1-methylurate     ✓    




2.5 Classification of Births  
 
It is important to be precise and consistent in defining the phenotype for a 
study population. From the omic studies discussed in this chapter there is wide 
heterogeneity between classifications of sPTB and the gestational ages of patients 
included in studies.  This is a hurdle for direct comparison of studies and makes 
meta-analysis of multiple studies arduous.   
The complexity of defining clear phenotypes of sPTB are discussed in a 
series of papers published in 2012 (Goldenberg et al. 2012, Kramer et al. 2012, Villar 
et al. 2012.). The authors of the articles in this series are recognised experts in PTB 
research across USA and Canada. They were brought together as a direct result of the 
Global Alliance to Prevent Prematurity and Stillbirth (GAPPS) meeting to define a 
prototype classification system for PTB for general consideration.  
The issues considered in their published discussions included difficulty 
defining the lower gestational age of PTB definitions. Frequently the clinical 
definition of a PTB is based on the potential for a ‘livebirth’ and excludes births 
below 23 weeks or other arbitrary gestational week, classifying this group as 
‘spontaneous miscarriage’. As causes of births between 16-22 weeks do not differ 
substantially from those after 22 weeks and the authors felt that there was no reason 
to exclude them from a classification system.  
The authors’ consensus was that the actual method of delivery (e.g. assisted 
delivery or caesarean section) should not be included in the phenotype. The focus of 
the clinical phenotype should derive from features of pregnancy and spontaneous 
labour, such as short cervix, bleeding and ruptured membranes. Risk factors such as 




data were recommended to be collected in a systematic way, it should not be part of a 
phenotypic classification system. 
The issue of potential causes such as stress and assisted reproductive 
technologies (ART) which are included in some classifications were considered but it 
was felt unless a condition can be clearly defined and there is a clear pathway to PTB 
causation it should not be included in a classification system and should also be 
reported as risk factors.  
A controversial area the authors covered was the issue of stillbirths. The 
preference of the authors was to include all births above a lower gestational age 
threshold for PTB, whether it was a termination or not. They felt “a system that 
includes some terminations but not others would likely be confusing for all” 
(Goldenberg et al. 2012). Although it is important to keep classification methods 
simple and understandable, I disagree with this rationale. My opinion is that it 
remains important that any birth included in the classification system, whether the 
infant was born alive or not, should be subject to the same phenotyping definitions 
and classifications.  Intrapartum and antepartum stillbirths should be included if the 
signs and symptoms of preterm labour are present, e.g. spontaneous contractions or 
ruptured membranes. However, if there is no evidence that the parturition process 
has started (i.e. no fluid leakage, no contractions or bleeding) and there is no 
likelihood that the baby would have delivered if not for the intervention of the 
obstetric team, it should be defined as care giver initiated or iatrogenic PTB. The 
same criteria would be applied to any livebirth or antepartum stillbirth. The key for 
the definition, in my view, is that the event of labour itself occurred spontaneously.   
To illustrate my point, if a baby with severe growth restriction was delivered 




classified as care giver initiated. If in another pregnancy, very early growth 
restriction occurred resulting in an intrauterine death before obstetric intervention 
could occur, the subsequent induction of delivery should also be classed as care 
giver initiated. By combining all stillbirths into a definition of spontaneous PTB, 
more heterogeneity of pathology is included under the umbrella term of sPTB. An 
increasingly puristic definition will only enable the scientific community to get 
closer to identifying true biological pathways and reducing “noise”.  
Despite wanting to avoid confusion, the authors recommend dividing 
iatrogenic deliveries into three or four groups of “urgent”, “discretionary”, 
“iatrogenic” or “social”. This seems to be largely unhelpful as these decisions are 
based on many factors including human decision making which itself is a very 
complex process. For the purpose of a sPTB classification, I feel that care giver-
initiated birth classifications are outside of this remit and should be identified as 
simply a single group of “care giver initiated”. Despite these areas of disagreement in 
approach, the authors make one thing clear; no matter what classification is used, it 
should be well defined with no ambiguity on how to classify difficult cases (e.g. 
threatened preterm labourers who are ultimately augmented).  
The authors subsequently published a prototype classification system based 
on their considerations and divided the phenotype into maternal, fetal, placental and 
signs of parturition (Villar et al. 2012). Manuck et al. (2015) attempted to use this 
classification system to retrospectively classify 1025 women delivering <34 weeks 
for whom data had been collected prospectively during a case-control study. They 
claimed they had successfully classified women into 9 sPTB phenotypes: 1) 
infection/inflammation, 2) decidual haemorrhage, 3) maternal stress, 4) cervical 




the membranes (PPROM), 8) maternal comorbidities, 9) familial factors. Despite a 
committed effort to apply a strict and well-defined classification system for 
phenotyping, there are certain limitations that makes this design difficult to translate 
across research studies. Firstly, 4% of that cohort had no evidence of any described 
phenotype. They were essentially unclassifiable, and this is a finding that cannot be 
ignored.  The authors could have created a 10th category for this group of women 
such as ‘unexplained PTB’. An additional 78% met the criteria for more than one 
phenotype which makes women hard to put into mutually exclusive groups for 
comparison. Unsurprisingly, in this attempt at using the prototype classification 
system by Manuck et al. (2015), more than half of women had evidence for strong, 
moderate or possible evidence of maternal stress. All clinical data including 
‘perceived stress’ was collected in the month following a PTB <34 weeks and is not 
reflective of stress levels during pregnancy. As prediction of PTB remains poor, it is 
hard to record self-reported stress, unless this is done prospectively. Evidence of 
biological stressors should be examined through omics signatures, rather than trying 
to include this in a classification system. As there is currently no clear mechanistic 
pathway to causation, this should be reported as a risk factor rather than being an 
integral part of the classification system.  
Most women in this cohort did not have antenatal cervical screening. The 
criteria for classifying “cervical insufficiency” was split into strong, moderate and 
weak. Moderate evidence for cervical insufficiency was “cervical length <1.5cm 
prior to 28 weeks”. Contrary to this assertion, this evidence should be viewed as 
exceptionally weak evidence for cervical insufficiency, if evidence at all, particularly 
in a population without previous PTB. To illustrate this point, evidence from a 




short cervix and randomised to expectant management or cerclage showed that only 
24% of women with cervix <15 mm delivered prior to 33 weeks. Therefore, although 
short cervix is certainly a recognised risk factor, it is insufficient to imply causation. 
Additionally, true cervical insufficiency has an unclear and often inconsistent 
definition. Overall, it is thought to apply to a very small group of women in the 
region of 1% of PTBs and generally presents before 24 weeks of pregnancy (ACOG 
practice bulletin No. 142. 2014). The American College of Obstetrics and 
Gynaecology defines cervical insufficiency as “the inability of the cervix to retain a 
pregnancy in the absence of contractions or labour or both”. The criteria defined in 
this study for cervical insufficiency does not make it exclusive of contractions and 
accounts for 14.4% of deliveries with a mean gestational age at delivery of 29.5 
weeks (+/-SD of 3.3). As cervical shortening and effacement must also occur in 
labour, this definition only serves to confuse these terms further. 
Therefore, an alternative classification system based on the considerations of 
these proposed classification systems of phenotyping will be used for my study and 





2.6 Methodologies for Integrating Omics  
Evaluating each ‘omic’ data type individually before integrating data is 
essential, as each data type poses unique challenges. Individual analysis methods, 
including quality control performed for each omics layer, will be presented in the 
relevant omics chapter. The methodologies to integrate the data layers will be 
discussed here.  
A review of omics data integration by Ritchie et al. (2015) broadly 
categorized all methods of data integration into two types of approaches; multi-
staged analysis and meta-dimensional analysis. (Figure 2.7)  
Figure 2.7. Alternative hypothesis of complex trait aetiology. Hypothesis A (grey arrow) is 
the theory that variation is hierarchical, such that variation in DNA leads to variation in RNA 
and so on in a linear manner. Hypothesis B (black arrow) is the idea that cross talk across 







In multi-staged analysis, predictive models are constructed in a stepwise or 
hierarchical manner reflecting hypothesis A of Figure 2.7. The analysis is divided 
into multiple steps and use genetic variation as the foundation of all the other omic 
variations. Steps usually include filtering SNPs associated with the disease on a 
genome-wide significance level, and then testing these SNPs for association with 
another level of omic data. For example, using transcriptomic data or gene 
expression levels. These SNPs are known as expression quantitative trait loci 
(eQTL). Alternatively, methylation QTLs (mQTLs) when SNPs are associated with 
DNA methylation levels or metabolite QTLs if associated with metabolite levels. 
These data are then used to test for correlation with the phenotype of interest.  
An example of such an integrative analysis is performed by Knijnenburg et 
al. (2019) who integrated molecular and clinical data for 629 families. Whole 
genome sequencing, mRNA sequencing, miRNA sequencing and DNA methylation 
profiling were carried out on maternal whole blood from the same individuals.  After 
performing a genome wide statistical test to identify candidate PTL genes, eQTL and 
mQTL analyses were performed to identify genes and methylation probes that 
overlapped with the candidate genes. Their study did not replicate the findings of the 
previously mentioned GWAS by Zhang et al. (2017) at a genome wide significance 
level of 10-8, but at a less stringent level could identify four of the same genes (albeit 
with different SNPs). Specifically, for the very early PTBs (<28 weeks) various 
significantly associated variants were uncovered as well as differentially expressed 
and methylated genes, many of which are involved in growth factor signalling, 
inflammation and immune related pathways. However, in this study maternal blood 




transcriptomics of preterm labour or involution of the uterus rather than any 
causative factor for sPTB (Knijnenberg et al., 2019). 
However, omic integration can occur on separate populations when samples 
cannot be obtained from within the same populations. Brubaker et al. (2016) 
disappointed with the poor results of multiple GWAS studies of PTB, examined top 
scoring SNPs just below genome wide threshold significance from PTB GWAS. 
They performed an integrative protein-protein interaction (PPI) network analysis 
including candidate genes associated with the relevant PTB-SNPs and myometrial 
tissue transcriptome data to try to identify networks of genes and proteins regulating 
the onset of labour. The genomic and transcriptomic data was obtained from different 
datasets but examined the same preterm labour phenotype.  Six hundred and twenty 
nine biological or cellular processes were enriched using the PTB-SNP data from a 
mixed cohort of 3,485 mother-child pairs, but when this was refined through 
functional mRNA expression data from a total of 22 tissue expression datasets (from 
either term or preterm, and both labour and non-labour myometrial tissue samples), 
38 significant subnetworks associated with preterm labour were found and 22 
networks associated with term labour. The authors concluded that TWIST1, MEF2C, 
PLA2G4C and LGALS2 may be worthy of further investigation as the MEF2C-
LGALS2 and MEF2C-PLA2G4C term subnetworks were the only ones noted to be 
dysregulated in the preterm myometrium. In term labour all these genes were 
downregulated, whereas in preterm labour they were upregulated by qRT-PCR plus 
there was evidence of coregulation of these genes. TWIST1 acts to modulate 
downstream genes and is a repressor of MEF2C, it carries a PTB associated SNP, 




NF-KB signalling pathway. Biological plausibility was offered for PLA2G4C as it is 
a phospholipase which regulates prostaglandin synthesis independent of oxytocin.  
Meta-Dimensional Analysis  
In meta-dimensional analysis all omics data are combined simultaneously to 
create a multivariate model associated with a given outcome, reflecting hypothesis B 
of Figure 2.7 (Ritchie et al. 2015). This allows for combinations of heterogenous 
datatypes, including clinical data and assays that cannot be mapped back to a specific 
gene. The three main approaches for this type of analysis are concatenation-based 
integration, transformation-based integration and model-based integration (Ritchie et 
al. 2015). 
Concatenation Based Integration  
In concatenation-based integration all available datasets are merged into a 
single matrix for modelling. An advantage of this method is that once a data matrix 
has been created, then multiple statistical tests or machine learning methods for 
modelling can be applied to the data for analysis. The challenge for this type of 
integration is identifying the best way to combine different types of data in a 
meaningful way, whilst avoiding bias from certain data types and ensuring it is 
computationally feasible (Ritchie et al. 2015).  
Transformation Based Integration 
Here data is combined only after the original data has been transformed into an 
intermediary state, such as a kernel or graph matrix. This is a matrix that represents 
relative positions of all samples by valid graph or kernel functions. In short, kernels 
allow transformation of randomly distributed or linearly inseparable data to linearly 




is robust to different measurement scales, but some data-specific properties may be 
lost when integrating them. As data is transformed independently, it may make it 
difficult to detect some of the effects between e.g. SNP/gene and metabolite 
interaction if the transformation removes the ability to detect the original interaction 
(Ritchie et al. 2015).  
Model-Based Integration 
In this method each omic data type is used as a training set to develop a 
model. A final model is then created from these training set models (Figure 2.8) 
which preserves the data specific properties. However, these methods of model 
integration are well known for overfitting and is suitable if the data types to combine 
are extremely heterogenous and the other methods of concatenation and 
transformation are not suitable.  
To my knowledge, Ghaemi et al. (2019) have performed the only study that 
has attempted to do this type of omics combination in pregnancy.  They compared 
multivariate predictive modelling using an Elastic Net (EN) algorithm to predict 
gestational age. Using stacked generalisation, the individual omics models were then 
combined into a single model. Three hundred and fifty seven samples taken at 51 
separate timepoints from seventeen women with term pregnancy were analysed for 
seven omic subtypes; cell-free transcriptomics, antibody-based cytokine 
measurements in plasma and serum, microbiome analyses (of vaginal swabs, stool, 
saliva and tooth/gum), mass cytometric analyses of whole blood, untargeted 
metabolomics and targeted proteomics analysis of plasma (Ghaemi et al. 2019). 
Their multi-variate analysis algorithm (EN model) with cross-validation steps (leave-
one-subject-out) were compared to the other machine learning algorithms of Random 




increased their predictive power by combining all the datasets and revealed novel 
biological interactions. A strong relationship between pregnanolone sulphate and the 
behaviour of the NF- ΚΒ myeloid dendritic cells and regulatory T cells was revealed 
by the model. These play a critical role in feto-maternal tolerance. Although 
modulation of immune cell function by progesterone and its derivatives is not a new 
concept, the specific immune cell subsets of this action are not well understood. 
Additionally, a strong interaction between the transcript of protein factor CSH-1 
(cell-free RNA) and STAT5activity in CD4+ T cells, may suggest that CSH-1 may 
directly activate the JAK2/STAT5 signalling pathway in CD4+ and CD8+ subsets in 
pregnancy. However, the limitations of this study are that the number of subjects in 
this proof of concept project (n=17) are small compared to the large number of 
variables generated by the seven omics platforms described increasing the possibility 




















































































































































































Prediction Modelling Bias-Variance Trade Off 
An important concept to understand in prediction modelling is the trade-off 
between a model’s ability to minimize bias and variance (Figure 2.9), the prediction 
errors leading to underfitting and overfitting a model. It is important to understand 
how closely the model follows the actual patterns of the data. 
Variance is the variability of a model prediction for a given data point or a 
value which tells us the spread of the data. A model with a high variance pays a lot of 
attention to training data and doesn’t generalise on data points that it has never seen. 
As a result, these models perform well on training data but has a high error rate on 
test data. This is also known as ‘overfitting’.   
Bias refers to the gap between the value predicted by your model and the 
actual value of the data. (Theobald. 2017. pp 93). A high bias can cause an algorithm 






Figure 2.9. Targets used to represent the trade-off between bias and variance. Adapted 











2.7 Limitations of omics approaches and data integration  
Multiple technical platforms are usually available for the same type of -omic. 
Various manufactures produce multiple versions of e.g. microarray and sequencing 
platforms which have different coverage of the genome. Alternatively, different 
types of technology can be used to investigate the same -omic, such as MS and NMR 
for metabolomics investigation which will ultimately result in the identification of 
different compounds within the same sample. Advances in technology usually mean 
that improvements in quality occur with new versions and researchers are keen to 
take advantage of the latest developments.  This technological heterogeneity makes 
reproducibility, validation and meta-analysis of results challenging. 
There are systematic differences in high throughput data between different 
laboratories, batch-effects and multiple operators which is widely accepted and 
documented. Efforts are made to reduce “batch-effects” by standardising 
experimental protocols and applying quality control steps prior to data analysis, but it 
is impossible to completely eliminate batch effects. They can be responsible for 
spurious findings unrelated to the outcome of interest. Using methods to account for 
these variations and applying appropriate statistical models such as mixed-effect 
models can at least address some issues in technical variation.  
Genomics is a unique -omic in so far as the genome is fixed per individual 
cell and tissue type; how the genome is expressed and the subsequent molecular 
states existing in each tissue will vary dramatically and will also be influenced by 
environmental factors. Therefore, the selection of tissue type for disease study and 
the heterogeneity of tissues chosen will play a factor in -omic combination and 
choosing the same fluid or tissue is preferable. Even within a tissue, a sample will 




of results depending on proportions of cell types within samples. Using purified cell 
types can be an answer but can become unrealistic when faced with the cost of 
performing different omics on multiple cell types. 
Recruitment to PTB studies will always remain challenging due to the 
difficulty in prediction of sPTB, the relatively low incidence in the general 
population and trying to clean or split data even further to investigate very specific 
phenotypes. Individual studies are almost certainly going to be underpowered for 
multiple omics analysis, and one solution is to try and improve power by obtaining 
more data. Meta-analysis of omics data may be the only way that power will be 
increased sufficiently to enable identification of candidate pathways following 
millions of comparisons between so many data points. This in itself poses its own 
challenges as data is likely to be collected, processed and recorded in very different 
ways introducing bias between studies for meta-analysis, as has been a challenge 
historically for comparison of randomised clinical trials.  
We are also limited by our current knowledge of gene-transcript-protein-
metabolite interactions. In network analysis we rely on pre-existing knowledge to 
inform pathways of data. The same analysis performed on the same data in the future 
may reveal a completely different result as our knowledge about the function of the 
human body in pregnancy at a cellular and sub-cellular level is likely to increase and 
pathways will become increasingly informed.  
Data reduction necessary to create models that are computationally feasible 
may accidentally filter out important associations. For example, a single functional 
SNP may associate with sPTB. However, if this SNP is in linkage disequilibrium 
with another non-functional SNP, the functional SNP may be filtered out in favour of 




any model and limitations of analysis before making inferences and interpretations of 





The development in “omics” technology has led to exciting breakthroughs 
and new avenues of investigation for sPTB prediction.  Although we are yet to 
translate these changes to clinical and patient benefit our increasing understanding of 
the complex pathways underpinning sPTB is increasing and this is a promising and 










Having argued in the previous chapter the importance of using omics 
technology for the prediction of sPTB and provided an overview of the various 
methodologies available; this chapter will describe the design and methodology 
selected to combine omics datasets for preterm birth prediction and investigate sPTB 
phenotypes using multiple omics and systems biology approaches. It was important 
to design a study that minimizes the limitations of the omics approaches described in 
chapter 2, to remain focused on the research hypothesis, but still to be sufficiently 
pragmatic to be achievable. 
Chapter 1 demonstrated that current ability to predict sPTB remains poor as 
mechanisms of disease are not understood. Currently used screening methods are 
insufficient to detect all women at risk. The sequelae of preterm birth can lead to 
significant mortality and morbidity and there is a clear need for improvements in 
disease prevention, which cannot be obtained until we have a better understanding of 
causation or a more robust way of accurately discriminating those at high risk.  
Our ultimate goal is to establish clinically useful personalized risk assessment 
with a combination of clinical and comprehensive molecular phenotyping. This 
approach will lead to better and safer use of currently available preventative 
therapies (drug repositioning) and development of novel, more effective therapies 






To investigate preterm birth phenotypes by using multiple omics and systems 
biology approaches in high risk population. My goals were: 
• To recruit over a 3-year period a prospective cohort of women with sPTB at 
<34 weeks gestation (cases) and a cohort of women with spontaneous term 
delivery (controls). All women should have well-characterized clinical 
phenotypes with biologic samples suitable for multi-platform systems biology 
analysis that were collected at a minimum of 2 time points during gestation 
and at delivery. 
• To apply multi-omic high-throughput technologies to generate longitudinal 
datasets. 





3.3 Population Identification 
The samples used for analysis in this study come from participants recruited as 
part of “The development of novel biomarkers for prediction of preterm labour in a 
high-risk population” study” (REC reference: 11/NW/0720) collected between 1st 
March 2012 and 28th May 2015 (Appendix A and B). This project was co-sponsored 
by Liverpool Women’s Hospital and the University of Liverpool (Appendix C). 
Women were consented and recruited at the Liverpool Women’s Hospital Harris-
Wellbeing Preterm Birth Prevention Clinic. In routine clinical practice women are 
screened for a short cervix in pregnancy if they have:  
• a history of sPTB or PPROM (between 16 and 33+6 weeks), or  
• if they have had significant excisional treatment of the cervix (2 x Large 
Loop Excision of the Transformation Zone (LLETZ) or single knife cone 
biopsy) from 16 weeks pregnancy onwards.  
To try to avoid large variation in aetiology of sPTB in our recruited women we 
limited this study to women who had only had a history of sPTB or PPROM. Women 
attending because of a history of excisional cervical surgery but no history of preterm 
labour were excluded.  
Our clinical audit figures from 2010-2013 showed that at the Liverpool Women’s 
Hospital the sPTB rate <34 weeks is 17% for women with a history of sPTB or 
PPROM. In 2011, 135 new women were referred, 95 (70%) had a history of sPTB or 
PPROM <34 weeks. Estimating a 50% recruitment rate, we expected to recruit 140 
women over 3 years, and approximately 24 cases of sPTB <34 weeks. The advantage 
of recruiting cases experiencing a recurrent preterm birth is that there may be 
positive selection of aetiologies of sPTB inherent to the mother rather than an 




may be more likely to have two pregnancies affected by sPTB than if infection was 
the cause, which may only affect a single pregnancy.  
Women with a history of sPTB or PPROM who had a subsequent term birth 
without treatment for short cervix were used as a control group.  
Inclusion Criteria  
• Previous PPROM >16 and <34 weeks 
• Previous sPTB >16 and <34 weeks 
• Singleton pregnancy 
• Willing to undergo transvaginal ultrasound scan 
• Age >18 years 
• Understands English 
• Understands study requirements, agrees to participate and written consent 
obtained. 
Exclusion Criteria 
• Iatrogenic PTB  
• PPROM <16 and >34weeks 





3.4 Time points and Sampling  
Two time points were chosen for sampling; 16 and 20 weeks. Serial sampling 
was chosen to provide more information than isolated measurements of biomarkers 
at a single timepoint. 
Sixteen weeks is the gestation at which high risk patients commonly attend 
for their first cervical length screening (Care et al. 2019). This is after the risk of first 
trimester miscarriage has passed, but prior to the risk of late second trimester 
miscarriage or preterm birth. At the first visit to the clinic, a member of the clinical 
staff recruiting team would discuss the project and provide an information leaflet to 
the potential participant (Appendix D). The woman would have her clinical 
appointment as normal and if she agreed to participate, a consent form was signed 
(Appendix E). Bloods were taken at the end of the appointment when the participants 
data was also collected. Twenty weeks is four weeks prior to the risk of sPTB and 
when low risk women would routinely attend hospital for anomaly scan, which 
would facilitate rolling out any successful screening tests.  
As recommended by the World Health Organisation (Wilson and Jungner. 
1968), a good screening test would detect pathology early to allow for enough time 
for intervention to decrease this risk. Sampling at 16 and 20 weeks in an 
asymptomatic population would hopefully allow for this time prior to the onset of 
labour. Although blood taking is widely accepted in medicine as a necessary test for 
a variety of conditions, it is invasive and can be painful. More frequent sampling 
every two weeks was considered. However, it was likely to deter women from 
participating. Accordingly, 16 and 20 weeks were considered to be the most useful 




Three omics layers per patient were selected to be analysed from blood for 
predictive biomarkers of preterm birth; genetics, transcriptomics and metabolomics. 
Venepuncture performed with BD Vacutainer® Eclipse™ blood collection needles 
allowed for a:  
• 6ml BD vacutainer® K2EDTA for maternal genome (lavender small),  
• 2.5ml PAXgene Blood RNA Tube  
• 6ml BD vacutainer® tubes containing clot activator for biomarkers (red 
tube) to allow storage of serum for metabolomics study 
All samples were inverted 10 times to allow for mixing between the blood and tube 
reagents then stored on ice immediately after collection until taken to the 
laboratory at a convenient time but no more than 1 hour after sampling. Samples 




3.5 Method of Classification 
 
Hospital records were used to ascertain delivery details for all women giving 
birth at Liverpool Women’s Hospital. For participants that delivered elsewhere, the 
research department at the delivering unit were contacted and asked to provide 
delivery details. Where this was not possible, as a final resort, participants were 
contacted directly by telephone. 
Figure 3.1 shows the workflow for the classification of births, and Table 3.1 
shows how clinical diagnoses were defined. The judgement of the 
contemporaneously recorded treating clinicians was used to record diagnoses unless 
further information became available later that refuted this. The clinical notes of 
participants whose first event (sPTB or PPROM) was ≤36+6 weeks gestation was 
accessed and reviewed independently by myself and senior clinical lecturer, Dr 
Andrew Sharp. In the cases where there was a discrepancy between reviewers, the 
case was reviewed by a third researcher, Professor Zarko Alfirevic, until the team 
reached a consensus on classification of the birth. Both Professor Alfirevic and Dr 
Andrew Sharp and have extensive experience both clinically and in research, in the 
field of preterm birth. They have both worked at the specialist preterm birth 
prevention clinic in Liverpool Women’s Hospital since it opened in 2010 and have 
published research papers in this field. 
For patients with PPROM the gestation at the time of ruptured membranes was 
taken as the significant gestation for the analysis, rather than the gestation at 
subsequent birth. For women with spontaneous preterm labour, the gestation at birth 
was used as the significant gestation for analysis. 
Additional risk factors and phenotypic pregnancy features related to preterm 




system. Table 3.2 shows a collection of risk factors that have been defined for 
reporting. An additional step was included for the women who had PPROM to 
describe whether infection was thought to be present at the time of PPROM. 
Infection is considered a cause of PPROM and a consequence of ascending genital 
tract infection without protection from intact membranes. Therefore, a seven-day 
period was used to distinguish between early chorioamnionitis (likely cause of 
PPROM) and late chorioamnionitis (likely consequence of PPROM). This workflow 
is detailed in Figure 3.2.  
If an intrauterine death or termination of pregnancy had been preceded by 
PPROM, this was included as a PPROM case. In cases where there was an induction 
of labour for suspected PPROM both the method of diagnosis (history and pad check 
only, history and speculum examination +/- bedside test +/- USS of mean pool depth 
of AF) and the success of the induction were evaluated. In cases where there was no 
definitive method of PPROM diagnosis (e.g. history and pad check only) or there 
was suspicion of a false positive diagnosis (recurrent USS showing normal AF 
volumes) the case would be excluded if an artificial rupture of membranes (ARM) 
was required during labour to facilitate progress.  
For cases where there was either growth restriction <5th centile or severe pre-
eclampsia diagnosed, providing that the onset of preterm labour was spontaneous 
these cases were included in our definition and these risk factors reported as possible 
signs of placental dysfunction.  
Threatened preterm labour that was later augmented were excluded (i.e. no 




































































The workflow used the following definitions: 




Regular uterine activity with cervical shortening or dilation 
such that the treating clinicians judged labour to be present 
Prelabour rupture 
of membranes 
Rupture of membranes confirmed either by speculum 
examination or the AmniSure ROM or ActimPROM bedside 




Induction of labour or Caesarean section ≤36+6 weeks 
gestation without evidence of PPROM or spontaneous 
preterm labour 
 
Figure 3.2. Workflow for additional classification for women with PPROM. See Table 3.2 for 
definition of chorioamnionitis. 
No
Evidence of chorioamnionitis within 7 
days of membrane rupture
Yes
PPROM with early onset 
chorioamnionitis
Additional classification for 
PPROM





Table 3.2. Definitions of contributing factors to sPTB based on the clinical phenotyping tool 
developed by Villar et al. (2012). 
Contributing 
factors to preterm 
birth 
Description 
Chorioamnionitis Contemporaneous clinical notes documenting diagnosis of 
chorioamnionitis due to one or more of; persistent 
maternal pyrexia (≥38oC), purulent or foul-smelling 
amniotic fluid, or the use of broad spectrum antibiotics to 
treat chorioamnionitis based on the clinical situation and 
evidence of chorioamnionitis on placental histology or 
blood culture. 
Note: IF histologic evidence of chorioamnionitis only and 
no clinical features this was classified as subclinical 
chorioamnionitis. 
Placental dysfunction Evidence of placental dysfunction contributing to preterm 
labour. Defined as evidence of placental abruption at time 
of delivery or on placental histology report, birthweight 
under 5th customised centile, or severe preeclampsia  
Extra amniotic 
infection  
Contemporaneous clinical notes documenting concern 
about major systemic infection due to one or more of; 
raised white cell count (>15 x 109/L), raised C-reactive 
protein (CRP >30), persistent maternal pyrexia (≥38oC), 
microbiological culture of pathological organism from a 
normally sterile site, or the use of broad-spectrum 
antibiotics for presumed extra amniotic infection (e.g. 
UTI). 
Polyhydramnios  Maximum pool depth ≥ 10cm on ultrasound assessment 
Uterine anomaly  Documented uterine anomaly 
Maternal 
comorbidities 
Maternal medical condition that affects a major organ 
system or is associated with preterm birth (for example 
antiphospholipid syndrome, chronic hypertension, chronic 
renal failure, Elhers-Danlos syndrome, epilepsy, pre-
existing and gestational diabetes) 
Cervical shortening Received treatment for short cervical length <28 weeks 
gestation. Short cervix is defined as ≤25 mm or <3rd 
centile for gestational age on a validated cervical reference 







All participants were classified in the following mutually exclusive categories: 
Table 3.3. Final classification system. Term births highlighted in green were included as 




Major classification Description of birth 






Term Birth ≥37+0 weeks gestation; no Rx 
for short cervix 
Birth ≥37+0 weeks gestation; Rx for 
short cervix. EXCLUDED 
Caregiver initiated 
preterm birth 
Caregiver initiated preterm birth 
Early PPROM PPROM ≤33+6 weeks gestation with 
early chorioamnionitis 
PPROM ≤33+6 weeks gestation with 
polyhydramnios 
PPROM ≤33+6 weeks gestation 
without early chorioamnionitis 
Late PPROM PPROM 34+0-≤36+6 weeks gestation 
with early chorioamnionitis 
PPROM 34+0-≤36+6 weeks gestation 
without early chorioamnionitis 
Early sPTB sPTB ≤33+6 with evidence of 
infection 
sPTB ≤33+6 without evidence of 
infection 
Late sPTB sPTB 34+0-≤36+6 




3.6 Sample Size and Power Calculation 
A challenge for multiomic studies is obtaining enough samples to power 
results. The power of a study is the probability of successfully detecting a given 
effect size. The importance of this remains paramount, as reflected by the American 
National Institute of Health’s funding application non-optional component of sample 
size and power analysis. Yet statisticians face challenges when asked to estimate a 
sample size required for a multiomics study.  Classical methods for calculating 
statistical power to reject a null hypothesis at a specified level of significance are not 
applicable to this problem (McKeigue. 2019). In “omics” the high dimensionality is a 
source of difficulties since the number of variables vastly exceeds the number of 
samples or participants in the studies. Some “omics” studies focus on reducing the 
risk of making a false assertion that an observed difference is true when it isn’t (type 
1 error). In GWAS studies, allele frequencies and effect size are taken into 
consideration and then a correction (e.g. Bonferroni correction) is applied for 
multiple comparisons. Most analyses of GWAS data sets consider genetic variants on 
a microarray chip comparing hundreds of thousands of SNPs. This leads to a 
stringent statistical cut-off level that defines a true variant for common and complex 
diseases (p value threshold of <5 x 10-8). Many sub significant hits may also be 
mapped to genes involved in disease that are true risk loci but differentiating them 
from false positives is difficult. 
Power analysis for high throughput sequencing based experiments (not used 
in this thesis) are even more complex. Firstly, due to the unique parameters for 
sequencing read depths that directly affect the ability to detect variants or gene 
expression and therefore need to be considered in the power analysis (Li et al. 2018). 




microarray, introducing a variation of unique statistical scenarios (Li et al. 2018). 
The data platforms used for omics studies assay thousands of SNPs, gene transcripts 
and metabolites to try and account for individual differences in disease susceptibility. 
Methods described to date for estimating the sample size required for classification 
using high dimensional biomarkers require more understanding of how changes in 
one variable are associated with changes in a second variable, or covariance of the 
biomarkers (Dobbin and Song. 2013).  
Unfortunately, most of the published methodologies for microarray 
summarised by Lin et al. (2010) and Jung et al. (2012) and high dimensional data (Li 
et al. 2018) are restricted to two group (case-control) comparisons and require a user-
defined effect size. This does not allow for comparison of three groups (PPROM, 
sPTB and control). Additionally, power is calculated individually on each type of 
omics analysis, to date there has been no described method to perform a power 
calculation for multiomics data from the same patient and published studies that have 
attempted omics data combination in omics have not discussed a power calculation 
(Knijnenberg et al. 2019). 
It might be tempting to increase sample sizes in groups by retaining a broad 
classification for sPTB, e.g. including all patients who deliver <37 weeks or 
combining cases of sPTB and PPROM. Unfortunately, this is likely to have the 
opposite effect, as increasing the heterogeneity within study groups makes it very 
difficult to separate true signals from noise and importantly it will become harder to 
validate the results. Clear or stricter phenotyping of sPTB will reduce the potential 
number of samples included in the analysis, but it may serve to increase biological 




the issue of heterogeneity is almost an inherent problem until we better understand 
the causes.  
Women experience labour at different gestational ages, experience different 
symptoms of labour, if at all. They rupture membranes and/or experience 
contractions and dilate the cervix at different relative time points of pregnancy and 
experience differences in predictive symptoms such as bleeding or a short cervix. 
However, there is sufficient evidence that, as a minimum, sPTB and PPROM behave 
differently to each other (Capece et al. 2014). 
A strength of omics data combination is that by combining multiple data 
types, this can provide increased power. Data integration can compensate for missing 
data in any single data type and multiple sources of evidence all pointing to the same 
biological pathway or gene reduce the likelihood of a false positive result.  
Our study sample is not therefore based on an a priori power calculation. 
This is a pilot analysis of the samples available from this project collected between 
1st March 2012 and 28th May 2015 to assess: 
• How many samples could be collected 
• How much ‘omics’ data would be available following quality control 
of samples due to technical requirements of the laboratory, 
• Financial limitations  





One hundred and twenty-nine women were recruited to the study. Written 
consent was obtained at the time of the first blood collection. One participant was 
subsequently excluded as she had previously only had an episode of threatened 
preterm labour. According to clinician signatures on the consent forms, I personally 
recruited 80% of all 128 participants. All women were followed up and gestational 
ages at delivery were obtained. For five participants birthweights were not available.   
Pregnancy Outcomes and Classifications 
Table 3.4 shows the final numbers recruited to each category of cases and 
controls. Twenty-four exclusions are detailed. For sPTB, PPROM and term control 
cases (highlighted in colour in Table 3.4) their demographics are shown in Table 3.5. 
Excluded cases 
Three cases were excluded as they were caregiver-initiated (iatrogenic) 
preterm births. These women did not require treatment for a short cervix and were 
delivered at 34+1, 35+3 and 36+1 for maternal cancer treatment, poorly controlled 
diabetes and fetal growth restriction respectively.  
All women who had received preterm birth prevention treatment and had a 
delivery after 37 weeks were excluded. We are unable to tell if the treatment they 
received affected the natural history of biological events and presume that 
intervention prevented a sPTB. However, it is entirely possible that some of these 
women may have achieved a term delivery without prevention treatment. As this 
group may have heterogenous biomarkers of risk, they have been excluded 




PPROM at 17+1 was found to have a supernumerary ring chromosome in 17/20 cell 




Table 3.4 Pregnancy outcomes following delivery of 128 participants. Control cases 
highlighted in green. Preterm prelabour rupture of the membranes (PPROM) cases 





Description of birth Number Recruited 







Term Birth ≥37+0 weeks gestation; 
no Rx for short cervix 
60 
Birth ≥37+0 weeks gestation; 






Caregiver initiated preterm 





discovered on post-mortem 
that may have influenced 
miscarriage risk - 
EXCLUDED 
1 
Early PPROM PPROM ≤33+6 weeks 
gestation with early 
chorioamnionitis 
2 




PPROM ≤33+6 weeks 
gestation without early 
chorioamnionitis or known 
polyhydramnios 
10 
Late PPROM PPROM 34+0-≤36+6 weeks 
gestation with early 
chorioamnionitis 
1 
PPROM 34+0-≤36+6 weeks 
gestation without early 
chorioamnionitis  
0 
Early sPTB sPTB ≤33+6 with evidence of 
infection  
2 
sPTB ≤33+6 without evidence 
of infection 
12 





Table 3.5. Demographics for participants in biomarker study split into women delivering 
after 37 weeks, Preterm prelabour rupture of membranes (PPROM) <34 weeks and 













Maternal age, mean years +/- SD 31 (6.7) 29 (5.3) 31 (5.2) .538a 
Booking BMI, mean +/- SD 27 (5.9) 25 (3.4) 25 (4.2) .289a 
Ethnicity     
Caucasian, n(%) 14 (100) 12 (92) 54 (89) .396b 
Non-Caucasian, n (%) 0 1 (8) 7 (11) 
Smoking during pregnancy   
Yes, n(%) 1 (7) 5 (39) 16 (26) .158b 
No, n(%) 13 (93) 8 (61) 45 (74) 
Clinical Characteristics 
Gravidity, mean+/-SD 3.21 (1.3) 2.9 (1.2) 3.4 (1.6) .503c 
Parity 1.21 (0.8) 1.36 (0.9) 1.75 (1.6) .422c 
History of previous PTB 
Previous sPTB, n (%) 6 (43) 5 (39) 27 (44) .187b 
Previous PPROM, n (%) 6 (43) 6 (46) 33 (54) 
Both previous sPTB and PPROM 
(%) 
2 (14) 2 (15) 1 (2) 
Previous twin sPTB, n (%) 0 0 0 N/A 
Cervical surgery, n (%) 3 (21) 1 (8) 1 (2) .002b 
Gestational age, visit 1, mean +/- SD 
days 
16+3 (6) 16+3(4) 16+3 (5) .908a 
Cervical length visit 1, mean +/- SD 33.3 (7) 35.5 (9) 36.5 (6) .352a 
Gestational age, visit 2 143 (7) 20+3 (4) 20+2 (6) .860a 
Cervical length visit 2, mean +/- SD 21.8 (12) 27 (12) 36.4 (7) .000a 
Antiphospholipid Syndrome     
Yes, n (%) 0 0 0  
No, n (%) 14 (100) 13 (100) 61 (100) N/A 
Other chronic medical conditions     
Yes, n (%) 9 (64) 10 (77) 24 (39) .022b 
No, n (%) 5 (36) 3 (23) 37 (61) 
Polyhydramnios      
Present, n (%) 0 1 (8) 0 .054 b 
Absent, n (%) 14 (100) 12 (92) 61 (100) 
Labour and Delivery Characteristics 
Onset of labour     
Spontaneous 12 (86) 3 (21) 33 (54) .011b 
Induction 2 (14) 10  (71) 19 (31) 
No labour 0 1 (7) 9 (15) 
Gestational age at PPROM, mean 
+/- SD  




Gestational age at delivery, mean +/- 
SD days 
29+0 (33) 29+2 (40) 39+1 (9) .000a 







Neonatal gender      
Female, n (%) 5 (36) 8 (62) 23 (38) .471b 
Male, n (%) 8 (57) 5 (38) 35 (57) 
Not recorded (%) 1 (7) 0 3 (5) 
Placental Abruption      
Yes, n (%) 0 0 0 N/A 
No, n (%) 14 (100) 14 (100) 61 (100) 
Chorioamnionitis / Infection     
Yes, n (%) 2 (14) 2 (15) 0 .009b 
No, n (%) 12 (86) 11 (85) 61 (100) 
Growth <10th centile     
Yes, n (%) 2 (14) 3 (21) 11 (18) .922b 
No, n (%)  11 (79) 11 (79) 48 (79) 




3.8 Recruitment Feasibility 
Monthly recruitment rates are shown below in Table 3.6 with the average 
monthly recruitment figures in Figure 3.3.  
Table 3.6. Monthly recruitment figures. 
Month Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec 
2012  - - 1 5 3 2 2 2 1 1 4 0 
2013  3 4 6 4 7 1 10 2 4 2 1 3 
2014  2 1 3 2 3 2 4 3 1 4 7 5 
2015.  6 5 4 6 9 - - - - - - - 
 
 
Figure 3.3. Average monthly recruitment figures per year of study from LWH preterm birth 
prevention clinic. The X axis shows year of recruitment and the Y axis shows average 
number of recruited women per month.  
 
Overall there was a gradual increase in recruits per month. There are several 
possible reasons for this; firstly, the preterm labour clinic increased the overall 
number of new patients from 2012 to 2015, increasing the number of eligible 
participants. Secondly, once more funding was available laboratory staff were 





































and recruit. Thirdly, to prevent eligible patients attending clinic at the same time, and 
therefore reducing the likelihood of only one patient being recruited eligible patients 
were offered appointments approximately 30 mins apart when possible. Lastly with 
time, the running of the study became more efficient with increasing help from the 
other clinical and auxiliary staff. 
In the laboratory, no RNA was extracted following an extraction run of 24 
samples (12 patients) due to an error with the reagents from a single defective RNA 
extraction kit. This was identified and rectified with the kit supplier, but these 
samples were lost.  This is likely to be an isolated incident but for future studies, 
performing a test run with an individual sample when opening a new kit would be 
advised to avoid the loss of samples. The total number of patients from 56 that ended 
the study with a complete set of omic data at both time points was 25 (45%), 
although this could have been as high as 37 (66%) if RNA had not failed to be 
extracted.  
For full omics integration, late sPTB and PPROM were excluded to try 
creating distinct biological groups to identify biomarkers for clinically important 
preterm birth. However, for independent omics analysis such as GWAS (where meta-
analysis with other studies would be possible), a cut-off of 37 weeks has been used 





3.9 Study Samples for Omic Integration  
At several stages of the recruitment process it was possible to reduce the 
number of samples contributing to the final omics analysis. Figure 3.4 illustrates at 
what stage a sample could be excluded from the dataset and the reason.  
Table 3.7 illustrates how many individual participants had datasets available 
for each layer of omics analysis and Table 3.8 shows how many participants had 





ONLY SAMPLED AT ONE TIMEPOINT 
Participant only recruited at second timepoint 
Participant did not attend scheduled follow-up 
ERROR AT VENIPUNCTURE 
Failure to collect sample, multiple attempts at collecting blood. 
Haemolysis during sampling 
Underfilling of sampling tube, inadequate ratios of blood to 
anticoagulant medium  
Specimen compromised  - e.g. clotting 
Unacceptable specimen – wrong tube container, incorrect labelling.  
  
LABORATORY ERROR 
Sample overturned, pipetting error. 
Sample unacceptable for analysis – not labelled in freezer 
 
SAMPLE PROCESSING / QUALITY CONTROL 
DNA / RNA degraded during storage or extraction.  
Contamination of sample 
Does not meet quality control thresholds  
Kit/Reagent Failure 
 




Table 3.7. Omics data collected for all 103 included pregnant participants (exclusions 























Yes No No No Yes No No 
2 TERM 
CONTROL 
Yes No No Yes Yes No No 
3 TERM 
CONTROL 
Yes No No No Yes No No 
4 TERM 
CONTROL 
Yes No No Yes Yes No No 
5 TERM 
CONTROL 
Yes No No Yes Yes No No 
6 TERM 
CONTROL 
Yes No No Yes Yes No No 
7 TERM 
CONTROL 
Yes No No Yes Yes No No 
8 TERM 
CONTROL 
Yes No No Yes Yes No No 
10 TERM 
CONTROL 
Yes No No Yes Yes No No 
12 TERM 
CONTROL 
Yes No No Yes No No No 
13 TERM 
CONTROL 
Yes No No Yes No No No 
14 LATE sPTB Yes No No Yes Yes No No 
15 LATE sPTB Yes No No Yes Yes No No 
16 PPROM Yes No No Yes Yes No No 
17 PPROM Yes No No Yes Yes No No 
18 TERM 
CONTROL 
Yes No No Yes Yes No No 
19 LATE sPTB Yes No No Yes Yes No No 
20 sPTB Yes No No Yes No No No 
21 TERM 
CONTROL 
Yes No No Yes Yes No No 
22 TERM 
CONTROL 
Yes No No Yes Yes No No 
23 TERM 
CONTROL 
Yes No No Yes No No No 
24 TERM 
CONTROL 
Yes No No Yes Yes No No 
25 TERM 
CONTROL 
Yes No No Yes Yes No No 
27 TERM 
CONTROL 
Yes No No No Yes No No 
28 TERM 
CONTROL 
Yes No No Yes Yes No No 
29 TERM 
CONTROL 
Yes No No Yes Yes No No 
31 TERM 
CONTROL 
Yes No No Yes Yes No No 
32 PPROM Yes No No Yes Yes No No 
33 PPROM Yes No No Yes Yes No No 
34 sPTB Yes No No Yes Yes No No 
35 sPTB – 
infection 
Yes No No No Yes No No 
37 PPROM Yes No No Yes Yes No No 






Yes No No Yes Yes No No 
41 TERM 
CONTROL 
Yes No No Yes Yes No No 
43 LATE sPTB Yes No No Yes Yes No No 
44 TERM 
CONTROL 
Yes No No Yes Yes No No 
45 TERM 
CONTROL 
Yes No No Yes Yes No No 
46 TERM 
CONTROL 
Yes No No Yes No No No 
47 TERM 
CONTROL 
Yes No No Yes Yes No No 
49 sPTB Yes No No Yes Yes No No 
52 TERM 
CONTROL 
Yes No No Yes Yes No No 
53 sPTB Yes No No No Yes No No 
54 PPROM + 
chorio 
Yes No No Yes Yes No No 
55 sPTB Yes No No Yes Yes No No 
57 LATE sPTB Yes No No Yes Yes No No 
59 TERM 
CONTROL 
Yes No No Yes Yes No No 
60 PPROM Yes No No Yes Yes No No 
61 TERM 
CONTROL 
Yes No No Yes Yes No No 
62 TERM 
CONTROL 
Yes No No Yes Yes No No 
63 sPTB Yes No No Yes Yes No No 
65 sPTB – 
infection 
Yes No No Yes Yes No No 
66 sPTB Yes No No Yes Yes No No 
67 LATE sPTB Yes No No Yes No No No 
68 TERM 
CONTROL 
Yes No No Yes Yes No No 
73 PPROM Yes Yes No Yes No Yes No 
74 TERM 
CONTROL 
Yes Yes Yes Yes Yes Yes Yes 
75 sPTB Yes Yes Yes Yes Yes Yes Yes 
76 TERM 
CONTROL 
Yes Yes Yes Yes No Yes No 
77 TERM 
CONTROL 
Yes Yes Yes Yes Yes Yes Yes 
78 PPROM Yes Yes Yes Yes Yes Yes Yes 
79 TERM 
CONTROL 
Yes Yes Yes Yes Yes Yes Yes 
81 PPROM + 
chorio 
Yes Yes No Yes No Yes No 
82 PPROM Yes Yes Yes Yes Yes Yes Yes 
83 sPTB Yes Yes Yes Yes Yes Yes Yes 
84 LATE sPTB Yes Yes Yes Yes Yes Yes Yes 
85 sPTB Yes Yes Yes Yes Yes Yes Yes 
86 TERM 
CONTROL 
Yes No Yes No Yes No Yes 
87 TERM 
CONTROL 
Yes Yes Yes Yes Yes Yes Yes 
88 sPTB Yes Yes Yes Yes Yes Yes Yes 
89 TERM 
CONTROL 
Yes Yes No Yes Yes Yes No 






Yes No Yes No Yes No Yes 
92 LATE sPTB No Yes Yes Yes Yes No No 
95 TERM 
CONTROL 
Yes Yes Yes Yes Yes Yes Yes 
96 TERM 
CONTROL 
Yes No Yes Yes Yes No Yes 
97 LATE sPTB Yes No Yes No Yes No Yes 
98 TERM 
CONTROL 
Yes Yes Yes Yes Yes Yes Yes 
101 TERM 
CONTROL 
Yes No No Yes Yes No No 
102 TERM 
CONTROL 
Yes No No Yes Yes No No 
103 TERM 
CONTROL 
Yes No No Yes Yes No No 
105 TERM 
CONTROL 
Yes No No Yes Yes No No 
107 TERM 
CONTROL 
Yes No No Yes Yes No No 
108 LATE sPTB Yes No No Yes Yes No No 
109 TERM 
CONTROL 
Yes No No Yes Yes No No 
110 LATE sPTB Yes No No Yes Yes No No 
111 TERM 
CONTROL 
Yes No Yes Yes Yes No Yes 
112 TERM 
CONTROL 
Yes No Yes Yes Yes No Yes 
113 TERM 
CONTROL 
Yes Yes Yes Yes Yes Yes Yes 
114 LATE sPTB Yes No Yes Yes Yes No Yes 
115 TERM 
CONTROL 
Yes Yes Yes Yes Yes Yes Yes 
116 TERM 
CONTROL 
Yes Yes Yes Yes Yes Yes Yes 
117 TERM 
CONTROL 
Yes No Yes Yes Yes No Yes 
118 TERM 
CONTROL 
Yes Yes Yes Yes Yes Yes Yes 
119 TERM 
CONTROL 
Yes Yes Yes Yes Yes Yes Yes 
120 LATE sPTB Yes Yes Yes Yes Yes Yes Yes 
121 LATE sPTB Yes Yes Yes Yes Yes Yes Yes 
122 TERM 
CONTROL 
Yes Yes Yes Yes Yes Yes Yes 
123 sPTB Yes Yes No Yes Yes Yes No 
124 TERM 
CONTROL 
Yes Yes Yes Yes Yes Yes Yes 
126 PPROM – 
poly 
Yes Yes Yes Yes Yes Yes Yes 
128 PPROM – 
genetic  
Yes Yes No Yes No Yes No 
129 TERM 
CONTROL 



































































































































































































































































































































































































Between 1st March 2012 and 28th May 2015 from a single large preterm birth 
prevention clinic (approx. 140 new patients per year) it was possible to recruit 128 
patients meeting our specific inclusion criteria. From these patients; 61 (48%) term 
controls, 14 (11%) sPTB and 14 (11%) PPROM cases were obtained.  
RNA was only collected for a subset of 56 patients in this cohort (29 controls, 
5 sPTB, 6 PPROM). However, following sample storage, extraction and laboratory 
quality control checks using our methodologies the available data for three set omic 
integration (genomics, transcriptomics and metabolomics) at 16 weeks was 15 (51%) 
term controls, 5 (100%) sPTB and 6 (100%) PPROM cases.  
For larger cohort studies it is important to consider all the potential areas that 
samples may be lost and collect enough samples to allow for error.  Recruiting from 
a larger pool of participants (multi-site studies) depending on timescales and a priori 





Chapter 4: Assessing genetic predisposition to 
preterm birth in women with recurrent 






In this chapter the quality control and genomic analysis is discussed prior to 
data integration. As described in chapter 1, sPTB is a complex disease with a 
complex pattern of inheritance. After consideration of different methods of genetic 
analysis in chapter 2, a genome wide association study (GWAS) was chosen as the 
analytical tool of choice. A case-control design was selected to integrate with the 
other ‘-omic’ data used in this thesis.  
The underlying hypothesis of a GWAS is that there are likely to be several 
susceptibility variants for common but complex diseases. This results in minor allele 
frequencies that are high in the population rather than a single gene disorder. This is 
better known as the “common disease/common variant” hypothesis (Reich and 
Lander. 2001).  The focus of a GWAS is the study of single nucleotide 
polymorphism (SNP) frequencies within populations of interest. These single base 
pair changes act as genetic markers in a region of the genome that may be involved 
in disease presentation. This can be directly, as a functional SNP, or indirectly as a 
tag SNP that is in linkage disequilibrium with an influential SNP. Therefore, 
significant SNP associations detected from GWAS cannot be assumed to be causal 
variants. As these genetic variants are so common in the population the effect size of 
a single variant must be small, therefore, inheritance of a single SNP may only 
confer a small change in risk for the woman in pregnancy. This study will examine 








From the 128 women included in this study, 127 women had whole blood 
available for GWAS analysis. As a case-control design was used for GWAS we were 
unable to perform a three-way comparison for sPTB, PPROM and our control group 
of women delivering >37 weeks (TERM). Therefore, cases of sPTB and PPROM 
were combined to create a single sPTB group for analysis of GWAS data. The 
gestational cut-off of <37 weeks was used for “cases” and therefore early and late 
sPTB and PPROM were combined (see definitions Table 3.3).  
Allele frequencies can differ between groups of people with different ethnic 
backgrounds, and multiple ‘subpopulations’ within a dataset can lead to false 
positive associations and/or conceal true associations. This is known as population 
stratification and is an important source of bias in GWAS studies (Marees et al. 
2018). Approximately 90% of our recruited population report as Caucasian (Table 
3.5). Hapmap3 Caucasians (CEU), Han Chinese (CHB), Japanese (JPT) and Yoruba 
(YRI) were included as reference populations and participants that anchored against 
the Caucasian population were retained in the study to increase homogeneity of our 
small sample size. All (genotyped) non-Caucasians were excluded. 
DNA extraction and genotyping 
DNA was extracted from the whole blood samples using the Chemagic 
Magnetic Separation Module I (Perkin Elmer) machine in runs of 12 at the Wolfson 
Centre for Personalised Medicine, University of Liverpool. Quantification of DNA 
per sample was subsequently performed under the supervision of Dr Laurence 
McEvoy using PicoGreen® fluorometric methods and normalised according to 




concentration of 10 ng/ul. (Appendix G) Samples were shipped to Oxford Genomics 
Centre, Oxford University for genome-wide genotyping using the UK Biobank 
Axiom Array (Affymetrix). 
The UK Biobank Axiom array chip raw data was saved in PLINK file 
formats, a tool for handling SNP data. Originally these were stored in .ped and .map 
PLINK files, and transferred to binary PLINK file format (.bed, .bim and .fam files). 
Quality control steps and analysis were performed using PLINK software version 
1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) on the bioinf1 cluster 
(www.bioinf.liv.ac.uk) accessible on the University of Liverpool campus (Appendix 
H). The quality control steps described below involved the identification and 
removal of DNA samples and markers that introduce bias to the study. These critical 
steps are paramount to the success of GWAS case-control study are well described in 
the literature, and are necessary before statistically testing for association (Anderson 
et al. 2010). These steps were performed with the help and guidance from Dr Eunice 
Zhang at the Wolfson Centre for Personalised Medicine.  
Quality Control of Samples  
The quality control (QC) filtering of single nucleotide polymorphisms (SNPs) 
is an important step as part of GWAS studies. This ensures minimisation of potential 
false positives. SNP QC uses expert guided filters based on QC variables such as 
Hardy-Weinberg equilibrium (HWE) for controls (HWE p ≤ 1x10-6) and mean allele 





Identification of individuals with discordant sex information 
Genetic gender was compared to clinically reported gender. As males only 
have a single X chromosome, genotypes of SNPs on chromosome X can be 
estimated to be homozygous. Females are expected to have an X chromosome 
homozygosity estimate (XHE) of <0.2 and males >0.8-1. As all participants in this 
study are female, any XHE >0.2 was considered to be a contaminant from another 
sample or a mix up and marked for exclusion.  
Low DNA quality - sample genotyping call rates  
Samples of low DNA quality or concentration often have below average 
genotyping call rates and genotype accuracy. The genotype failure rate is a measure 
of DNA sample quality. Files were created to identify missing genotypes per sample 
(.imiss file) and per SNP (.lmiss). A pre-specified threshold of > 95% individual call 
rate was required for inclusion in the analysis. 
Heterozygosity Assessment  
An excessive individual heterozygosity rate can indicate sample 
contamination with DNA from another individual, and excessively reduced 
heterozygosity can signify inbreeding, both of which require removal to ensure data 
quality.  The heterozygosity rate was calculated for each individual. The threshold 
used was 5 ± standard deviations (SD) to include as many samples as possible.  
Identity by Descent (IBD)  
Related individuals will share more alleles than what is expected by chance 
and it is important to exclude related individuals to avoid over representation from a 
particular genome. The degree of recent shared ancestry for a pair of individuals 




0.5 for first degree relatives, IBD = 0.25 for second degree relatives and IBD = 0.125 
for third degree relatives. Due to genotyping error, population structure and linkage 
disequilibrium there is often some variation around these theoretical values and it is 
typical to remove one individual from each pair with IBD > 0.1875 (Anderson et al. 
2010).  
Pooled Data Analysis 
To try to ensure good quality data in our GWAS we chose a cut off for sPTB 
of <37 weeks instead of <34 weeks. Given the relatively small sample size for this 
group we compared our results to the largest published GWAS for preterm birth to 
assess whether our results showed similar findings, albeit without reaching a 
significance threshold. A pooled data-analysis with published GWAS data (Zhang et 
al. 2017) was then performed to test whether our data shows similar findings for the 
SNPs that have previously reached genome wide significance (GWAS) in a mostly 
low risk population. The R script used for this analysis has been included in the 
appendix (Appendix J). This work was performed with Dr. Till Andlauer at the Max-
Planck Institute, Munich. 
Statistical Analysis 
Descriptive statistics were performed for this case-control cohort. SPSS v.22 
was used to examine the clinical variables of the cohort for effects on sPTB outcome. 
Continuous variables; age, BMI and cervical length, were analysed using analysis of 
variance test (ANOVA).  For binary data, cervical surgery and smoking, a chi-
squared test was used. Gestational age at delivery is reported for interest as median 
and range and compared with Mann Whitney U test.  
Plink v.107 was used to perform the QC steps and add the binary file sets and 




student Juhi Gupta using the free online Michigan Imputation Server (Das et al, 
2016), available at https://imputationserver.sph.umich.edu/index .html using 
Minimac3 (Howie et al. 2012). Minimac is a low memory, computationally efficient 
implementation of the MaCH algorithm for genotype imputation and it can handle 
very large reference panels. The genotype data were imputed against the Haplotype 
Reference Consortium (HRC) (Version r1.1 2016). The HRC is the largest and most 
relevant available panel consisting of 64,976 haplotypes of predominantly European 
ancestry. Additional phasing tools Eagle (v2.3.2) and ShapeIT (v2) allow pre-
phasing of input haplotypes for improved imputation accuracy (Delaneau et al. 
2011). Initially an extensive QC process is performed. This is to ensure the SNPs 
have the correct ID (n = 625518), same position in the genome (n=634721), SNPs 
are removed if there is a mean allele frequency difference of greater than 20% 
(n=336) and palindromic SNPs are removed (n=2713).  
Manhattan plots were generated using RStudio v.3.1.1. (R, 2017). The 
threshold for genome-wide significance is 5 x 10-8 and a suggested significance 
threshold of p= 1x10-5 was applied. LocusZoom (v0.4.8), a web based plotting tool 
(Pruim et al. 2010) was used to focus on the regions of potential genomic interest. 
Statistical software R (http://cran.r-project.org/) was used for all graphical 
representation of the results.  
Pooled data analysis was performed using RStudio v 3.1.1. (R, 2017) and 
summary statistical outcomes of the top 10,000 SNPs from Zhang et al. (2017) were 






From a pool of 127 participants, 82 individuals remained for analysis (35 
cases and 47 controls) following all QC steps.  
Low DNA quality 
In the total dataset there were 830,115 SNPs present originally. After 
frequency and genotyping pruning 644,287 SNPs were remaining. 
Discordant sex information  
One sample failed gender check. This sample failed to meet the XHE of <0.2 
but did not score >0.8 to test male. Given the nature of the study it is certain the 
sample that we collected and processed in Liverpool is female, and inclusion of the 
sample was considered.  However not all processing of the sample occurred in 
Liverpool and sample contamination or mix up could not be excluded. Additionally, 
the quality of the DNA in the sample may be insufficient for reliable results and 
therefore the sample was excluded. 
Heterozygosity Assessment  
No samples were excluded after applying an individual genotyping call rate 
and heterozygosity rate QC step (Figure 4.1). 
Identity by Descent (IBD)  
Four participants samples were excluded due to cryptic relatedness with an 
identity by descent (PI_HAT) threshold score >0.1875 when paired with another 








Figure 4.1 Individual genotyping call rate and heterozygosity rate. The horizontal red 
dashed line indicates the 95% genotyping call rate applied, the vertical red dashed lines 





Figure 4.2 Estimated mean pairwise Identity by descent (IBD) of each participant.  
 
 
Individual removed from pairs 




Table 4.1 Pairwise comparison of individuals with shared ancestry (PI_HAT >0.1875) F_MISS 
indicates the missing call rate. PI_HAT indicates the identity by descent threshold. The 







PTB_11A 0.01272 PTB_107A 0.009018 0.2213 
PTB_11A 0.01272 PTB_23A 0.007393 0.2192 
PTB_11A 0.01272 PTB_31A 0.01267 0.2164 
PTB_11A 0.01272 PTB_60B 0.01336 0.2306 
PTB_11A 0.01272 PTB_62B 0.005675 0.2288 
PTB_107A 0.009018 PTB_23A 0.007393 0.2139 
PTB_107A 0.009018 PTB_31A 0.01267 0.2164 
PTB_107A 0.009018 PTB_60B 0.01336 0.2231 
PTB_107A 0.009018 PTB_62B 0.005675 0.2253 
PTB_23A 0.007393 PTB_31A 0.01267 0.2266 
PTB_23A 0.007393 PTB_60B 0.01336 0.2286 
PTB_23A 0.007393 PTB_62B 0.005675 0.2249 






Twenty-three additional participants were excluded after being identified as 
ethnic outliers according to their projection onto the reference populations (Figure 
4.3). One hundred participants that clustered within the Caucasian population were 
retained in the study (n=100). This was ten less than expected from self-reported 
ethnicity (Table 4.2). 
 
Figure 4.3. Principal component analysis (PCA) of genetic ethnicities of PTB pilot 
study participants. (C1 = Principal component 1, C2 = Principal component 2). 
Study samples are labelled in purple, most overlap with blue circles (Caucasian 
Hapmap population) 27 ethnic outliers were identified for removal. PTB - Liverpool 
PTB Clinic Cohort; CEU - Utah residents with Northern and Western European 
ancestry from the CEPH collection;  CHB - Han Chinese in Beijing; China JPT 











Caucasian (White British)  110 100 
Caucasian (other)  2 Excluded 
African Origin / YRI (Black British) 6 Excluded 




Not reported 2 Excluded 
Mixed ethnicity 2 Excluded 
 
Population 
The seventeen cases treated for short cervix were removed from the final 
quality control file before imputation for reasons discussed in chapter three. 
Participant Characteristics 
Demographic and pregnancy related outcome for all preterm birth 
participants are described in chapter 3. Table 4.3 describes just the participant 
characteristics for the 35 cases and 47 controls whose data was available for this 
GWAS analysis.  
The groups show no demographic differences in age, BMI, parity and 
smoking rates. Of note are six women who have had cervical surgery in addition to a 
previous pregnancy loss (4 single LLETZ, 2 multiple LLETZ and 1 knife cone 





Table 4.3. Demographic and clinical characteristics for preterm birth biomarker study 
participants included in genome wide association analysis 
 sPTB <37 weeks 
(n=35) 
Term delivery ≥37 
weeks (n=47) 
P value 
Maternal Demographics    
Age (SD) 29.0 (5.0) 30.4 (4.8) .216 
BMI (SD) 25.4 (4.9) 24.2 (4.2) .226 
Parity (SD) 1.4 (1.0) 1.7 (1.6) .296 
Cervical surgery 6 (17%) 0  .016 
Smoking in Pregnancy 9 (25.7%) 13 (28%) .503 
History of sPTB  21 (60%) 20 (43%) .205 
History of PPROM 12 (34%) 24 (51%) .130 
Pregnancy Features    
Cervical length at 16 weeks 
(SD) 
32.4 (8.0) 36.83 (6.5) .009 
Cervical length at 20 weeks 
(SD) 
26.32 (10.7) 37.28 (6.3) .000 
Delivery Outcomes    
Gestational Age at Delivery 
(median, range) 
33+5 (17+2 – 36+6) 39+3 (37+0 – 41+5) .000 
 
women with a history of cervical surgery in the term pregnancy group, however this 
difference is not shown to be statistically significant (p 0.16).  
There is an expected statistically significant difference between cervical length at 16 
and 20 weeks between the sPTB group and the term cohort. Cervical length is a 




receive preventative treatment. Participants who required treatment for a short 
cervix, and reached term, possibly suggesting successful treatment, have been 
removed from the term/control cohort. Thus, artificially increasing the difference in 
cervical lengths between these groups. Interestingly the mean cervical length 
difference between 16 and 20 weeks is approximately a change of 6 mm shorter in 
the high-risk group compared to no change in the term delivery group. 
Genome Wide Association Analysis  
SNP frequencies of women with recurrent sPTB <37 weeks were compared 
to women with only a history of sPTB <34 weeks. No SNPs reached genome wide 
significance (Red line on Figure 4.4). However top SNPs on chromosome 3 and 16 
fell just below genome wide significance and some interesting SNPs and SNP stacks 
can be seen in chromosome 11, 12, 21 and 22 which were investigated further.  
On the Manhattan plot (Figure 4.4) the x -axis shows each SNP position 
organised by chromosome, shown in black and grey blocks. On the Y-axis is the 
negative logarithm of the P-value for association of sPTB in cases compared to 
controls for each single SNP. Each block is composed of thousands of dots, each dot 
representing one SNP. The strongest associations with the trait have the smallest p 
values, therefore their negative logarithms will be the largest number on the Y axis.  
The areas of interest include SNPs that fall just below genome wide 
significance but also the appearance of stacked towers of SNPs suggesting that 
potentially multiple SNPs from the same chromosome region or even gene are 
associated with the sPTB trait.  
These regions of interest on the Manhattan plot were then examined using 
LocusZoom, to identify the SNPs of interest above the suggestive threshold. (Figures 




function of the gene made the gene target a possible candidate for a risk profile of 























































































































































































































































































Figure 4.5 Regional LocusZoom plot of top hit from the Manhattan plot in Figure 4.4 on 
chromosome 3 
 






Figure 4.7 Regional LocusZoom plot of top hits from the Manhattan plot in Figure 4.4 on 
chromosome 22
 










Pooled Data Analysis 
Figure 4.10 is taken from the GWAS publication by Zheng et al. (2017) who also 
used <37 weeks as their cut off for sPTB. They identified two genes, EEFSEC and 
EBF1 (shown in Figure 4.10) associated with sPTB above the genome-wide 
threshold level. Pooled data analysis with the same SNPs used to tag these genes 
using both published data (Zhang et al. 2017) and Liverpool data and found that only 
EEFSEC shows similar odds ratios (OR) in our population. Our data remains 
inconclusive for EBF1 due to wide confidence intervals. (Table 4.4; Figures 4.11).  
 
 
Figure 4.10. Figure from Zhang et al. “Genetic Associations with Gestational Duration and 
Spontaneous Preterm Birth”, N Engl J Med 2017;377:1159 demonstrating SNPS that reach 








Table 4.4. Comparison of odds ratios for sPTB SNPs associated with EEFSEC and EBF1 from 
Zhang et al. (published data) and Liverpool data from this thesis. 
 Alleles Zhang et al. (2017)  
Odds Ratio (95% 
CI) 
Liverpool 
Odds Ratio (95% CI) 
EEFSEC    
rs2955117 A/G 1.20 (1.14 – 1.26) 2.01 (1.28 – 2.74) 
EBF1    




Figure 4.11. Forest plot demonstrating comparison of odds ratio (OR) band confidence 
intervals (CI) between Liverpool and Zhang et al. 2017 data for A) SNP rs2955117_A 




4.4 Discussion  
Our study did not reveal any genes with genome wide significance, but 
several SNPs were identified above a pre-specified threshold level for significant 
association. The top SNPs and SNP towers were investigated on chromosomes 3, 11, 
12, 16 and 22. All but rs35156804 on chromosome 3 and rs17298557 on 
chromosome 12 were identified as intronic variants and did not map directly to a 
known gene.   
SNP rs35156804 mapped just under the genome wide significance level was 
located to chromosome 3 on EPHB1 gene. EPH receptors are the largest family of 
receptor tyrosine kinases (RTKs) and are divided into two subclasses, EPH A and 
EPH B (Figure 4.12). Originally, they were identified as mediators of axon guidance 
but now EPH receptors are implicated in many processes, including injury and 
inflammation (Ivanov and Romanovsky. 2006).  
Figure 4.12 Domain structures of EPH receptors and ephrins. Figure taken from Wei, W., 
Wang, H., & Ji, S. 2017. Paradoxes of the EphB1 receptor in malignant brain tumours. 




Their role in inflammation and the immune system remains unclear. A study 
found that ephrin-B1 is highly expressed in peripheral blood lymphocytes (PBLs) 
obtained from patients with rheumatoid arthritis (Kitamura T. 2008). Ephrin-B1 
ligand and EphB1 receptor are thought to play an important role in this inflammatory 
condition through influencing function of T cells through stimulation of the 
production of TNF-alpha in PBLs and IL-6 in synovial cells (Kitamura T. 2008). The 
function of EphB1/ephrin signalling in the development of immune organs and the 
corresponding mechanism of immune regulation are an area for future study and may 
also be implicated in pregnancy.  
The EPHB1 gene has been previously linked to sPTB but only, at present, in 
animal models investigating mechanisms of uterine stretch and over-distension. One 
study using a non-human primate model of pigtail macaques demonstrated that 
EPHB1 was significantly downregulated in uterine myometrium that had been 
excessively stretched using balloon catheterisation to trigger preterm labour 
compared to controls when measuring mRNA levels (Waldorf et al. 2015). 
Therefore, this provides a rationale to explore the mechanistic role of EPHB1 
further in reproductive tissues. 
SNP rs17298557 mapped to gene PLXNC1 on chromosome 12 (Figure 4.9). 
However, there was no evidence of a tower of SNPs to suggest that other SNPs in 
this area or on this gene showed an association between cases and controls making it 
less likely that this gene is truly associated with preterm birth. PLXNC1 has been 
linked to involvement in inflammatory response which suggests potential biological 
plausibility behind this finding. This gene encodes a member of the plexin family. 
Plexins are transmembrane receptors for semaphorins, a large family of proteins that 




2018. Accessed https://www.ncbi.nlm.nih.gov/ gene/10154). There are, to date, no 
published associations of this gene in pregnancy in either human or non-human 
models, therefore further validation of this finding would be required before planned 
investigation of its role in sPTB is taken further.  
Pooled data analysis of Liverpool data compared to Zhang et al. (2017) 
investigated the performance of just a couple of SNPs on known genes of interest 
rather than all SNPs. In the EEFSEC gene; the Liverpool data shows strong 
agreement with the directionality of this gene with an odds ratio and 95% CI of 2.01 
(1.28 – 2.74) for sPTB <37 weeks for SNP rs2955117 (Figure 4.11). This gene 
encodes selenocysteine tRNA-specific eukaryotic elongation factor which is aides in 
the incorporation of selenocysteine into selenoproteins. The physiologic functions of 
selenium have been linked both to the parturition process and preterm birth (Rayman 
et al. 2011, Zhang et al. 2017). Additionally, in a population of preterm very low 
birth weights neonates they have been found to be deficient in selenium at birth and 
supplementation at 10 µg/day reduces their risk of late-onset sepsis (Aggarwal et al. 
2016). Therefore, we would agree that further evaluation of the role of maternal 
selenium micronutrient status on prematurity risk should be investigated, both in the 
general obstetric population and specifically within the Liverpool population. 
Interestingly, our data was not able to support the association of EBF1 
involvement with sPTB within our population with an OR (95%CI) of 0.93 (0.19-
1.66) compared to Zhang et al. OR (95%CI) 1.23 (1.18-1.28). There is a large 
confidence interval around the Liverpool OR and these data are largely inconclusive 
with relation to this gene and its association with sPTB in the Liverpool population. 
This is most likely to be due to weaknesses in our study design with very low 




directionality of the EEFSEC gene more interesting. Alternatively, this difference 
may be related to the comparison of a high-risk population (Liverpool) with a low 
risk population (Zhang et al. 2017). 
EBF1 encodes for early B-cell factor and is important for B-cell 
development. It has been associated with control of blood pressure and metabolic 
risk (Zhang et al. 2017) and therefore may contribute to preterm birth more generally 
through these pathways that influence gestation, rather than pregnancy or sPTB 
specific pathways. A high-risk population with recurrent preterm births such as ours 
may not select for this gene as strongly as a low risk or general pregnancy 
population.  
There are two primary platforms in chip-based microarray technology for 
assaying upwards of one million SNPs. These two competing technologies, 
Affymetrix (Santa Clara, CA) and Illumina (San Diego, CA) will choose different 
SNPs for their assays and use slightly different technologies. The UK Biobank 
Axiom Array (Affymetrix) was chosen for this project due to the overall genomic 
coverage which comprises of 820,967 genetic markers. This is also the array used by 
the UK Biobank (www.ukbiobank.ac.uk), a large research biobank of 500,000 
participants from the UK which could provide data for meta-analysis. As we have 
demonstrated results of multiple GWAS can be pooled together to perform meta-
analysis, developed to examine and refine significant effect sizes of published 
GWAS investigating the same disease. Meta-analysis becomes increasingly difficult 
if studies use different genotyping platforms and different SNP marker sets, therefore 
we have tried to stay in line with current major health resources. 
The small sample size of our study is a significant limitation that increases 




multiple comparisons on only a relatively small number of cases and controls. 
Nevertheless, despite the small number the quality of the clinical phenotype is 
excellent, and this cohort is particularly unusual as the women represented by the 
‘cases’ have had recurrent sPTB not just a single preterm birth. To obtain this type 
and quality of data on the scale necessary to be confident in the findings and validate 
SNPs of interest will take years of work and the collaboration of many groups, 
therefore meta-analysis is likely to become a predominant method of genomic and -
omic research in the field of sPTB research.  
The ability to extrapolate our findings into other non-Caucasian populations 
is another potential weakness, as we excluded non-Caucasians to reduce spurious 
findings. Disease associating alleles can have different frequencies in different 
populations as a result of demographic events, such as migration.  
The most difficult decision for this –omics analysis was deciding on a 
preterm birth cut-off for our groups. A <34 week cut-off would be more in keeping 
with the other omics analysis layers (where this has been used as a cut-off), however 
making the number of cases smaller would have negatively affected the quality of 
our results and increased the likelihood of false positive findings resulting in poor 
data quality for the –omics combination. Consequently, a <37 week cut-off was 
chosen for this omic layer only. Encouragingly the SNP rs2955117_A mapped to the 
EEFSEC gene showed the same directionality as the largest GWAS published in this 
field of research, which supports our findings that this SNP falls just below the 





There is recent evidence from a GWAS study that supports the genetic 
predisposition of sPTB. Our data reinforces the finding that EEFSEC, a gene 
involved in the creation of selenoproteins, is associated with sPTB. Inconclusive 
results were found for EBF1 which may be attributed to the small sample size or due 
to our rare population of women with recurrent sPTB, as opposed to women with just 
one sPTB. We found no SNPs in our cohort that were of genome wide significance, 
but several SNPs fell above a suggestive threshold. A SNP from the EPHB1 gene fell 
just below genome wide significance and further investigation of this gene in the role 
of sPTB should be considered in other omic layers from this cohort; particularly as 
this gene has previously been shown to be downregulated in mammal models of 





Chapter 5: Longitudinal Transcriptomic Analysis 






Transcriptomics is the study of all RNA molecules in a cell, otherwise known 
as ‘the transcriptome’ (Wang et al. 2009). The biomarker potential for disease 
prediction of RNA was identified over two decades ago (Kusec et al. 1994, Seal et al. 
1995, Gillis et al. 1995) and since then biomarker discovery in transcriptomics has 
occurred for many diseases, but most prominently in the field of oncology (Xi X. 
2017). Most transcription studies focus on the measurement of cell messenger RNA 
(mRNA) and microarray technology allows examination of relative levels of gene 
transcripts to establish which genes are being up or down regulated at a given 
moment in time.  
As addressed in the literature review in Chapter 2 there have been several 
studies looking at transcriptomics in both the threatened and asymptomatic high-risk 
sPTB population. A metanalysis of three studies (n=339 maternal whole blood 
samples; n=134 preterm, n=205 term) identified by the Gene Expression Omnibus 
(GEO) database found a set of 210 significant differentially expressed genes in 
maternal blood (Vora et al. 2018). Many of these were downregulated immune 
related genes. Based on the maternal data from this study, genes and cell types 
associated with innate immunity were upregulated in sPTB, while those relevant to 
adaptive immunity were downregulated. However, several limitations still exist with 
the data, including the small number of studies with publicly available data that can 
be aggregated. Samples lack demographic information as well as detailed clinical 
annotations and are heterogeneous, making comparison difficult. Examples of 
heterogeneity include the type of study (cohort or case-control), definitions and 
populations or phenotypes of preterm birth (i.e. asymptomatic and threatened 




immune function is a recurring theme in sPTB research and study of the 
transcriptome demonstrates potential for biomarker discovery.  
Due to the limitations of cost only a subset of the women in this study 
provided RNA samples. I examined gene expression across the transcriptome, at 16 
and 20 weeks of pregnancy between women with sPTB, PPROM and term deliveries 
(>37 weeks) in our cohort to identify the leading pathways demonstrating 




5.2 Methods  
Population 
Samples of whole blood were obtained from 58 participants (94 samples). 
2.5ml of whole blood was stored in PAXgene Blood RNA Tube and frozen at -80oC 
until RNA extraction. Following thawing to room temperature, total RNA was 
extracted using the PAX gene blood RNA Kit (PreAnalytix/QIAGEN) adhering to 
the manufacturer’s protocol (Appendix I). Purification occurred with a centrifugation 
step to pellet nucleic acids in the PAXgene Blood RNA Tube. The pellet was washed 
and resuspended, followed by manual purification.   
Quality Control of RNA prior to Hybridization 
RNA quantity and purity was established using a NanoDrop (ND) 
spectrophotometer. The A260 value was used for RNA quantification. RNA has a 
maximum absorption at 260 nm and RNA concentration is determined by the 
following conversion; an A260 of 1.0 is equivalent to 40 µg/mL of RNA. 
In addition, measurements were also taken at 280nm.  The A260/A280 ratio 
is an indication of the level of contamination of protein, DNA, phenol, ethanol and 
salts in the sample. A high-quality RNA sample is free of these and contamination 
affects how efficiently RNA is amplified prior to hybridisation to the array chip. Pure 
RNA has an A260/A280 ratio of 2.1, however values between 1.7-2.2 were 
considered acceptable for our protocol. The ND sample values were checked prior to 
freezing at -80 in preparation for transfer to the Centre for Genomic Research 
(CGR), University of Liverpool.  
The RNA integrity was established using the Agilent 2100 Bioanalyser 




mRNA can generate cDNA that lacks parts of the coding region. Therefore, only 
samples with an RNA integrity number (RIN) >7 were hybridised to Clariom™ D 
Assay, human (Affymetrix/Thermo Fischer Scientific).  
RNA Amplification, Purification, Quantitation & Hybridization 
For RNA amplification and gene chip cartridge array hybridization the 
GeneChip™ WT PLUS Reagent Kit was used and the manufacturers protocol was 
followed (Figure 5.1). Initially RNA controls were prepared and diluted and labelled 
together with the total sample RNA. The hybridization intensities of the controls help 
to monitor the labelling process independently from the quality of the starting RNA 
samples. Then first strand complimentary DNA (cDNA) was synthesised in a reverse 
transcription procedure. Total RNA was primed with primers containing a T7 
promoter sequence. The reaction synthesized single-stranded cDNA with T7 
promoter sequence at the 5' end. Then second strand cDNA was synthesised. Single 
stranded cDNA was converted to double stranded cDNA. This step used RNase H to 
degrade RNA whilst DNA polymerase synthesised the second strand to act as a 
template for synthesising and amplifying antisense RNA (complimentary RNA). 
This method of RNA sample preparation is based on the original T7 RNA 
polymerase in vitro transcription (IVT) technology known as the Eberwine or RT-
IVT method (Van Gelder et al. 1990). A purification step then removed 
unincorporated nucleotides, salts, enzymes and inorganic phosphates in preparation 
for the next single stranded cDNA synthesis step. Second cycle primers including 




Figure 5.1. WT PLUS Amplification and Labelling Process. Image taken from 
GeneChip™ WT PLUS Reagent Kit Manual Target Preparation for 







dTTP were then used in the next cDNA synthesis step. This was to allow 
incorporation of uracil into the cDNA strand to allow for easier fragmentation. 
Template RNA was then hydrolysed by RNase H leaving single-stranded cDNA. To 
prepare the cDNA for fragmentation and labelling another purification step removed 
excess salts and unincorporated nucleotides. Fragmentation then occurred by uracil-
DNA glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE 1) at the 
unnatural dUTP sites in the cDNA. The fragmented cDNA is then labelled by 
terminal deoxynucleotidyl transferase (TdT) and a proprietary labelling reagent 
covalently linked to biotin ready for chip hybridization. The chip was loaded onto the 
Affymetrix GeneChip™ Scanner 3000 7G for scanning.  
The Clariom™ D chip was selected, as at the time of the study it had the most 
comprehensive cover of the human genome. Clariom D can detect greater than 
540,000 transcripts, which was the most comprehensive coverage of the human 
transcriptome at the time of the study. This was to maximise discovery of any 
actionable biomarkers and ensure any rare or low expressing transcripts not detected 
by other methodologies were not missed. 
Affymetrix® Expression Console™ software was required to perform QC 
analysis of transcriptome data and was downloaded from the Affymetrix website as 
part of the Transcriptome Analysis Control (TAC) Software. 
(https://www.thermofisher.com/uk/en/home/life-science/microarray-
analysis/microarray-analysis-instruments-software-services/microarray-analysis-
software/affymetrix-expression-console-software.html). Probes were annotated by 
this software using NetAffx information associated with this particular probe set. 
Outliers were identified if they had two standard deviations away from the mean of 




values at the tails of distribution were removed to prevent problematic downstream 
analysis. An overview of the quality control steps performed by CGR are shown in 
Figure 5.2. 
Once the metrics were run, a link was prepared by the Centre for Genomics 
Research to access the data. Further bioinformatic analysis was performed by Juhi 
Gupta (University of Liverpool) and Professor Bertram Müller-Myhsok (Max-Planck 
Institute, Munich, Germany and University of Liverpool). Microarray CHP files were 
normalised using Robust Multi-array Average and scaled (Bioconductor, R).  
Once the QC steps were completed, clinical data and phenotypic 
classification was used to remove cases that did not qualify as sPTB <37 weeks, 
PPROM <37 weeks or TERM delivery. Only samples that had both timepoints were 
included in the analysis.  
Differential gene expression was initially performed between sPTB and 
PPROM at Timepoint 1 (16 weeks) and Timepoint 2 (20 weeks) to determine if any 





Figure 5.2. Expression Console Software Workflow. The steps in red were performed by the 






Statistical Analysis  
The machine learning approach used was random forest methodology 
(Breiman. 2001) performed with the R-package “rager”. The basis of the machine 
learning method is the ‘decision tree’ which asks questions of the data and plots all 
the possible answers (Figure 5.3). The random forest combines many decision trees 
together into a single model. The target is what the model should predict, those 
women with sPTB, PPROM or term delivery. The features are the columns of data in 
the data matrix used as input data (i.e. transcript levels per individual). We expect 
there to be some relationship between the features and the target value and the model 
will ‘learn’ these relationships during training. To do this, the model splits the data 
into a training set and a test set. On the test set, the model will ‘see’ the preterm birth 
classifications of the target and formulate ‘questions’ of the features to create a 
predictive model.  Then on the test set, the model does not know the target 
classifications and tries to classify them using just the data features. The answers can 
be compared to our classifications (‘true’ values) to judge how accurate the model 
performs.  This is performed in an out-of-bag (OOB) fashion so model building and 
testing are not confounded.  
The name “random” forest gets its name because each decision tree in the 
model considers a random subset of the data features when forming its ‘questions’. 
The random collection of features is called a ‘node’ and these input co-ordinates are 
what the model subsequently splits on.  Individually decision trees may have a wide 
variance in prediction of the outcome, but on average many thousands of decision 
trees will get closer to the correct answer. This leads to more overall robust 























































































Of note, for this analysis we did not use the random forest for prediction in its 
original usage, but rather focussed on the possibility of obtaining variable 
importance’s in a multivariate setting. In this analysis, 10,000 trees were generated 
aiming to predict the phenotype of interest. Historically random forest models have 
been biased in such a way that categorical variables with a large number of 
categories are preferred (Altmann et al. 2010). Therefore, we used a normalising 
feature importance measure to correct feature importance bias called permutation 
importance score (Altmann et al. 2010). From this, the permutation importance was 
taken and the scale function in R was executed expressing the permuted importance 
in terms of a pearsonised variate. Variable importance values of five standard 
deviations above the mean variable importance was used for further Gene Set 
Enrichment Analysis (GSEA). In addition, we also performed a confirmatory 
analysis to verify the variable importance’s identified using the alternative method of 
Janitza et al. (2016) and found very good agreement between the two approaches.  
Gene Set Enrichment Analysis (GSEA) 
Pre-ranked GSEA (Subramanian et al. 2005) was used to determine 
significantly enriched gene sets/pathways.  To achieve our aim, Functional Mapping 
and Annotation (FUMA) tool (Watanabe et al. 2017) was used to identify the 
enriched genes and associated systems. As described above, transcripts exhibiting 
more than five standard deviations above the mean variable importance were used. 
GENE2FUNC (gene to function) option was used to explore the significance of 
identified pathways. Identified pathways were further explored using the Kyoto 




Hierarchical Clustering of Expression Profiles  
To measure the non-linear statistical dependence between random variables a 
Randomised Dependence Coefficient (RDC) was used (Lopez-Paz et al. 2013) and 
extended (Jia et al. 2019, in preparation) to define the distance metric used in 





From 58 women with whole blood RNA samples, 27 women were included 
in the final analysis. (Figure 5.4/Appendix K) RNA was available for analysis on 16 
term controls (NORM), 9 sPTB <37 weeks (SPON), 2 PPROM < 37 weeks 
(PPROM). No predictive clinical variables were significantly associated with sPTB 
(Table 5.1).  
Quality Control RIN values can be seen in Appendix J. Classical differential 
expression analysis did not reveal significantly different expression values for any of 
the transcripts measured, likely owing to small sample size.  
Following random forest analysis, 178 transcripts had ENSEMBLE ID’s 
suitable for further analysis and were subject to GSEA. The R code used for the 
random forest analysis is available to view in Appendix K and an example of one of 
the 10,000 trees is shown in Figure 5.5. Functional Mapping and Annotation of 
Genome-Wide Association Studies (FUMA) demonstrated significant enrichment of 
the selenoamino acid metabolism pathway in the high-risk preterm birth population 
(Figure 5.6). Three significant genes highlighted out of 26 genes from the selenium 
metabolism pathway (CTH, LCMT1, TRMT11) (Table 5.2). The p value is 3.84e-3 
after adjusting for multiple testing across the entirety of KEGG pathways.  
Clusters of women delivering at term (NORM), sPTB (SPON) and PPROM 
(PPROM) are represented in Figure 5.7. The hierarchical clustering indicates there 






























































Maternal age, mean years +/- SD 31.3 (5.8) 32.5 (0.7) 31.3(5.6) .959 a 
Booking BMI, mean +/- SD 27.9 (6.7) 24.5 (1.8) 24.6 (3.0 .250a 
Ethnicity     
Caucasian, n(%) 8 (89) 2 (100) 14 (87.5) .492 b 
Non-Caucasian, n (%) 1 (11) 0 2 (12.5) 
Smoking during pregnancy   
Yes, n(%) 2 (22)  0 5 (31) .606b 
No, n(%) 7 (88) 2 (0) 11 (69) 
Clinical Characteristics 
Gravidity, mean+/-SD 4.1 (1.6) 3 (0) 3.75 (2.1) .507 c 
Parity 1.4 (1.0) 1.5 (.71) 1.7 (2.3) .771 c 
History of previous PTB 
Previous sPTB, n (%) 5 (56) 1 (50) 8 (50) .964 b 
Previous PPROM, n (%) 4 (44) 1 (50) 8 (50) 
Both previous sPTB and PPROM 
(%) 
0 0 0 N/A 
Previous twin sPTB, n (%) 0 0 0 N/A 
Cervical surgery (single LLETZ), n 
(%) 
0 0 1 (6.3) .700 b 
Gestational age, visit 1, mean +-/- 
SD days 
114 (4) 111.5 (.7) 115 (4) .574 a 
Cervical length visit 1, mean +/- SD 33.3 (5) 38 (4) 34.6 (5) .545 a 
Gestational age, visit 2 141 (4) 140 (.7) 142 (6) .669a 
Cervical length visit 2, mean +/- SD 30 (8) 23 (4) 36.6 (7) .0.16 a 
Other chronic medical conditions     
Yes, n (%) 6 (67) 2 (100) 5 (31) .074 b 
No, n (%) 3 (33) 0 11 (69) 
Polyhydramnios      
Present, n (%) 0 0 0 N/A 
Absent, n (%) 9 (100) 2 (100) 16 (100) 
Labour and Delivery Characteristics 
Onset of labour     
Spontaneous 7 (78) 0 5 (31) .037 
Induction 0 1 (50) 9 (56) 
No labour 2 (22) 1 (50) 2 (13) 
Gestational age at delivery, mean +/- 
SD days 
239 (18) 221.5 
(25) 
271 (8) .000 







Neonatal gender      
Female, n (%) 4 (44) 2 (100) 6 (38) .245 





Figure 5.5. One of 10,000 trees from random forest analysis. Nodes are using data from 
week 16, week 20 and the difference between both weeks to differentiate the data into 




Table 5.2. Functional Mapping and Annotation (FUMA) summary of enriched genes. N = 
total no genes in the gene-set, n = number of genes enriched in the gene set. 








































































































































































































































































































































































































































In this part of the thesis, we investigated the association of whole blood gene 
expression across two clinically relevant timepoints between women who had 
recurrent sPTB, PPROM and women who had term births following a history of a 
sPTB. The findings of our GSEA suggest a role or an association of selenium in the 
initiation of early labour.  
After adjusting for multiple testing, three genes in the selenium pathway were 
found to be statistically significant: CTH, LCMT1, TRMT11.  
• CTH gene encodes a cytoplasmic enzyme in the trans-sulfuration 
pathway that converts cystathionine derived from methionine into 
cysteine (Figure 5.8).  
• LCMT1 catalyses the methylation of the carboxyl group of the C-
terminal leucine residue (leu309) of the catalytic subunit of protein 
phosphatase-2A (De Baere et al. 1999).  
• TRMT11 is a protein coding gene for tRNA methyltransferase 11 
homolog that transfers a methyl group onto a single guanidine residue 
present in most tRNAs and thereby modifies them post 
transcriptionally (Hori H. 2014).  
It is possible that the effects of a dysfunctional selenoprotein may change this 
metabolite pathway in gestational or maternal tissues affecting gene expression and 
may also associate with low maternal selenium status. Selenium is known to be 
involved in attenuating inflammation and low maternal levels have been reported in 
the literature as associated with preterm birth (Rayman et al. 2011).  
Our pilot analysis was based solely on random forest profiling which are fast 




large number of input variables without overfitting (Biau. 2012, Ahmad et al. 2018.). 
Random forests are considered to be one of the most accurate general-purpose 
learning techniques available (Biau. 2012). It generates data trees at random and is 
therefore completely unbiased from prior knowledge of the possibility of selenium 
involvement in PTB pathways. Strengthening our interest in the Se hypothesis is:  
1) the recent discovery of association of the EEFSEC gene discussed in 
chapter 4,  
2) Dutch PTB cohorts demonstrating women in the lowest quartile of 
serum selenium having twice the risk of PTB as the women in the 
highest quartile (OR 2.0, 95% CI 1.19-3.47) (Rayman et al. 2011). 
3) low serum selenium concentration being independently related to PTB 
(OR 2.18, 95% CI1.25-3.77). (Rayman et al. 2011). 
Interestingly, there are comparably low serum concentrations of selenium that 
have been found in a UK obstetric population compared to the Dutch population 
(Rayman et al. 2003). This important result from our pilot work requires validation 
before more credence can be given to this theory, but there are potential translational 
implications for patients. 
With regards to the science and plausibility of this theory, the trace mineral 
selenium plays a role in immune response and the body’s resistance to infection. 
Enzymes containing selenoenzymes can attenuate the inflammatory response 
associated with sPTB by downregulating the expression of pro-inflammatory genes 
(Vunta et al. 2007). The amino acid residue selenocysteine (Sec) is a major form of 
Se in the cell and Sec is encoded by the UGA codon. Proteins containing Sec are 
thought to be largely responsible for the health benefits of Se. Sec is introduced into 




Sec-tRNA (Shetty et al. 2014). When UGA codon is encountered by a ribosome this 
normally signals as a “stop” codon and translation is terminated, however Sec 
machinery interacts with translational machinery to prevent premature termination. 
At least two trans-acting factors are required for efficient recoding of UGA as Sec in 
eukaryotes; SBP2 and EEFSEC. It is not clear if women with higher levels of this 
Sec-specific translation elongation factor are more genetically capable of translating 
selenoproteins that cascade to prevent inflammation or if there are the creation of 
selenoproteins that are causing sPTB birth or PPROM.  
Our hierarchical clustering analysis suggests that this high-risk group could 
be differentiated on their expression profiles of the selenium pathway by machine 
learning (Figure 5.7).  
Further studies are required to validate these findings, but our data are 
strengthened by our GWAS data from the same cohort in chapter 4 reflecting 






This analysis used whole blood gene expression across two timepoints to 
differentiate sPTB and PPROM from women delivering at term in asymptomatic 
women. Using expression levels and random forest alone, no predictors were found. 
However, a gene set enrichment in this population demonstrates that the selenoamino 
acid pathway differentiates asymptomatic high-risk women. Hierarchical clustering 
in a non-linear distance matrix can differentiate all but one of the sPTB cases. More 




Chapter 6: Metabolomic Profiling of Pregnant 
Women to Assess for Candidate Metabolites 






The advantage of metabolomics for biomarker discovery is that this “omics” 
layer is the most downstream from gene expression and protein synthesis and may be 
more representative of physiology at a functional level (Romero et al. 2010). 
Pregnancy is a state of adaptation for the human female with many processes 
changing over the course of gestation (Lain KY. 2007). Glucose, protein, calcium 
and lipid metabolism change to accommodate the growing fetus, with additional 
adaptation in maternal respiratory, endocrine, renal and cardiac physiology. Maternal 
blood as a candidate biological fluid should detect these changing biochemical 
dynamics and remains easily accessible for study or screening. Blood also remains in 
constant exchange with the fetus through the placenta providing nutrients required 
for growth and development.  
As discussed in Chapter 2, two main approaches to the generation of 
metabolomics data are nuclear magnetic resonance (NMR) and mass spectrometry 
(MS). I chose to use NMR for analysis as it is a fast and highly reproducible 
technique that requires very little sample preparation or manipulation and typically 
identifies around 50 metabolites in serum. It is based on energy absorption and re-
emission from the atom nuclei due to variations in the external magnetic field 
(Bothwell and Griffin. 2011). Hydrogen is the most commonly targeted nucleus (1H-
NMR) due to its natural abundance in biological samples. The resulting spectral data 
allows for indirect quantification of the concentration of the metabolite but also 
provides information about the chemical structure (Alonso et al. 2015). The pattern 
of the spectral peaks informs the physical properties (chemical structure, oxidative 
state, phosphorylation etc.) of the metabolite and is used in metabolite identification, 




sample. Aside from the high reproducibility and short acquisition times, other 
advantages of 1H-NMR include requirement of small sample volumes, low cost of 
analysis, non-destructiveness of the sample which remains intact after analysis. As a 
spectroscopic technique (rather than spectrometric) metabolite profiles obtained are 
virtually independent of the operator and instrument. Its main disadvantages include 
a high instrument cost and relatively low sensitivity to molecules present in low 
volumes (Kamath-Rayne et al. 2013). This chapter will discuss using NMR 







1) To compare the metabolite profiles at 16 and 20 weeks of gestation in all 
participants (sPTB, PPROM and TERM groups) 
2) To compare temporal metabolite profile changes between 16 and 20 weeks 
(sPTB, PPROM and TERM groups). 
3) To assess the differences in metabolite profiles between women experiencing 






From the population described in chapter three, of 128 women who had given 
at least one serum sample for analysis 46 were excluded from participation. To 
summarise, women were excluded if they had a 1) caregiver initiated preterm birth 
(i.e. not spontaneous), 2) sPTB that had a likely identifiable cause (i.e. infection or 
placental abruption), 3) women with PPROM that were associated with 
polyhydramnios or chorioamnionitis, 4) genetic abnormality associated with 
spontaneous preterm birth or miscarriage, 5) late spontaneous preterm birth (34+1-
36+6) and 6) women delivering >37 weeks who had treatment for short cervix.  
Materials 
500 µl aliquots of serum were securely stored at -80°C in the NMR Centre for 
Structural Biology laboratory after transfer from the Centre for Women and 
Children’s Health, prior to processing in batches. On the day of analysis, samples 
were thawed for 1 hour and 330µl aliquots of serum and 330 µl of phosphate buffer; 
consisting of 66µl of 1M Sodium Phosphate (Na+PO4
3-) buffer prepared in 99.8% 
deuterated water (2H2O or D2O); pH 7.4, and 264 µl of double distilled water 
(ddH20) prepared in Eppendorf tubes following established protocols (Beckonert et 
al. 2007) (Figure 6.1). The Eppendorf tubes were centrifuged at 21,500g for 5 





Figure 6.1 Ratio of Serum, Water and Phosphate Buffer 
Spectral Acquisition 
Spectra were acquired using Bruker Avance spectrometer operating at the 
proton frequency of 600MHz and equipped with a triple resonance TCI cryoprobe 
(Bruker, GmBH, Germany). A one-dimensional Carr-Purcell-Meiboom-Gill (CPMG) 
1H NMR echo pulse sequence with water suppression was employed to filter out 
broad spectral resonances arising from the macromolecules (such as lipoproteins and 
albumins). Spectra were manually phased and the baseline corrected using the 
Topspin 3.1 software (Bruker, GmBH, Germany). The whole spectrum was 
referenced and aligned to the glucose anomeric hydrogen signal (δ= 5.23 ppm). The 
residual water region (4.40-5.00ppm) was selectively removed.  
Binning NMR spectra 
NMR outputs are extremely complex spectra of metabolite resonances that 
are produced without any prior separation of the sample. Therefore, overlap of 
chemical signals makes it impossible to identify all the components in a spectrum. 




splitting up spectra into integral regions is called “binning” or “bucketing”. Each 
sample spectra were subsequently divided into bins, assigning peak boundaries as 
they appeared on the spectra. Background noise had previously been removed using 
the QC steps discussed above.  
Spectral Annotation and Metabolite Identification  
Characteristic metabolite peaks have previously been identified and can now 
be used to annotate spectra via pattern recognition (Soininen et al. 2009). The 
schematic in Figure 6.2 shows A) the spectra produced from this analysis and B) an 
animation showing the characteristic identification peaks. Most spectra overlap, 
however some spectra showed obvious differences. Using Chenomx™ metabolomics 
software, compounds were annotated by comparison to databases of independently 
verified and externally validated metabolites. If a bin could not be annotated it was 
labelled as ‘unknown’ and each unknown bin was given a unique identifying 
number. 
Statistical Analysis  
SPSS v.24 (IBM Corporation, USA) was used for statistical analysis of 
clinical demographic data of the participants involved in this analysis. Descriptive 
statistics for the cohort included median and range values for age, BMI, smoking 
status, gestational age and cervical lengths at sampling.  
The metabolomic data were analyzed using Metaboanalyst 4.0 Statistical 
Analysis (Xia and Wishart. 2016), an online tool for metabolomics analysis and 












































































































Data filtering identifies and removes variables unlikely to be of use during 
data modelling. No phenotype information is used in the filtering process, so the 
result can be used with any downstream analysis. This step is strongly recommended 
with untargeted datasets such as spectral binning, as the large number of variables 
provide baseline noise. (Hackstadt and Hess. 2009) 
Preprocessing of the data matrix plays a crucial role in ensuring that 
subsequent data analysis is more robust and accurate. Two key steps in preprocessing 
are i) normalization and ii) scaling of the data. Probabilistic quotient normalization 
(PQN) was used to normalize our spectra (Dieterle et al. 2006, Kohl et al. 2012). The 
data were scaled using auto-scaling (mean-centred and divided by the standard 
deviation of each variable) (Jackson. 2006, Van den Berg et al. 2006).  Together 
these normalization and scaling methods gave the most Gaussian distribution of the 
dataset prior to univariate statistical analysis.  
Outlier Identification 
An overview of the data was initially performed with a principal component 
analysis (PCA) to identify any outliers prior to further analysis. If an outlier was 
identified, then the participant clinical data was considered as a whole to explain why 
this was an outlier (i.e. medications taken within 48 hours of sampling). If no 
explanation was found for the outlier, the point was removed from the dataset in case 
of errors being introduced during sampling or the NMR process.  
Univariate Analysis 
Univariate analyses were used to identify difference in metabolite bins 
between groups. When all three groups (sPTB, PPROM, Term) were compared, 
statistically significant differences were evaluated using the one-way analysis of 




significant. To address the problem of multiple testing, adjusted p values were 
determined using the False Discovery Rate (FDR) approach. Post hoc analyses using 
Tukey’s Method was used to explore any statistically significant differences between 
multiple group means while controlling the experiment-wise error rate to assess 
between which groups were the biggest differences When comparing two groups 
(SPTB and PPROM) fold change (FC) analysis, t-test and volcano plots were used. 
The purpose of fold change was to compare absolute value change between two 
group means per metabolite. The result is plotted in log2 scale, so the same +/- fold 
change was plotted the same distance from the zero baseline. T-test was used to 
determine if there was a significant difference between the means of the two groups.  
Multivariate Analysis  
PCA was conducted for detection of inherent trends and separation of group 
data. PCA is a powerful method of data extraction, which finds combination of 
variables that describe trends in large data, called principle components visualized in 
scores and loading plots. 
To attempt to get sharper separation between the two groups a Partial Least 
Squares- Discriminant Analysis (PLS-DA) was performed. This is a supervised 
multivariate analysis that attempts to maximise the variances that separate the groups 
and minimise the differences within the patient groups to build a discriminant model. 
The model required cross-validation to ensure that the data was not overfit. A leave-
one-out cross-validation was used to establish a sum of squares value (R2) and a 
predicted sum of squares value (Q2) to describe the sample clustering and the 







From 128 women recruited to the biomarker pilot study, 46 participants were 
excluded prior to analysis. (Figure 6.3) Following exclusions three groups remained:  
1) Women with sPTB ≤33+6 without evidence of infection; n=12  
(16wk n= 11, 20 wk. n=11, paired samples n=9)  
2) Women with PPROM ≤33+6 without known cause for PPROM; n=10  
(16 wk. n=10, 20 wk. n=9, paired samples n=9) 
3) Term controls; TERM n = 60 
(16wk n=55, 20wk n=53, paired sample n=50) 
Metabolites Identified 
 Background noise was removed using the QC steps outlined. A data matrix of 
145 bins per sample, with 101 bins assigned to 35 metabolites was produced. 
Appendix M details the full list of metabolites identified.  
Removing Outliers 
Once phenotype exclusions had occurred (Figure 6.3), the initial PCA for 16 
weeks (Figure 6.4a) and 20 weeks (Figure 6.4b) demonstrated outlying samples in 
the term control group. 
Both samples for participant 129 were flagged as outliers at both 16 and 20 
weeks. This makes a measuring error during NMR processing less likely. Her 
clinical data was examined for potential causes. Apart from reporting eczema, 
smoking 6-10 cigarettes and taking pregnancy vitamins, no unusual medications or 
drug use was reported. Specific questions regarding diet were not explored beyond 































































































































































































Therefore, a specific diet or undisclosed drug consumption may have affected this 
profile. As no explanation was found, this patient was excluded. The sample for 
control participant no. 28 was also noted to be an outlier. In an otherwise fit and 
healthy individual, it was considered that this could be a sampling or measuring error 
and was removed.  
Participant Demographics 
Table 6.1 shows the clinical characteristics of these study participants. There 
are no significant differences between groups based on age, BMI, smoking or the 
gestation the samples were taken. The cervical length measured at 16 weeks does not 
show a statistical difference, but at 20 weeks it does fitting with this as a known 
predictor of sPTB.  
 
Table 6.1 Characteristics of Study Participants 
Data sPTB (n=12) PPROM 
(n=10) 
TERM (n=59) p-val 
Age, yr.* 31 (20-40) 31 (21-36) 31 (19-40) .557 
BMI, *  28 (20-39) 25 (23-33) 25 (18-35) .312 
Smoking, (%) 1 (8) 3 (30) 16 (27) .322 
n, samples A visit 11 10 54 NA 









CL at sampling, 16wk 
visit* 
33 (20-42) 39 (19-52) 36 (25-60) .277 
n, samples 20wk visit 11 9 51 NA 









CL at sampling, 20wk 
visit* 
25 (5-37) 28 (0-37) 35 (23-56) <.001 
n, paired samples 10 9 46 NA 







*median(range). sPTB Spontaneous labour <34 weeks, PPROM PPROM <34 weeks, TERM women with term 






Comparison of all participants at 16-week gestation (TERM n=54, PPROM n=10, 
sPTB n=11).  
The uploaded data matrix file contained 75 samples by 145 spectra bins for 
analysis, with zero missing values. Normalisation and scaling were performed before 
analysis (Figure 6.5).  
The one-way ANOVA is shown in Figure 6.6. The metabolites meeting the p 
value threshold of 0.05 are labelled in blue. To show the differences in normalised 
metabolite concentrations between the groups, Figure 6.7 presents the boxplots of the 
assigned metabolites per group (PPROM – red, sPTB – green, TERM – blue). The 
median values of the PPROM group and TERM group appear consistently more 
similar in this analysis compared to the sPTB group coloured in green. However, 
none of these metabolites were statistically significant after adjusting for multiple 




Figure 6.5. Box plots and kernel density plots before and after normalisation prior to 
data analysis at 16 weeks. Normalisation: Probabilistic quotient normalization 



































































































































Figure 6.7. Boxplots of the assigned metabolite per group. The bottom and top of the box 
are the 25th and 75th percentile. The black dots represent the concentrations of the selected 









Comparison of all participants at 20-week gestation (TERM n=51, PPROM n=9, 
sPTB n=11).  
The uploaded data matrix file contained 73 samples by 145 spectra bins for 
analysis with zero missing values for the three analysis groups. Normalisation and 
scaling of the data were performed as described. 
The one-way ANOVA comparing assigned metabolites is shown in Figure 
6.8. Ten metabolite peaks annotated above the black line represent the features that 
showed a statistical difference based on p value <0.05. The box plots to allow 
comparison of groups is shown in Figure 6.9. Although the PPROM group (labelled 
in red) appears to have consistently lower mean values than sPTB and term groups, 
the variance around normal is large and there is overlap between the concentrations 
of metabolite in the PPROM/sPTB and the term group. There were no metabolites 












































































































































Figure 6.9. Boxplots of the assigned metabolite per group. The bottom and top of the box are 
the 25th and 75th percentile. The black dots represent the concentrations of the selected 





Time-paired Sample Analysis  
The next analysis compared temporal changes in the metabolites from week 
16 to week 20. For this analysis a balanced design was required to perform one way 
repeated measures (within subjects) ANOVA, the groups had to be equal and 
therefore nine pairs of samples sPTB (n=9), PPROM (n=9) and TERM (n= 9) were 
analysed, with the TERM samples selected at random. 54 samples were included in 
the analysis matrix of 145 bins per sample, with 101 bins assigned to 35 metabolites. 
Following normalisation of the data, the data was viewed as 3D PCA plot (Figure 
6.10), no outliers were identified and no clear separation between groups was 
demonstrated. The results of the temporal analysis ANOVA are shown in Figure 6.11 
and Table 6.2. 
 
Figure 6.10. Still image taken from an interactive 3D PCA plot. No clear separation can be 






































   
 
   
 
    
  
    











            
     
    
    
            
       






Figure 5. ANOVA for metabolites between 16 and 20 weeks. The table below the graph 
shows the p values and FDR (adjusted P-val) for the metabolites showing the biggest 
difference between groups over time. None remain statistically significant (<0.05) following 




Table 6.2. Metabolites showing the largest temporal change between groups, p values and 
FDR (adjusted P-val) shown. None remain statistically significant (<0.05) following 
adjustment for multiple testing 
 
Name F-value Raw P-val Adjusted P-val 
desaminotyrosine_12 38.642 0.024915 0.71431 
Isoleucine_138 31.609 0.030211 0.71431 
unknown_73 30.251 0.031503 0.71431 




Comparison of sPTB (n=11) versus PPROM (n=10) groups at 16 weeks 
Samples taken at 16 weeks for women with sPTB (n=11) and women with 
PPROM (n=10) were compared. Fold change (FC) analysis compared absolute 
values of group means per assigned metabolite. The four metabolites reaching the FC 
threshold (1.2) are highlighted in pink (Figure 6.12). Boxplots of concentration 
values for these four metabolites, unknown 21/22, proline and acetoacetate are 
shown in Figure 6.13. 
T test results found no significant features between the two groups for an 
adjusted p-value cut-off of 0.05 (FDR). Figure 6.14 shows the summary volcano plot 
of FC change and t test results (p values). Only acetoacetate showed a difference 
between the two groups with lower concentrations on average in the PPROM group 
(Figure 6.15). However, if using adjusted p values, acetoacetate is not associated 
with a difference between groups. 
Principal component analysis score plot (Figure 6.16) shows no separation 
between the groups at 16 weeks. As no obvious differences can be seen between the 





























































































































































































































































































































































































































































































































































Figure 6.15. Boxplot of acetoacetate. The black dots represent the concentrations of 
acetoacetate in all samples. The mean concentration of the group is represented with a 
yellow diamond. The whiskers extend to the highest and lowest observations. 
Score plot for top PCA to differentiate sPTB and PPROM at 16 weeks 
 
Figure 6.16. Score plot between top principal components (PC). The explained variances are 




Comparison of sPTB (n=11) versus PPROM (n=9) group metabolites at 20 weeks 
gestation 
Serum analysis comparing metabolite spectra from the second 20-week 
timepoint was performed on 11 sPTB samples and 9 PPROM samples. 
Normalisation and scaling were performed as previously to achieve Gaussian 
distribution of data.  
FC analysis (Figure 6.17) echoed the findings for 16 weeks and with a 
threshold of 1.2 both unknown metabolite 21 and 22 were differentiated between the 
groups (higher in PPROM group compared to sPTB). In addition, mannose, 
desaminotyrosine and unknown metabolite peak 1 had lower concentrations in the 
PPROM group compared to sPTB. T test analysis found no statistically significant 
differences between the two groups with an FDR of 0.05. The volcano plot (Figure 
6.18) are shown below, with desaminotyrosine shown to be the metabolite with the 
largest difference between the two groups. The normalised concentrations are shown 
by boxplots in Figure 6.19. 
A principal component analysis (PCA) was performed but shows little 
separation between the two groups with mostly overlapping 95% CI (Figure 6.20). A 
discriminant analysis was performed to sharpen the separation of the groups based on 
the metabolomic observations. This gives a better distinction between the groups 
(Figure 6.21a). However, when the cross validation of the model is investigated, it 
shows the model is a poor predictor and almost certainly overfitted due to the small 










































































































































































































































































































































































































Score plot for top PCA to differentiate sPTB and PPROM at 20 weeks  
 
Figure 6.20. Score plot between top principal components (PC). The explained variances are 
shown in brackets. 95% CI are shown by coloured circles. 
Figure 6.19. Boxplots to show differences in the metabolomic feature desaminotyrosine 
between PPROM and sPTB. The black dots show the normalised concentration for each 
















































































































































































































































































































6.5 Discussion  
 
A detailed assessment has been made of the NMR profile of serum collected 
at two different time points in the second trimester from women at high risk of sPTB.  
This study found that overall maternal serum samples could not differentiate 
between women experiencing PPROM, sPTB and TERM deliveries based on their 
metabolite profiles at 16 or 20 weeks. A subset of data to give balanced groups were 
used to perform a time paired analysis across 16 to 20 weeks in all three groups; 
sPTB, PPROM and TERM. No metabolites with temporal change showed any 
association with sPTB or PPROM. 
No metabolites differentiated between PPROM and sPTB groups at 16 
weeks. Acetoacetate showed a greater magnitude fold change than other metabolites 
and statistical significance (p value), however, it did not associate with sPTB 
following adjustment for multiple testing, which is not surprising given the small 
number of samples tested. However, this finding was not seen at the 20-week 
comparative analysis, which might be expected if this metabolite was predictive of a 
difference between sPTB and PPROM. It has also not been reported in other 
metabolomic studies of PTB. Acetoacetate is the conjugate base of acetoacetic acid 
and is released into the bloodstream during periods of fasting (Berg et al. 2002). As 
we have no information on time from last meal, we cannot be sure if the difference in 
fasting times between groups may have caused this result. 
At 20 weeks, desaminotyrosine differentiated the groups after fold change 
and t-test analysis showed a lower maternal serum concentration level in women 
subsequently experiencing PPROM. Again, given the small sample size, it is not 




comparing all three groups (PPROM, sPTB and TERM), showed that mean levels for 
sPTB and TERM were similar, and only PPROM appears to have lower levels. Adding 
strength to this finding was the differentiation at multiple metabolite peaks for the 
same metabolite on the spectra. The NMR spectral signature for desaminotyrosine 
is shown in Figure 6.22. Desaminotyrosine (DAT) has four peaks on the spectra, 
Figure 8. Figure 60. 1H NMR Spectrum (HMDB0002199). Compound name 
'Desaminotyrosine'. Image taken from the Human Metabolome Database (accessed at 




however only the two peaks in the ppm range 2-3 were detected by NMR, and both 
differentiated between groups.  
It is difficult to understand biological plausibility behind participants with 
PPROM having lower DAT. Desaminotyrosine, also known as 4-
hydroxyphenylpropionic acid, is a degradation product of flavonoids, a compound 
most commonly found in plants. The gut microbiota generates many small 
metabolites that enter the systemic circulation, and DAT is produced by human 
enteric bacteria from flavonoids and amino acids (Steed et al 2017). In mice, DAT 
produced by gut bacteria has been shown in mice to be protective against influenza 
through the augmentation of type 1 interferon (IFN) (Steed et al. 2017). However, 
when type 1 IFN has been studied in a pregnant mouse model, upregulation of type 
1 IFN sensitises the animals to bacterial products predisposing to spontaneous PTB. 
(Cappelletti et al. 2017). Therefore, it is not clear how reduced DAT serum levels 
could contribute to PPROM. We did not collect detailed dietary information and low 
levels of DAT may be simply a surrogate for a poor diet containing low quantities of 
plants (i.e. low flavonoids) which also contain other antioxidant properties. If DAT is 
protective against viral illnesses through augmentation of type 1 IFN, it could be 
surmised that potentially there is a viral cause for PPROM and the sPTB and TERM 
groups are protected. This is highly unlikely as there has been very little evidence 
for the role of viral infection in PPROM to date. Out of 174 AF samples from 
patients with PPROM tested with PCR for human cytomegalovirus (HCMV), herpes 




(EV) and human parechovirus (HPeV), only 1 was positive for a viral genome 
(Bopegamage et al. 2013).  
Of interest are the two unknown metabolites (or a single metabolite with two 
closely related peaks) found to differentiate the groups on fold change analysis at 
both 16 and 20 weeks increases the possibility that this may not be a chance finding. 
If this is truly a novel metabolite or drug degradation product to be identified, then 
the next step would be to try to perform a full structure elucidation. This would 
typically entail isolation and purification of the metabolite from serum and using 
techniques of NMR spectroscopy, MS, infrared spectroscopy and ultraviolet 
spectroscopy detail the metabolites full structure. (Dona et al. 2016).  
Overall principal component analysis showed comparable variance between 
the two groups at both gestations tested and a predictive model could not be 
generated without overfitting data. This may be due to the small sample size and the 
community recognition of PLS-DA as a limited technique (Gromski et al. 2015). 
This study is the first metabolomic study that has compared multiple 
timepoints in high risk women with a preterm birth <34 weeks, that has also 
attempted to establish if there are different metabolomic phenotype profiles between 
sPTB and PPROM.  
Strengths of this study are the unique high-risk population from which these 
samples are obtained, the extent to which births have been phenotyped and that 
samples are available for multiple timepoints in the second trimester. Prior studies 
examining metabolites associated with preterm birth have noted the importance of 
collecting samples at the same timepoints instead of immediately prior to labour 
which is a limitation of some metabolomic studies (Menon et al. 2014, Lizewska et 




A particular strength of this study is focussing on predictors in the early 
preterm birth group (<34 weeks). Naturally it is a harder group from which to obtain 
samples as there is a much lower incidence than late preterm births (34-37 weeks). 
Many studies which at first glance appear to present impressive numbers of 
participants, often have included all sPTBs <37 weeks which clinically has less value 
due to the burden of morbidity and mortality associated with the earlier gestations of 
delivery. An example would be the largest metabolomic study from the SCOPE 
cohort that recruited 5,690 low risk nulliparous women across several hospital sites 
in four different countries (Souza et al. 2019). Data was available from 55 sPTB 
from Cork in Ireland (discovery) and 55 women with sPTB from Auckland in New 
Zealand (validation). Approximately half of whom had been classified as PPROM, 
but unlike our study not analysed as a separate group. Only 16 women in Auckland 
and 13 women in Cork delivered <34 weeks, similar to the numbers in our study 
(n=21 at 16 weeks, n=20 at 20 weeks if PPROM and sPTB were combined). Using 
GC-MS analysis they found that elevated alkanes (decane, undecane and dodecane) 
were higher in sPTB <37 weeks in the Cork cohort only, but there was no evidence 
these alkanes were associated with sPTB < 34 weeks in either study site. (Souza et al. 
2019) 
The strength of NMR analysis is that it isn’t hypothesis driven and can 
provide new insights into the pathology of complex diseases such as preterm birth. 
The entire visible metabolome is taken into account and metabolites with both large 
and small effect contribute to differentiation of groups and predictive modelling.  
Appropriate scaling and normalisation was performed as part of the study 
design. PQN normalisation has been shown to be more accurate than integral 




Limitations of this study include 1) small sample size, 2) methodological 
limitations in identifying all metabolites, 3) absent validation cohort, 4) no 
controlling for type of diet or fasting times.  
Our findings are somewhat limited by the relatively small number of cases 
used, despite the well phenotyped cohort of births <34 weeks. Our small number of 
cases and controls may increase the risk of reporting false negatives. This is 
particularly important for our smaller sub-groups of sPTB (n=12) and PPROM 
(n=10) that did not differentiate in this analysis when false positives were properly 
controlled for however, some differences have been suggested by the data that 
warrants further exploration. Therefore, the null hypothesis cannot be confidently 
excluded. 
The disadvantages of the 1H NMR method using multiple bins are that it is 
time consuming to assign metabolite peaks to get maximum identification of 
metabolites and can be subject to data interpretation errors due to overlapping peaks. 
However overall, NMR is highly reproducible but limitations in our current 
knowledge meant that not all metabolite peaks could be identified at this time, 
illustrated by unknown samples 21 and 22. 
We did not perform a validation study as the purpose of this thesis was to 
combine different omic layers. However, an important progression of this study is to 
identify a validation cohort to establish the reliability of these results. Additionally, 
studying samples from low risk women (i.e. no previous preterm births) may see 
bigger discrepancies in effect sizes that are captured more easily.  
We did not control for other probable sources of variability in the metabolite 
profile such as time of day, type of diet and time from most recent meal. Normalising 




However, we did not collect this type of self-reported data from our participants and 






From 1H NMR analysis of different birth phenotypes there is no data to 
suggest there are metabolite differences at 16 and 20 weeks or between 16 and 20 
weeks, that can contribute to prediction of birth phenotype. Our data suggests some 
potential differences between sPTB and PPROM groups, but these findings should 
be interpreted with caution given the small study size. Further work in this area 
should be pursued before ruling in our out any differences. Overall, there was no 
purely NMR metabolic model that could clearly discriminate the groups leading to 
the possibility that any successful model would require additional information 





Chapter 7: Integromics for the Prediction of 




7.1 Introduction  
 
The objective of integrating multi-omic data (Integromics) is to construct a 
model that can be used to predict women who will have sPTB. By integrating the 
omics data from the same women, as opposed to data sets from different populations, 
we are increasing the chance of identifying ‘cross-talk’ across omics platforms and 
potentially identifying predictive biomarkers.  The previous four chapters explored 
the data from individual “omics” layers and phenotypes from this cohort of pregnant 
individuals and highlighted the quality control methods employed to ensure a reliable 
input dataset. This chapter will outline the combination of these data. 
Different analysis methods of combining omics data were previously 
discussed in chapter 2. In summary, the meta-dimensional approaches to combine 
different omics dataset for analysis included concatenation, transformation and 
model-based integrations, each with their own strengths and weaknesses. We chose a 
concatenation-based model as it’s a) is relatively easy to apply statistical tests for 
categorical data analysis and b) does allow for crosstalk between omics layers via 
interaction. We tested seven different machine learning strategies on our dataset to 
identify the most predictive strategy and provided a prediction of sample sizes for a 
new multi-omic study required for replication. Finally, we interrogated the most 






Study Population  
From the cohort described in chapter 3 we included only women that had data 
genomics, transcriptomics and proteomics once quality control processes were 
complete. How these results were obtained is described in chapters 4, 5 and 6. 
Women with a sPTB or PPROM <34 weeks (as per chapter 3 definition) were 
included as cases and women with delivery >37 weeks were controls. All women 
delivering between 34-37 weeks (late sPTB) were excluded.  
Multivariate Modelling 
Using concatenation-based integration, a large matrix of all data types was 
created from the raw data. Data combination followed by machine learning analysis 
performed by Professor. Bertram Müller-Myhsok, an expert in statistical genetics 
and machine learning based at the Max-Planck Institute of Psychiatry, Munich, 
Germany. 
Cross Validation 
In this analysis, while the subjects were independent, the samples collected 
from various trimesters of the same subject were not. The unsupervised nature of the 
multi-omic methods makes it difficult to determine whether a method is overfitting or 
identifying a true biological relationship. To account for this, we designed a ‘leave-
one-out’ cross-validation strategy. A model was trained on all available samples 
except for all the samples at 16 and 20-week timepoints of a given subject. The 
model was then tested on all samples of the subject that it was blinded to. This 
process was repeated for all subjects until a blinded prediction was produced for all 




close to the error in the training set. Final results are reported using these blinded 
predictions. This ensures complete independence from any inter-subject correlations.  
Multi-Omic Machine Learning Method Comparisons 
We ran prediction algorithms on the cross-validation data. The seven 
statistical approaches used were 1)‘linear discriminant analysis’ (Fisher. 1936) 
2)‘Genetic expression programming’ (Ferreira. 2001), 3)‘K-means’ (MacQueen. 
1967), 4)‘Support vector machine with a linear kernel’, (Cortes and Vapnik. 1998, 
Bradley and Mangasarian. 1998), 5)‘Support vector machine with a Gaussian 
Kernel’ (Cortes and Vapnik. 1998, Bradley and Mangasarian. 1998), 6)‘Probabilistic 
neural network (Specht. 1990)’ and 7)‘Random Forest’ (Ho. 1995). These were 
chosen as representatives of commonly used types of methods. We estimated the area 
under the curve (AUC) of the receiver operating characteristic (ROC) in cross-
validation data with the null set equal to an AUC score of 0.5 (equal to random 
guess), which enabled comparison of the performance of the different methods on 
this dataset. This methodology also permits calculation of sample sizes for future 
multi-omics project.  
Linear Discriminant Analysis 
Discriminant analysis is a popular method for multiple class classification 
(sPTB, PPROM and TERM). In its original form it goes back to Fisher (1936). It 
focuses on reducing the original variable data matrix into a lower dimensional space 
and maximises the separability among known categories. This is performed through 
three steps; the first is calculating between-class variance, the second is calculating 
within-class variance. The third step is to reduce the dimensional space to maximise 




separate variable means whilst minimising the variation (or scatter) within each 
category (Tharwat et al. 2017). 
Genetic Expression Programming 
Genetic Expression Programming (GEP) is a learning algorithm invented by 
Candida Ferrerira in 2001 (Ferreira. 2001). GEP learns specifically about 
relationships between variables in sets of data and subsequently builds models to 
explain these relationships. It functions through an architecture based on two entities; 
‘the chromosome’ and the ‘expression tree (ET)’. This is a full-fledged 
genotype/phenotype system with expression trees of different sizes and shapes 
encoded in linear chromosomes of fixed length. GEP chromosomes are multigenic, 
encoding multiple expression trees or sub-programs that can be organized into a 
much more complex program. Figure 7.1 shows the reproduction process containing 
the modifications performed by the algorithm operations that allows for the evolution 
of a simple replicator system.  
K-means 
The term “k-means” was first coined by James MacQueen in 1967 (MacQueen. 
1967). K-means is the most popular clustering algorithm (Jain. 2010). It is an 
unsupervised learning algorithm. K-means clustering attempts to divide data into “k” 
number of separate groups and is effective at uncovering novel patterns (Theobald. 
2017). In our analysis, K was set to two (sPTB and TERM). In the first step, the 
algorithm examines the unclustered data and selects a central point or centroid for 
each of the clusters. The rest of the datapoints are then assigned to a centroid using 
the Euclidean distance. Once all datapoints are allocated, the mean value of the 
datapoints in each cluster is aggregated. These are then used to update the centroid 




some datapoints switching clusters. If this happens the whole process is repeated, 




Figure 7.1. Flowchart from GEP algorithm. From Gullu, H. 2012. Prediction of peak 
ground acceleration by genetic expression programming. Engineering Geology. 141-142: 
92-113. Adapted from Ferreria, C. 2001. Gene Expression Programming: A New Adaptive 




Support Vector Machine with a Linear Kernel 
Support vector machine formulation is used to enlarge the feature space of 
predictors to create a decision boundary that is linear, where the original decision 
boundaries are non-linear. With already so many features, enlarging a feature space 
even further may make the data unmanageable. However, the support vector machine 
allows for enlargement of the feature space in a way that leads to efficient 
computation (James et al. 2013). It creates a fast, linear programming algorithm that 
will discriminate between massive datasets in n-dimensional space and results in an 
optimal separating plane for the entire dataset (Bradley and Mangasarian. 1998). 
Support Vector Machine with a Gaussian Kernel 
A Kernel is a computational function that quantifies the similarity of two 
observations (James et al. 2013). A kernel does not always have to be linear, it could 
be polynomial, radial, or as used here, gaussian. The advantage of using a kernel, 
rather than enlarging the feature space, is that it makes it computationally faster to 
perform these functions on data pairs, avoiding always having to work in the 
enlarged feature space. In summary, this is another way of creating hyperplanes to 
capture decision boundaries between groups.  
Probabilistic Neural Network  
This is a popular classification technique in machine learning to process data 
through layers of analysis. Like neurons in the human brain, networks are formed by 
interconnecting neurons, called nodes, which interact with each other through axons, 
called edges (Figure 7.2). There is an “all or nothing” arrangement as the sum of the 
connected edges must satisfy an activation threshold to communicate with the node 




 The final decision node will output the class with the highest summed 
activation. This has the advantage of being a very flexible type of analysis, but 
computationally takes much longer to complete. The specific implementation used 
here goes back to Specht (1990). 
Random Forest 
The random forest methodology has been previously explained in detail in 
section 5.2. In short, this technique uses multiple decision trees with an artificial cap 
on the number of variables that can be considered for each split. It has the advantage 
of being relatively easy to perform and computationally fast. 
 
Figure 7.2 Schematic of basic neural network. Nodes are stacked in layers. The first layer of 
input is the raw omics data divided into nodes. Each node sends information to the next layer 
via edges. If the sum of the connected edges satisfies a set threshold (activation function) this 




Sample Size Estimations 
Once all classification algorithms were run, we then calculated the predicted 
sample size required for a three-layer multiomics study against different accuracies 
of AUC. Under the assumption that we would have 80% term controls and the same 
biomarker effect sizes as well as phenotypic distribution, we estimated the sample 





Four women with sPTB, one woman with PPROM and ten women delivering 
at term had full omic data available at both timepoints analysis. As there was only 
one PPROM participant this could not constitute a group and would not have been 
classified by machine learning. Having had such poor differentiation of PPROM and 
sPTB classes in the omics analysis performed in the other chapters, we kept this as a 
case and included it as a case of sPTB (Figure 7.3). 
The AUCs for all six tests can be seen in Figures 7.4-7.10. A summary of the 
results of the machine learning analysis are shown in table 7.1. K-means and 
probabilistic neural network were the most predictive statistical tests with an AUC of 
1.00. The variable importance’s for each test are included in Appendix M. 
Figure 7.11 demonstrates that for a clinically predictive AUC (>90) it would 
be possible to obtain reasonable power with a relatively small number of women 
recruited to a multi-omics study. Using this graph, if we expected a minimum AUC 
of 0.9 to be found with a repeat study, with an alpha level of 0.001 (probability of 
rejecting the null hypothesis when true) being desirable, then we can estimate that a 
sample size of 50 would be required This calculation is based on 80% term controls 

















































Figure 9. AUC for Linear Discriminant Analysis 
 





Figure 7.6. AUC for K-means 
 





Figure 7.8. AUC for Support Vector Machine with Gaussian Kernel 
 
 










Table 7.1. Summary of results of machine learning algorithms to predict sPTB in our cohort. 
Algorithm used AUC of ROC 
obtained 
Linear discriminant analysis 0.90 
Genetic expression programming 0.70 
K-Means 1.00 
Linear support vector machine 0.96 
Support vector machine with a Gaussian Kernel 0.94 
Probabilistic neural network 1.00 












Figure 11. Estimates of sample size across AUC's with significance levels colour 






This chapter shows that combination of multiomics from individuals to 
predict sPTB is possible. Nearly all analysis methods that were tested on our dataset 
found good levels of prediction except for genetic expression profiling (GEP). GEP 
only gave an AUC of 0.7, which was much lower than other methods with excellent 
prediction (≥0.9). These findings clearly need to be validated in another multiomics 
study. 
A challenge for designing multiomic studies is obtaining enough samples to 
generate enough statistical power, particularly when testing a relatively rare 
population or condition that is hard to predict, such as sPTB. Simulation tools such 
as OmicsSIMLA have the ability to combine omics and calculate sample size and 
power for a new multiomics study (Chung and Kang. 2019). McKeigue (2019) has 
described a simple method based on a Gaussian approximation for calculating the 
predictive performance of the learned classifier, given the size of the biomarker 
panel, the size of the training sample, and the optimal predictive performance of the 
biomarker panel if a training sample of unlimited size were available, however these 
are not based on real data. We have provided a more accurate estimate for the 
purposes of trying to calculate a sample size that would provide enough power to 
predict sPTB classification.  
A criticism of the data would be that we have such small groups in our final 
analysis. RNA analysis was only collected and performed for a subset of 56 patients 
in this cohort (of which 29 controls, 5 sPTB, 6 PPROM) which has been the largest 
limiting factor for numbers in our overall omic analysis. However, following sample 
storage, extraction and laboratory quality control checks using our methodologies the 




metabolomics) at 16 weeks were limited to only 10 term controls and 5 sPTB cases 
(4sPTB and 1 PPROM). This means, at this stage, that we cannot clearly answer if 
omics can differentiate between sPTB and PPROM as we have insufficient sized 
subgroups. We had to combine the sPTB and PPROM to create a single sPTB group, 
predominantly represented by sPTB. This is disappointing as the purpose of rigorous 
classification was to avoid heterogenous groupings as much as possible. However, 
when compared to other sPTB studies in the literature, it is not uncommon to have 
such small comparison groups. For example, Chan et al (2014) compared RNA 
sequencing data in the myometrium collected at caesarean section of n=5 sPTB cases 
and n=5 term births,  Gray et al (2017) compared miRNA of n=7 sPTB with n=8 
term controls, Pereyra et al (2019) published a transcriptomic analysis of fetal 
membranes comparing n=15 term birth cases and n=9 sPTB cases and chapter 2 of 
this thesis contains many more examples. Not only did these examples study only 
one type of omic, but for two of these studies listed above the samples were taken at 
delivery, for which they do not have a gestational age matched control. A clear 
strength of this study is that our samples were not only taken at the same gestational 
age timepoints, we also have different layers of omics data from the same individual 
which we have shown can reduce the number of samples required to power this type 
of study.  
After discussing different methods of combining omics data for further 
analysis in chapter 2, we chose a concatenation-based model as it’s a) is relatively 
easy to apply statistical tests for categorical data analysis and b) does allow for 
crosstalk between omics layers via interaction. 
The obvious question is, why is it necessary to evaluate so many different 




priori? As the different methods work better or worse depending on the dataset, there 
is no one method that dominates all the others on every dataset. (James et al. 2013) 
With a specific dataset, it is an important task to decide which method produces the 
best result, but this is not necessarily transferable to a similar but different dataset.  
With prediction accuracy and model interpretability there will always be a 
trade-off between the flexibility of the model to fit the available data points and 
interpretability. In general, as the flexibility increases the interpretability decreases. 
(James et al. 2013) Some methods can lead to very complicated estimates of the 
unknown function of predictor variables. It can become too difficult to work out how 
individual predictors are associated with outcome. This can be seen clearly with 
support vector machines with non-linear kernels which are higher in flexibility than 
trees, but also much harder to interpret. There are many more variable importance’s 
produced from the random forest than the support vector machines (Appendix M). 
The type of model that we would ultimately choose may depend on how much 
inference is important once prediction was established.  
To try and better understand sPTB, particularly to design new preventative 
interventions, it is important that we ultimately understand how our dependent 
variable changes as a result of important predictors. However, the primary purpose of 
this thesis was first and foremost to establish accurate prediction, therefore the 
interpretability when choosing models was a secondary consideration. This does not 
necessarily mean that the most flexible model is either the most accurate or best 
choice. Highly flexible models can model so closely to the known data points (and 
errors), that they become poor predictors when attempting to classify new datasets – 





This analysis shows that it is possible to combine multiomics data to predict sPTB. 
For a future study using multiomics methodology we would expect an AUC of >0.9 
for prediction of sPTB. Only a sample size of approximately 50 participants (with 10 
sPTB cases) would be required for validation at a power of 0.8. However, in view of 
the small size of this discovery set, there is a possibility of an overfitted model. In 
addition, the practical issues in obtaining the samples and sample dropout rate should 
be taken into consideration when planning a validation study. This recruitment figure 
would need to be doubled, as a minimum, to allow for a complete omics data set at 
the analysis. Lastly, this calculation only accounts for the combination of sPTB and 
PPROM cases as a single group – if further analysis of different subtypes were to be 









8.1 Addressing Aims 
 
The primary aim of the thesis was to establish a way of combining three 
different types of ‘omics’ analyses used in a pilot study for the prediction of sPTB. 
Chapters 3, 4, 5 and 6 showed the analysis of the individual layers of omics data 
including how the participants were divided based on phenotype. Chapter 7 
addresses the multi-omic machine learning comparisons that were used for 
‘prediction’ using this pilot cohort group. Overall, this thesis shows that this type of 
analysis is possible. It may not only be a useful tool to establish predictors of preterm 
birth but may allow us to evaluate the most important cross-omic biological signals 
that weight these predictions.  
I also aimed to establish if there were distinct differences in biomarkers 
between PPROM and sPTB subgroups of sPTB within my results. Contrary to my 
expectations, I did not find many signals suggesting differences between the 
subgroups, but I feel there is further work to perform in this area. The GWAS data 
analysis require large sample size to find differences in groups, and for this analysis 
the groups were kept as large as possible (sPTB and PPROM cases were combined 
into one larger group) – therefore genetic data could not contribute to finding 
differences. The transcriptomic data found no differences between sPTB and 
PPROM groups. After FUMA analysis demonstrated enrichment of the selenoamino 
acid metabolism pathway in the high-risk preterm birth population, the hierarchical 
clustering analysis that followed clustered the PPROM cases among the sPTB cases 
(Figure 5.7). Only metabolomic data showed a suggestion that there might be 
differences between sPTB and PPROM, but these data were not controlled for diet or 
time from fasting and there is a high chance that any differences seen are potential 




8.2 Key Findings 
 
Perhaps the most interesting, clinically relevant and unexpected finding from 
this work was the support for selenium playing a key role in sPTB. Existing work 
from a GWAS study (Zheng et al. 2017) had already suggested that the EEFSEC 
(Selenocysteine elongation factor) gene is associated with sPTB. When we compared 
odds ratios for a SNP on the EEFSEC gene with published data from the Zheng et al. 
study, our data agreed that this gene is associated with sPTB <37 weeks. 
Independently, the findings of our GSEA of the transcriptomic data also suggest a 
role of selenium in the initiation of sPTB. After adjusting for multiple testing three 
genes in the selenium pathway were found to be statistically significant; CTH, 
LCMT1, TRMT11. The machine learning method of analysis we used could not have 
been influenced by any prior knowledge. Having both omic layers (genomic and 
transcriptomic) support this data independently is far more powerful than either on 
its own and suggests this is an important area for future study.  
Another important output from this study is the ‘feasibility’ of performing a 
multi-omic study with well phenotyped groups. There are several stages at which 
samples are ‘lost’ despite good overall recruitment of participants to the study. 
Patients not attending (n=6) or declining participation (n=2) at follow up occurred. 
Declining participation occurred at follow up as one woman had experience of a 
difficult venepuncture at her GP practice and remained bruised. She did not wish to 
have any further unnecessary blood tests. Another woman could not wait to see the 
recruitment team following her clinic appointment due to time pressures with 
childcare. The biggest area to impact recruitment Figures was establishing a clear 
delivery phenotype, which frequently resulted in exclusion from the study. 




analysis are fewer than those recruited. Of 128 women recruited, 41 (32%) women 
were excluded once delivery phenotypes were available (Table 3.4, page 126). For 
future multi-omic studies, this data will be useful for setting recruitment targets and 
remaining realistic about what any single centre can achieve. Collaboration of 
multiple centres is likely to be necessary to achieve a study size of value in multi-
omic work to allow for discovery and validation and allow for subgroup analysis of 
sPTB and PPROM. 
8.3 Discussion Points 
 
One of the major strengths of this study is the unique nature of the sPTB 
population. All the participants had a history of sPTB and therefore this is a study of 
recurrent sPTB versus a high-risk control. The advantage of recruiting cases 
experiencing a recurrent preterm birth is there may be positive selection of 
aetiologies of sPTB inherent to the mother rather than an individual pregnancy. For 
example, women with a genetic predisposition to sPTB may be more likely to have 
two pregnancies affected by sPTB than if infection was the cause, which may only 
affect a single pregnancy.  
Although recruitment was performed in a high-risk population for sPTB < 34 
weeks gestation, recruiting both low and other high-risk populations for sPTB were 
considered. Opening recruitment to the whole obstetric (low risk) population would 
enable recruitment of women with sPTB/PPROM <34 weeks and additionally 
women with only term deliveries >37 weeks (i.e. no previous preterm births, a low 
risk control). However, the incidence of preterm birth in a low risk population <37 
weeks is approximately 7.1% in the UK (Office of National Statistics 2017). When 
considering only early sPTB or PPROM between 23 and 34 weeks this figure 




difficult in the low risk population as too many participants overall would be 
required to achieve the same number of cases. Additionally, the design of our study 
would have changed if we had decided to recruit from the general obstetric 
population. Scheduled hospital contact for ultrasound scans occur at 12 and 20 
weeks, with additional midwifery appointments frequently occurring in the 
community; therefore 12 and/or 20 weeks would pragmatically have been the best 
recruiting timepoints at hospital for a low risk population. Compared to recruiting 
from the preterm birth clinic, difficulties with this method of recruiting include 
identifying and contacting women for participation in advance of their first scan, 
particularly as the viability of the pregnancy may not be known. Recruitment would 
take a long time, and bias may be introduced by the type of women choosing to 
participate in the research study, potentially leading to fewer preterm births amongst 
the participants than planned. However, adding a low risk control group to this study 
in the future is an area to consider and would be feasible if only “healthy” volunteers 
with a history of term birth are approached. To get samples at the 16- and 20-week 
gestation timepoints, women would have to be invited to participate and a separate 
research appointment scheduled. Women could be identified after viability was 
confirmed at the 12-week scan, there is a singleton gestation and no abnormal or 
concerning USS features are present. Hospital records could be searched to ensure 
that only women with previous term pregnancies are approached. Even if only 50% 
of women approached from this population accept participation in the study, they are 
all highly likely to have a subsequent term birth and the prevalence of this population 
is high, therefore recruitment will be faster than the high risk cohort even if take up 




There were other risk factors for sPTB/PPROM that I chose to exclude when 
recruiting. Women with short cervix without a history of sPTB, women who had 
‘significant’ cervical surgery and multiple pregnancies are three of the most 
significant examples. One of the strengths of this cohort was the homogeneous 
(“clean”) phenotype. Given that our analysis involved so many variables within the 
omics layers, the more we could minimise the differences in the aetiologies of sPTB, 
the more the groups may cluster and give us significant findings or new results that 
may have been missed in more heterogenous cohorts. Additionally, in the UK, 
screening for short cervical length does not occur routinely at present and therefore 
recruiting women with short cervix, but no history of sPTB is not feasible for our 
recruitment setting. Multiple pregnancies are seen frequently throughout pregnancy 
in the multiple pregnancy clinic (MPC) therefore recruitment would be feasible; 
however, the aetiology of preterm delivery in twin pregnancies is likely different 
from that of singletons.  
We also considered obtaining samples from large UK pregnancy biobanks. On 
enquiry, the samples obtained frequently did not have multiple timepoints from the 
same individual, the samples were not collected in the second trimester, the type of 
biological fluid we wished to use was not available or there would only be enough 
sample available for one type of omic analysis. The heterogeneity would have been 
too large and further highlights the uniqueness and importance of our recruited 
cohort.  
It was challenging to decide how to analyse the group of women who had a 
treatment for a short cervix, but ultimately delivered at term. It could be argued that 
these women had “successful” treatment i.e. the treatment prevented another sPTB. 




treatment given was superfluous. The truth is likely to be somewhere in between 
these two positions; therefore, we excluded these women.  
A criticism of our phenotyping is that despite being as thorough as possible, we 
were dependent on information recorded in clinical notes and made retrospective 
judgements on groupings. Relevant information may have been missed from the 
records. In the UK we do not perform specific screening for polyhydramnios or 
infection in pregnancy. It is possible that there may have been other cases of 
polyhydramnios where PPROM occurred before the increased amniotic fluid 
volumes were ever noted. Additionally, women who bled throughout pregnancy may 
have never reported this symptom or might not have been recorded clearly  
We did not see the differences between sPTB and PPROM that we had 
hypothesised that we might. A possible explanation, and another criticism of this 
data, is that our groups were too small to see significant differences at an individual 
omic level. We also did not have enough samples in the multi-omic comparison 
(chapter 7) to have PPROM as its own group, and therefore differences could not be 
tested. Another possible explanation is that there are no differences between these 
groups, i.e. we are not seeing a difference because there isn’t one. However, our 
phenotyping of the PPROM group was strict and we may have excluded cases with 
an aetiology that would have shown significant differences like infection or 
polyhydramnios. Without these, sPTB and PPROM are in fact the same when 
defined by omics signatures. This may also explain why other studies in the literature 
have suggested there are differences as they were not phenotyped with this degree of 
precision. To address this, further research with larger groups of sPTB and PPROM 




these groups, such as mass spectroscopy which typically identifies more metabolites 
than NMR. 
Of note, our population in this study is predominantly Caucasian (90%), as is 
typical for a Liverpool population. On one hand this makes our cohort increasingly 
homogenous, reducing known genetic variation based on ethnicity. On the other 
hand, this may reduce the generalisability of our results to a wider population. 
The issue of the small dataset was addressed in the discussion in Chapter 7 
(section 7.4). Despite being an obvious criticism of the data across all ‘omic’ analysis 
in this thesis, the evidence in the literature demonstrates how common other studies 
with comparatively small figures are. These studies are frequently only a single time 
point, and only investigating one specific omic analysis or panel of biomarkers. This 
highlights again the strength of this dataset, including the well-designed study 
methodology, use of multiple omics to increase predictive value and data from 
multiple timepoints. 
RNA was only collected for a subset of 56 patients in this cohort (29 controls, 
5 sPTB, 6 PPROM) and this is certainly the largest limiting factor for the 
integromics, as many women were excluded as they didn’t have RNA despite 
samples for genetics and metabolomics being available. Following all other 
exclusions only 15 women were left for analysis in Chapter 7. This data is essential 
for planning further omic studies as we would expect approximately a quarter of the 
women recruited to proceed to the final analysis, based on our estimates.  
Should we have collected a different sample for omics analysis such as urine 
or saliva, or used a more pregnancy specific tissue such as placenta or amniotic fluid 
instead of blood? I think it is reasonable to use blood as a source for biomarker 




are required to have blood taken at various stages during pregnancy. It is common for 
genetic studies to use whole blood for DNA extraction, but would gene expression 
from blood truly reflect a difference between the pregnancy cohorts? Popular belief 
initially assumed that mammalian erythroid cells, lacking a nucleus, were devoid of 
mRNA and therefore incapable of protein synthesis, making it a poor fluid for omics 
analysis, particularly transcriptomic analysis. Microarray studies on mRNA isolated 
from whole blood demonstrated that up to 70% of the total RNA isolate was actually 
from haemoglobin/erythrocytes and not the leukocyte fraction. (Tian et al. 2009). 
Blood quickly became a surrogate for tissue-specific RNA. Studies using microarray 
analysis have shown that blood cells share more than 80% of the transcriptome with 
each of nine tissues studied (brain, colon, heart, kidney, liver, lung, prostate, spleen 
and stomach), and estimates are that the blood transcriptome contains 16,000–20,000 
transcripts (Liew et al. 2006). Therefore, we felt that this was an appropriate fluid to 
study. As although it is not pregnancy specific like for example amniotic fluid, it 
may still detect signals from the uterus/placenta and has the advantage of being safe 
to collect in the mid-trimester to provide a gestational age matched control. 
A criticism of using cross-omics data as a predictive tool is that there could 
be a long way to go before any positive results of this type of research become 
translatable to a clinical setting for patient benefit. Omics analysis is unlikely to ever 
be fast enough for a bedside test. Omic services will remain highly specialised, 
samples require time and care to process, pass strict quality control thresholds and 
frequently require shipment to a specialist laboratory which may have a wait time for 
results that is incompatible with clinical need. Interpretation of omic data requires 




analysed using the techniques here, a woman would have already delivered. That is 
without mention of the prohibitive cost of the tests.  
A more realistic goal of data integration using advanced omic technologies is 
to identify key variables that are used by machine learning to classify women based 
on their outcome. These variables may subsequently be used to create a panel of 
predictive biomarkers that can be used in the clinic.  
Therefore, it would be prudent to move away from machine learning analyses 
that are very difficult to interpret. One disadvantage of neural networks is the “black 
box” dilemma. Despite the networks ability to approximate accurate outcomes, there 
is no way of tracing its decision structure, which then reveals very little insight about 
the variables that impact the final classification outcome (Theobald. 2017). Even 
given a dataset and network topology, there can be two neural networks with 
different weights and same result. This makes the analysis hard. The ‘Random 
Forest’ analysis struck the best balance in our dataset between being a good 
predictor, not being prone to overfitting and remaining interpretable. It is also 
unaffected by prior knowledge and completely at random generates trees from the 
predictor variables.  
8.4 Implications for Future Research 
Validation of results and training our models on new cohorts is required to 
understand the reliability of our results. Although we have used very advanced cross-
validation methods on all our machine learning algorithms to ensure accurate model 
performance, this should be repeated on an independent cohort to ensure the results 




a future direction would be to examine model interpretability to assess the key 
variables leading to prediction. 
We have only used three omics in this pilot study. More omic layers may be 
included in future analysis, particularly omics that are starting to show some promise 
towards differentiating sPTB from term outcomes. The vaginal microbiome 
discussed on pages 23 to 25 is a promising area of research and proteomics using 
electrophoresis techniques or mass spectroscopy may complement the 
transcriptomics and metabolomics analysis. Mitochondrial RNA might also be a 
useful analysis in addition to messenger RNA. MiR223, a mitochondrial RNA, has 
been found to be increased in sPTB when compared to term (Hassan et al. 2015, 
Sanders et al. 2015, Gray et al. 2017). However, this would also require significantly 
more funding and may become prohibitively expensive or require too many vials of 
blood to be taken from the participant. Additionally, for each layer of omic analysis 
there is the potential to create more “noise” as hundreds, and sometimes thousands, 
of variables are added  
Assessing other groups such as a low risk pregnant cohort would also be 
useful. Examining omics in women who have not had a history of preterm birth may 
show a greater discrepancy between some of the most significant variables between 
cases and controls.   
Our initial results are suggestive of a link between selenium and sPTB. The 
next logical research step is to evaluate the selenium pathway or markers of selenium 
in our groups. If there is a large difference in selenium concentrations between the 
sPTB group and the term group this result may suggest that there are possible clinical 




8.5 Final Conclusions 
This research aimed to combine different types of ‘omics’ analysis for the 
prediction of sPTB. Following integration of genomic, transcriptomic and 
metabolomic data, six out of seven machine learning algorithms to predict sPTB 
provided excellent prediction, making individualized preterm prediction a realistic 
possibility and a research area that should be pursued. This research provides 
valuable insight into planning future omic studies. 
A key limiting factor in our study was the small overall number of samples 
that were included as cases and controls in the final analysis. This did not allow us to 
investigate the differences between sPTB and PPROM groups and this remains an 
area for future study.  While the sample size limits the generalisability of the results, 
our results did provide new insights into the role of selenium in the prediction of 
sPTB and identified the selenium pathway as an important avenue for future study 
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Appendix F: Standard Operating Procedure for Sample Collection  
 
The development of novel biomarkers for the prediction of preterm labour in a 
high risk population 
  
Standard Operating Procedure for Sample Identification, Collection, Processing 
and Storage. 
 
The purpose of this document is to provide instruction on correct sample 
identification, collection, processing and storage for the precision medicine for 
preterm birth prevention project.  
Sample Identification – High Risk (150) 
Women who are eligible for recruitment must have: 
• Singleton pregnancy 
• History of previous preterm delivery >16 weeks and  <34 weeks / history PPROM 
>16 weeks - <34 weeks 
• Able to provide informed consent 
Sample Identification – Low Risk (250) 
• Singleton pregnancy 
• Previous uncomplicated term birth  
o (Exclude if e.g. gestational diabetes, pre-eclampsia, abruption, IUGR,  fetal 
anomaly, medical condition necessitating iatrogenic preterm delivery) 
Exclude women who have: 
 Uterine anomaly 
 Fetal congenital anomaly 
 History of “care-giver” indicated (iatrogenic) preterm birth 
Visit 1 – 16 weeks (sample A) 
Patient should have samples collected 16+0-16+6 weeks of gestation. (For practical 
purposes samples will be accepted between 15+0-18+0)  
Samples required:  
• Blood 
• Vaginal Swabs 
• Urine (optional) 
• Stool (optional) 
Visit 2 – 20 weeks (sample B) 
Patients should give samples between 20+0-20+6 weeks of gestation (for practical 
purposes samples will be accepted between 19+0-22+0). 
Samples required: 
• Blood  
• Vaginal Swabs  
• Urine (optional) 






1 . Maternal Blood  
Materials needed: 
Transport Container 
Coolbox with ice 
BD Vacutainer® Eclipse™ blood collection needles 
6ml BD vacutainer® tubes containing clot activator for biomarkers (Red tube) 
6ml BD vacutainer® K2EDTA for maternal genome (Lavender small) 
10mL BD vacutainer® K2EDTA for plasma (Lavender large) 












1ml cryotubes (approx. 9) 
 
1. Place a small polystyrene box with crushed ice or cool block into a transport 
container. 
2. Venepuncture will be performed with BD Vacutainer® Eclipse™ blood 
collection needles. 24ml maternal blood will be obtained at 16 (sample A) 
and 20 (sample B) week visits by staff trained in venepuncture at the preterm 
labour clinic. Bottles required for the study are listed above. 
3. Skin should be prepared with an alcowipe prior to blood sampling. Cotton 
wool can be used to apply pressure once the needle is withdrawn post 
sampling, prior to putting a plaster over the puncture site if required. 
4. Immediately after blood has been taken gently invert all tubes 3-5 times to 
mix with any reagent in the vacutainer. 
5. Label all specimens with study number, letter to indicate sample visit (e.g. 
1A), “PTB study”, date and time of sample collection. 
e.g. 1A         PTB study 
       1/1/2015     14:00  
6. 10mL  and 6 mL BD vacutainer® K2EDTA (largeand small lavender top 
tube) should be stored on crushed ice immediately following labelling and 
arrive at lab within 90 minutes of collection, but as soon as possible. 
7. 6ml BD vacutainer® tubes (red top) and 2ml PAXgene RNA tube (clear/red) 




8.  On arrival to laboratory 0618, log the samples in the Sample Reception Log 
(black file) 
9. The proprietary reagent in the PAXgene Blood RNA tubes stabilizes 
intracellular RNA in collected blood specimens for 3 days at room 
temperature (15–25°C).  Therefore from time of arrival to lab they are stored 
at room temperature for 2 hours standing.  
10. Turn the centrifuge on. Set the centrifuge speed to 3000rpm, the time to 
10mins, temperature to 4°C. 
11. Place 6ml BD vacutainer® with clot activator (Red tube) tubes and 10mL BD 
vacutainer® K2EDTA (lavender large) in the bucket inserts in the centrifuge 
ensuring samples are balanced by both volume and position. Using water 
filled blood bottles next to the centrifuge on left hand side if necessary for 
balance. The 6mL BD vacutainer® K2EDTA for maternal genome (Lavender 
small) and 2ml PAXgene RNA tube should NOT be centrifuged. 
12. Place clear lid over rotor buckets in use. Close the lid and press start. 
13. Ensure rotor buckets and centrifuge basin are cleaned with ethanol and dried 
after use. Switch off the centrifuge and leave lid open. Complete user log.  
14. Turn on safety hood.  
15. Spray work surface with 1:100 Trigene spray and wipe with paper towels 
before starting. 
16. Prepare all equipment required.  i) Partly fill one waste container 
(approximately one eighth full) with Virkon 2% solution. ii) polystyrene cold 
block (located to left of hood) iii) Pastettes iv) Sharps bin (already in hood), 
cooled cryotube holder (located top drawer LEC freezer in Prep lab), 1000ml 
Gilson pipette and racked (sterile autoclaved) blue tips. 
17. Carefully transfer centrifuged blood to hood. Remove lid from serum (red 
top) blood tube and aspirate serum layer into 7ml bijou using a pastette. Eject 
any residue from pastette into waste container containing Virkon. Transfer 
1ml aliquot into 1ml cryotubes using Gilson pipette (approx. 2-3 x 1ml 
cryotube per sample), any remaining serum into 500μl aliquots. Any residual 
serum will be stored if a minimum of 250μl.  Fill blood tube with Virkon and 
replace the lid securely prior to disposal in sharps bin. 
18. Remove lid from 10ml BD vacutainer® K2EDTA. Using fresh pastette 
aspirate plasma layer into 7ml labelled bijou. Pipette plasma in 1ml aliquots 
into 1ml cryovials.  
19. Using a fresh pastette, aspirate 2ml sample of packed red blood cells with 




20. Eject any residue from pastette into waste container containing Virkon. Fill 
blood tube with Virkon and replace the lid securely prior to disposal in sharps 
bin. 
21.  Remove cold block containing samples from hood. Ensure all samples 
correctly labelled with unique study number, sample A, sample B or sample 
C, date of collection and substance (plasma, serum, or RBC) with sample 
number (e.g. serum 1, serum 2 etc).  
22. Remove equipment once finished. Clean hood surface with Trigene and 
switch off hood.  Allow waste products to stand for 24hours for disinfection 
prior to disposal.  
23. Store labelled cryotubes in freezer at -80°C and log location of cryotubes 
under “PTL Biomarker study” (study 12) in freezer log.  
24. The PAX gene blood RNA tube will be moved to the -20 freezer for 24hours 
and then moved to the -80 freezer until RNA extraction. 
25. The 6ml vacutainer® K2EDTA is stored in the freezer in the original tube 
labelled with date of collection, unique study number, sample A or B and 
study name. The box is located in freezer 4. Shelf 3. Enter into freezer log 
(study 12). 




















Appendix G: Standard Operating Procedure for Quantifying DNA using 
PicoGreen Reagent Kit 
 
STANDARD OPERATING PROCEDURE 




Description Supplier Catalogue 
Number 
Quant-iT™ PicoGreen® dsDNA Assay 





1xTE buffer (10mM Tris-HCl, 1mM EDTA, pH7.5) – must be nucleic acid free. 
 
 
Preparing the Assay Buffer  
 
Prepare a 1X TE working solution by diluting the concentrated buffer 20-fold with 
sterile, distilled, DNase-free water.  
 
For a complete 96 well plate add 2.5ml of 20X TE to 47.5ml of  DNase-free water. 
 
Preparing the DNA Standard Curve  
 
Dilute the lambda DNA standard (100μg/ml), provided in the Quant-iT™ 50-fold in 
1X TE to make a 2 μg/ml working solution.  
 
To prepare sufficient for the standard curve, pipette 5μl of the 100 μg/ml dsDNA 
standard and 245μl of 1X TE into a sterile eppendorf tube. Briefly mix by pipetting up 
and down.  
 
To create a five-point standard curve from 1 ng/ml to 1 μg/ml, dilute the 2 μg/ml DNA 
stock solution in sterile eppendorf tubes as shown in the table below. Briefly mix the 
standards by pipetting up and down. 
 
 
Volume of 1X TE (μl) 
Volume of 2 μg/ml DNA 
stock (μl) 
 [DNA Standard] 
0 220 2 μg/ml 
228 22 200 ng/ml 
247.8 2.2 20 ng/ml 
999 1 2 ng/ml 
220 0 0 ng/ml 
Unused 1 ng/ml standard and 2 μg/ml DNA stock can be stored with the Quant-iT™ 





Add 100µl of each DNA standard to the wells of a 96-well plate according to the 
following wells: 
 
[DNA Standard] (ng/ml) Wells 
2 μg/ml A1 + A2 
200 ng/ml B1 + B2 
20 ng/ml C1 + C2 
2 ng/ml D1 + D2 




Sample Analysis  
 
For samples measuring under 200 ng/μl by nanodrop, add 1ul to 99 ul 1xTE (1/100 
dilution). 
 
For samples measuring over 200 ng/μl by nanodrop, add 1 to 9 ul 1xTE (1/10 dilution) 
and add 1ul diluted solution to 99 ul 1xTE (total 1/1000 dilution). 
 
Add 1xTE followed by your DNA samples to the wells of a 96-well plate according to 
your plate plan.  
 
 
Preparing the Reagent  
 
On the day of the experiment, allow the Quant-iT™ PicoGreen® reagent to warm to 
room temperature before opening the vial. 
 
In a plastic container, prepare a diluted working solution of the Quant-iT™ 
PicoGreen® reagent by making a 200-fold dilution of the concentrated solution in 1X 
TE.  
 
For a 96-well plate, prepare enough diluted solution to assay 100 samples in a 100 µl 
final volume per well, add 50μl of Quant-iT™ PicoGreen® dsDNA reagent to 9.95ml 
of 1X TE. 
 
Protect the working solution from light by covering with foil or placing in the dark. 
Use this solution within a few hours of its preparation. 
 
In reduced lighting add 100µl of the aqueous working solution of PicoGreen® reagent 
to each sample and DNA standard.  
 
Incubate the plate for 2 to 5 minutes at room temperature, protected from light. 
 
Measure the sample fluorescence using the Beckman Coulter DTX880, Warehouse 











Using the Beckman Coulter DTX880 Multimode Detector 
Turn on the machine using the switch at the back.  Press the “load/eject” button the 
front of the machine and place the assay plate on the tray that emerges ensuring that 
well A1 is in the left-rear position as shown below: 
 
Press the “load/eject” button to send the tray back in. On the desktop of the PC 





Select “Protocols” and highlight “Ana Picogreen assay 96 Well”.  Click on the “Run 






On the “Prepare to Run” screen (below) click “Next” (highlighted below) to 











Click finish (highlighted) and an Excel spreadsheet of your data will be opened.  
Save this file to an appropriate folder. 
 
In the “Cycle 1” tab (highlighted), select and copy the 8x12 grid of numbers 




Open the file “Standard Template for Picogreen Assay.xlsx”.
 
Paste the raw data into the green box in the top left (1).  As instructed, type the 
figures from the trend line equation into the Red and Green boxes (2).  Your 
unknown sample concentrations will appear in “Column U” with the associated Well 







Appendix H: GWAS QC protocol 
 
From UK Biobank Axiom array chip raw data is saved in PLINK file formats. 
Originally these are stored in .ped and .map PLINK files, but they may be 
transferred in binary PLINK file format (.bed, .bim and .fam files).  
GWAS QC protocol 
[Key: yellow highlight = file names; can be changed 
Blue highlight = subfolder the files are saved in (after this full protocol has been 
carried out) 
Green highlight = name of covariate in analysis; can be changed] 
 
Using binary files (ptb.bed, ptb.bim and ptb.fam). Add sex information to original 
fam file (i.e. 2 for females) to all samples in fam file (open up in excel, keep FID, 
IID and replace column E with 2 for all samples, then remove columns C, D and F). 
Save at text file, then use following command to create an updated fam file: 
 
plink --noweb --bfile ptb --update-sex ptb_gender.txt --make-bed --out ptb_gender 
 
Resulting files are saved in subfolder: 1_ptb_gender 
 
1) Remove duplicate 
No duplicate samples present. 
 
2) Gender check 
 
plink --noweb --bfile ptb_gender  --check-sex --out ptb_gender_sex_check    
Generates .sexcheck file. 
 
grep PROBLEM ptb_gender_sex_check.sexcheck > fail_sex_check_ptb.txt  
 
Produce a text file of samples that have failed sex check - first table of patients to exclude, 
include FID and IID (GWAS write-up). 
 
Resulting files are saved in subfolder: 2_ptb_gender_sex_check 
 
3) Missing data 
 
plink --noweb  --bfile ptb_gender --missing  --out ptb_missing  
 
This produces imiss and lmiss files. 
 
Resulting files are saved in subfolder: 3_ptb_missing 
 
4) Remove non-autosomes 
 
Generate a list of nonautosome SNPs by filtering original study bim file for 
chromosomes: 23, 24, 25 and 26. Make a text file of these SNPs/rs IDs 





plink --noweb --bfile ptb_gender  --exclude ptbnonautosomes.txt  --make-bed  --out 
ptb_gender_ex 
 




plink --noweb --bfile ptb_gender_ex  --het --out ptb_gender_het 
 
Use script to produce imiss vs het plot - can adapt to make it for 98% call rate. To use R 
scripts to use command: r_submit (script filename). 
File imiss_script.R contains: 
# IMISS-vs-Het plot for all SNPs, 95% Call rate: 
imiss=read.table("ptb_missing.imiss",h=T) 
imiss$logF_MISS = log10(imiss[,6]) 
het=read.table("ptb_gender_het.het",h=T) 
het$meanHet = (het$N.NM.-het$O.HOM.)/het$N.NM. 
colors  <- densCols(het$meanHet,imiss$logF_MISS) 
png("ptb_imiss-vs-het.png") 
plot(het$meanHet,imiss$logF_MISS,col=colors,xlim=c(0,0.3),ylim=c(-
3,0),pch=20,xlab="Heterozygosity rate",ylab="Proportion of missing 







abline(h=-1.301030, col="RED", lty=2) 
dev.off() 
 
If there are any patient outliers then this has to be recorded in a table for write-up.  
 
Resulting files are saved in subfolder: 5_ptb_gender_het 
 
6) IBD  
 
plink --noweb --bfile ptb_gender_ex --indep-pairwise 50 5 0.2 --out ptb_gender_ex_thin 
This command will produce .prune.in and .prune.out files.  
 
plink --noweb --bfile ptb_gender_ex --extract ptb_gender_ex_thin.prune.in --genome --out 
ptb_gender_ex_thin.genome 
This second command will produce a .genome file.  
 
Use IBD script to produced histogram. Second table of patients to exclude for GWAS write-
up (need to check F_MISS values from imiss file to decide which samples to remove form 
the pairs that are reported. Include PI_HAT and F_MISS values in the table). 
 
File ptb_ibd_plot.r contains: 











To output a file with outliers use: 
awk '$10 >=0.1875 {print}' ptb_gender_ex_thin.genome.genome > ptb_ibd_outliers 
 
Resulting files are saved in subfolder: 6_ptb_gender_ex_thin.prune 
 
7) Merge with HapMap3 
 
Open ptb_gender_ex bim file. Keep all rs IDs, (delete top two rows and other 
columns). Create text file and save as snplist_ptb.txt. Use HapMap3 bed, bim and 
fam files (provided).  
 
plink --noweb --bfile Hapmap3 --extract snplist_ptb.txt --make-bed --out 
Hapmap3_ptb 
 
Open Hapmap3_ptb bim file in Excel and remove all columns but keep the rs IDs. 
Save as text file, snplist_Hapmap3.txt. 
 
plink --noweb --bfile ptb_gender_ex --extract snplist_Hapmap3.txt --make-bed --out 
ptb_Hapmap3 
 
plink --noweb --bfile Hapmap3_ptb --bmerge ptb_Hapmap3.bed ptb_Hapmap3.bim 
ptb_Hapmap3.fam  --make-bed  --out Hapmap3_ptb_merged1 
 
If a missnp file has been created that means the strands needs flipping. Therefore use: 
plink --noweb --bfile Hapmap3_ptb  --flip Hapmap3_ptb_merged1.missnp --make-
bed  --out Hapmap3_ptb_flipped 
 
If this works, then continue with merge (like in the previous step but with updated 
name of bfile and output only). 
 
plink --noweb --bfile Hapmap3_ptb_flipped --bmerge ptb_Hapmap3.bed ptb_Hapmap3.bim 
ptb_Hapmap3.fam  --make-bed  --out Hapmap3_ptb_merged2 
 
If that still does not work, exclude the missnp file from the previous flip attempt. 
 
plink --noweb --bfile Hapmap3_ptb_flipped --exclude 
Hapmap3_ptb_merged2.missnp  --make-bed --out Hapmap3_ptb_flipped_excl 
 
Exclude .missnp from the ptb_Hapmap3 file.  
 
plink --noweb --bfile ptb_Hapmap3 --exclude Hapmap3_ptb_merged2.missnp  --
make-bed --out ptb_Hapmap3_excl 
 
Then use --bmerge to merge the previous output files with 





plink --noweb --bfile Hapmap3_ptb_flipped_excl --bmerge ptb_Hapmap3_excl.bed 
ptb_Hapmap3_excl.bim ptb_Hapmap3_excl.fam  --make-bed  --out 
Hapmap3_ptb_merged_final_excl 
 
Resulting files are saved in subfolder: 7_ptb_merged 
 
8) Ethnicity  
 
plink --noweb --bfile Hapmap3_ptb_merged_final_excl --indep-pairwise 50 5 0.2  --out 
Hapmap3_ptb_merged_thin_excl 
 
plink --noweb --bfile Hapmap3_ptb_merged_final_excl --extract 
Hapmap3_ptb_merged_thin_excl.prune.in  --genome  --out 
Hapmap3_ptb_merged_thin_MDS_excl 
 
plink --noweb --bfile Hapmap3_ptb_merged_final_excl --cluster --mds-plot 10  --out 
Hapmap3_ptb_merged_MDS10_excl  --read-genome 
Hapmap3_ptb_merged_thin_MDS_excl.genome 
 
Process output .mds file: 
• Open up MDS10.mds file in excel to add ethnicities for patient samples. Use file 
Hapmap3_populationID_502_CEU_CHB_JPT_YRI.txt for Hapmap ethnicity information. 
• Sort file by IID column, Z to A. Check this has been done correctly, otherwise the plot 
will not be correct. Add in columns: Population and Data label. 
• Excel file should now contain: FID, IID, Population, Data label, Sol, C1, C2 to C10 
• Population column:  
▪ order the Hapmap ethnicities in the same order (IID column, Z to A) as the 
output file 
▪ copy and paste the ethnicities into the population column from Hapmap  
▪ only the study samples should not have ethnicity inputs (i.e. leave blank) 
• Data label column: show Eunice the plot without data labels, then label only the 
outliers identified 
• Use script to produce a PCA plot or SPSS - check the graph is correct, if not, repeat sort 
column step  
• The outliers identified should be used to produce the third table of patients to exclude 
(GWAS write-up). 
 
SPSS: File > open > data (select file). Chart builder > scatterplot > drag on: y-axis (C1), x-axis 




Use mds file used to plot ethnicity graph. Sort C1 column smallest to largest. Highlight 
values that deviate from the general ethnicity trend e.g. patient 22 drops from -0.044 (C1) 
to -0.02 (C2), this would be an ethnic outlier. Also select outliers that are found between 
ethnicities (when ordered) and have values that deviate. [For ptb study need to select 
everything that is not CEU]. Repeat this step with C2 column using a different colour to 





Plot a graph in Excel, by selecting the C1 and C2 column to see if the outliers are present or 
not in the ethnicity plot.  
   
Samples to Exclude 
 
Open the .het file in Excel and calculate the het score to determine the outliers due to the 
heterozygosity (samples outside the 3SD and 5SD thresholds on the het-imiss graph from 
earlier).  
Het_score = (N(NM)-O(HOM))/N(NM) 
Sort by the het scores column smallest to largest. Plot this as a graph.  
Identify the lowest values (also compare back to imiss vs het plot to see which samples they 
are) 
 
Create a text file of all samples to be excluded based on sex check, ethnicity, heterozygosity 
and IBD: excludesexhetIBDethnicity.txt. Only include FID and IID columns. This will be 
removed in the next step.  
For ptb do not exclude any of the treated or excluded for clinical reasons patients yet. Do 
this after final QC step. 
 
Resulting files are saved in subfolder: 8_ptb_ethnicity 
 
9) Remove samples outliers  
 
Exclude outliers from the original fam file which includes the nonautosomes, but has 
no duplicate samples.  
 
plink --noweb --bfile ptb_gender --make-bed --out ptb_sampleqc --remove 
excludesexhetIBDethnicity.txt 
 
Resulting files are saved in subfolder: 9_ptb_sampleqc 
 
10) SNP QC 
 
For ptb study use 95% threshold. (Using 98% (0.02) removes more SNPs). Set up a 
text file with FID, IID and phenotype (ptb column) for case-controls (1 = control; 2 = 
case (female): -9 = missing/exclusion). Name file as ptb_pheno.txt. 
 
plink --noweb --bfile ptb_sampleqc --pheno ptb_pheno.txt --pheno-name ptb --geno 
0.05 --hwe 0.000001 --maf 0.01 --make-bed --out ptb_finalqc 
 




Use ANOVA for continuous data. Use Chi-square for binary data. Generated values 
will be used for results analysis. 
Select variables to investigate. In Excel, format the data. 
• 3 columns: IID, outcome (binary code, 0 or 1) and third column for variable. 
• Code outcomes as 0 = term (normal outcome) and 1 = PTB (for PPROM and SPON, 




• Leave samples with no outcomes blank for outcomes and variable column (these 
samples will be excluded from phenotypes later). 
• Independent variable (factor/x variable) is outcome. Dependent variable (y 
variable) is the variable under investigation, e.g. BMI. 
• Run ANOVA [open data in SPSS > Analyze > compare means > one way ANOVA]  
• Or run Chi-square [open data > Analyze > Descriptive Statistics > Crosstabs > (rows 
= outcome; column = cervix) > statistics > Chi-square and Phi and Cramer's V > 
continue > cells > Select Observed, Row, Column and Total > ok] 
• For chi-square, report the Pearson Chi-Square value and the Asymp. Sig value in 
the same row (this tells us the significance). 
•  
Preparation for results analysis 
 
Open ptb_finalqc.fam: 
• Delete column 3 to 6  
• Add column headers:  FID, IID, C1, C2, cervix 
• Add in cervix column/phenotype information (-9 for exclusion [for ptb all treated 
and excluded samples] or missing values), write cervix values (for binary variables 
use 0 or 1) for other samples. This file will be used for analysis. 
• Enter C1 and C2 values from previous mds file (should have less samples in fam file 
as samples were excluded from qc) 





Use ptb_pheno.txt produced in step 10)SNP QC 
plink --noweb --bfile ptb_finalqc --logistic --pheno ptb_pheno.txt --pheno-name ptb -
-covar ptb_covar_cervix.txt --covar-name C1,C2,Cervix --out ptb_cervix --hide-
covar 
 
This produces an assoc.logistic file. 
 
Run command without cervix and rename output file. 
 
plink --noweb --bfile ptb_finalqc --logistic --pheno ptb_pheno.txt --pheno-name ptb -
-covar ptb_covar_cervix.txt --covar-name C1,C2 --out ptb_PCA--hide-covar 
 






▪ Plink file format 
▪ Upload .logistic output file 
▪ Select integrated Map info box 
▪ Click ‘ok’ 
▪ A table will appear in a new window. Click ‘plot’. 




▪ Select x-axis as chromosome. Y-axis as P (for p value). Y-axis scale should be –log10. 
▪ Enter suggested threshold (1x10^-5) as 5 
▪ Enter significance threshold (5x10^-8) as 7.3 
▪ Right-click on Manhattan plot and save as png. 
 
Identify any significant SNPs or SNPs with high p values form Manhattan plot. Open 
the ptb_cervix.assoc.logistic file in Excel and order by p value. Filter p-values <= 
5x10^-4 (less than or equal to 0.0005) to view rsID of SNPs of interest. Order by 
chromosome number, this will tell you how many SNPs per chromosome are top 
SNPs. Chromosomes with more than 1 top SNP are of most interesting to investigate 
further.  
 
Regional plots can be produced in order to further investigate specific SNP calls. Go 
back to original table window, select chromosome and specify marker (can type SNP 






• Select plot your data > single data > set for: PLINK data > upload 
ptb_cervix.assoc.logistic file 
• Copy & paste rs ID of SNP of interest into SNP reference name.  
• For genome build ensure the option selected is hg19/1000 Genomes Nov 2014 EUR 
• Legend location: right.   
• Click plot data.  
• A pdf of the graph will automatically be downloaded from the server.  
• Repeat for all relevant SNPs.  
 
Resulting files are saved in subfolder: 11_ptb_analysis_graphs (consists of folders: 
locus_zoom_plots and PTB_study_GWAS_analysis, with graphs produced from 
haploview) 
 
GWAS Pre-Imputation QC 
1) Download latest perl script from Will Rayner to QC your PLINK data against the HRC 
reference panel: http://www.well.ox.ac.uk/~wrayner/tools/#Checking (HRC-1000G-
check-bim.pl) 
 
2) Generate a freq file of final qc binary files using this command: 
plink --noweb --bfile ptb_finalqc --freq --out ptb_feq 
Resulting files are saved in subfolder: 12_ptb_frq 
 
3) Check your genetic variants against the HRC panel using the following command. Latest 
HRC panel is located in the shared bioinf1 directory (use this path name in the reference 
panel part of the following command): /ph-users/shared/Eunice/HRC/HRC.r1-
1.GRCh37.wgs.mac5.sites.tab 
Make sure you have a frequency file generated prior to executing this command: 





gwas_perl_command.sh file contains the following command: 
perl HRC-1000G-check-bim.pl -b ptb_finalqc.bim  -f ptb_feq.frq -r /ph-
users/shared/Eunice/HRC/HRC.r1-1.GRCh37.wgs.mac5.sites.tab -h 
script_submit gwas_perl_command.sh 
The script will produce several .txt files. 
Resulting files are saved in subfolder: 13_ptb_perl 
 
4) Perform SNP QC using the PLINK2 script generated from the perl script run. 
script_submit Run-plink.sh 
This script will produce binary files per chromosome (e.g. ptb_finalqc-updated-
chr1.bed). 
Resulting files are saved in subfolder: 14_ptb_finalqc_updated 
 
5) For each chromosome, convert binary PLINK into VCF format: 
## For chromosomes 1-22, use the "--recode vcf-iid --out" command in PLINK2 
plink2_submit --bfile ptb_finalqc-updated-chr1 --recode vcf-iid --out ptb_chr1 
For chr2-22 use commands: 
plink2_submit --bfile ptb_finalqc-updated-chr2 --recode vcf-iid --out ptb_chr2 
plink2_submit --bfile ptb_finalqc-updated-chr3 --recode vcf-iid --out ptb_chr3 
plink2_submit --bfile ptb_finalqc-updated-chr4 --recode vcf-iid --out ptb_chr4 
plink2_submit --bfile ptb_finalqc-updated-chr5 --recode vcf-iid --out ptb_chr5 
plink2_submit --bfile ptb_finalqc-updated-chr6 --recode vcf-iid --out ptb_chr6 
plink2_submit --bfile ptb_finalqc-updated-chr7 --recode vcf-iid --out ptb_chr7 
plink2_submit --bfile ptb_finalqc-updated-chr8 --recode vcf-iid --out ptb_chr8 
plink2_submit --bfile ptb_finalqc-updated-chr9 --recode vcf-iid --out ptb_chr9 
plink2_submit --bfile ptb_finalqc-updated-chr10 --recode vcf-iid --out ptb_chr10 
plink2_submit --bfile ptb_finalqc-updated-chr11 --recode vcf-iid --out ptb_chr11 
plink2_submit --bfile ptb_finalqc-updated-chr12 --recode vcf-iid --out ptb_chr12 
plink2_submit --bfile ptb_finalqc-updated-chr13 --recode vcf-iid --out ptb_chr13 
plink2_submit --bfile ptb_finalqc-updated-chr14 --recode vcf-iid --out ptb_chr14 
plink2_submit --bfile ptb_finalqc-updated-chr15 --recode vcf-iid --out ptb_chr15 
plink2_submit --bfile ptb_finalqc-updated-chr16 --recode vcf-iid --out ptb_chr16 
plink2_submit --bfile ptb_finalqc-updated-chr17 --recode vcf-iid --out ptb_chr17 
plink2_submit --bfile ptb_finalqc-updated-chr18 --recode vcf-iid --out ptb_chr18 
plink2_submit --bfile ptb_finalqc-updated-chr19 --recode vcf-iid --out ptb_chr19 
plink2_submit --bfile ptb_finalqc-updated-chr20 --recode vcf-iid --out ptb_chr20 
plink2_submit --bfile ptb_finalqc-updated-chr21 --recode vcf-iid --out ptb_chr21 
plink2_submit --bfile ptb_finalqc-updated-chr22 --recode vcf-iid --out ptb_chr22 
 
For chromosome 23, use the "--set-hh-missing --recode vcf-iid --out" command in 
PLINK2 
plink2_submit --bfile ptb_finalqc-updated-chr23 --set-hh-missing --recode vcf-iid --
out ptb_chr23 
 
Important note! HRC does not recognise chr23 for imputation, make sure you 
change chr23 to chrX within your VCF file. 




Resulting files are saved in subfolder: 15_ptb_vcf (this folder contains the .log files 
for the commands run, but due to the next zip commands being run, the .vcf files 
have been converted to vcf.gz and are not in this subfolder as .vcf files).  
 


























Command for ChrX: 
/users/apps/htslib/htslib-1.3.2/bgzip ptb_chrX.vcf 
Files produced with extension .vcf.gz 
Resulting files are saved in subfolder: 16_ptb_vcf_gz 
 
7) Tabix each bgzipped VCF file. Bioinf1 Tabix location: /users/apps/htslib/htslib-
1.3.2/tabixb -p vcf 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr1.vcf.gz 
 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr2.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr3.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr4.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr5.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr6.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr7.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr8.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr9.vcf.gz 




/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr11.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr12.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr13.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr14.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr15.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr16.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr17.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr18.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr19.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr20.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr21.vcf.gz 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chr22.vcf.gz 
 
Command for ChrX: 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf ptb_chrX.vcf.gz 
 
Files produced with extension .vcf.gz.tbi 
Resulting files are saved in subfolder: 17_ptb_vcf_gz_tbi 
 
 
8) Upload your VCF files to the Michigan Imputation Server for imputation: 
https://imputationserver.sph.umich.edu/index.html  
Eunice logged into her account for this upload. Imputed files downloaded by Eunice.  
Select the following options: 
• Select latest HRC reference panel 
• Use Eagle to phase chromosomes 1-22 
• Use ShapeIT to phase chromosome X  
• Specify population 
 
Imputation can take around 2 weeks when server is moderately busy. Files will be 
available to download from the website, but has to be done within 2-3 days. These 
will be zip files per uploaded chromosome. 





GWAS post-imputation protocol 
 
Preparation to unzip files from Imputation server 
1) Download from https://sourceforge.net/projects/p7zip/?source=typ_redirect  
Copy and paste file onto cluster where zipped, results files are. 
Use command to unzip:  
tar xvjf p7zip_16.02_src_all.tar.bz2  
A file called p7zip_16.02 will be created in the cluster.  
Use command:  
cd p7zip_16.02 
Open file for instructions: /ph-users/juhi/PTB_study/p7zip_16.02/README 
 
2) From this weblink use the command: make all3 
http://www.linuxfromscratch.org/blfs/view/svn/general/p7zip.html  
Then use command:  
make DEST_HOME=/usr \ 
           DEST_MAN=/usr/share/man \ 
           DEST_SHARE_DOC=/usr/share/doc/p7zip-16.02 install 
File 7z should now be located in /ph-users/juhi/PTB_study/p7zip_16.02/bin 
 
Password (generated by Imputation server) for chromosomes 1-22: 
SRObVBj8vTl7uW  
Password (generated by Imputation server) for chromosome X: MBe3PfqEccwPb6 
 
3) To extract files use command:  
/ph-users/juhi/PTB_study/p7zip_16.02/bin/7z x -pSRObVBj8vTl7uW chr_1.zip 
This will give 3 resulting files in the directory for that chr. Repeat this command for 
all chr including chr22. 
For Chr X, change working directing to /ph-users/juhi/PTB_study/chrX  
Then use command:  
/ph-users/juhi/PTB_study/p7zip_16.02/bin/7z x -pMBe3PfqEccwPb6 
chr_X.no.auto_female.zip 
Resulting files are saved in subfolder: 19_ptb_imputation_files 
 
Post-imputation QC steps 
1) View .info.gz files without unzipping the files (they are too large to unzip). Use 
command:  
less chr1.info.gz 
Press q to quit. 
To filter SNPs with score less than 0.3, use command:  
gzip -dc chr1.info.gz | awk '$7<0.3 {print$1, $7}' > chr1_rsq_snps_toexclude.txt 
Repeat this for all chromosomes. (Change working directory for chrX before running 
this command). 
gzip -dc chrX.no.auto_female.info.gz | awk '$7<0.3 {print$1, $7}' > 
chrX_rsq_snps_toexclude.txt 





2) Convert vcf to plink files using plink2. Use command:  
plink2_submit --vcf chr1.dose.vcf.gz --out chr1_plink 
Repeat for all chromosomes.  
Change directory for chr X and use:  
plink2_submit --vcf chrX.no.auto_female.dose.vcf.gz --out chrX_plink 
Resulting files are saved in subfolder: 21_ptb_plink 
 
3) Generate frequency files. Use:  
plink --noweb --bfile chr1_plink --freq --out chr1_freq 
Repeat for all chromosomes.  
Change directory for chr X and use:  
plink --noweb --bfile chrX_plink --freq --out chrX_freq [problem reading BIM file 
line 1] No file produced for chrX 
Resulting files are saved in subfolder: 22_ptb_frequency 
 
4) Extract SNPS with maf= 0. Use:  
awk '$5==0 {print$2, $5}' chr1_freq.frq > chr1_maf_toexclude.txt 
Repeat for chr2-22. 
Resulting files are saved in subfolder: 23_ptb_maf_toexclude 
 
5) Combine SNP ID columns from rsq txt file and maf txt file. This is to add one list to 
another list in a new file (duplicates are not removed by this command). Use command:  
awk '{print $1}' chr1_rsq_snps_toexclude.txt <(awk '{print $1}' 
chr1_maf_toexclude.txt)  > chr1_excludesnps.txt 
Repeat for chr2-22. 
Resulting files are saved in subfolder: 24_ptb_excludesnps 
 
6) To exclude snps from original vcf file. Use this command in a script not login node!! The 
file produced will be fairly large, so will take a while to run. Use command:  
script_submit exc_snp_chr1.sh 
Script contains the following command for chr1: 
/ph-users/shared/Eunice/vcftools_0.1.13/bin/vcftools --gzvcf chr1.dose.vcf.gz 
--exclude chr1_excludesnps.txt --recode --stdout 
Use the following command in the login node to compress the stdout file (this is a 
temporary file that will get overwritten by next command) before running the next 
command! 
/users/apps/htslib/htslib-1.3.2/bgzip -c stdout > chr1_qc_bgzip.vcf.gz 
For chr2-22, use the --exclude command above in separate .sh script per 
chromosome. For the bgzip command type directly into login node. 
Resulting files are saved in subfolder: 25_ptb_qc_bgzip 
 
7) Use this command in the login node (separately per chr) for bgzip output: 
/users/apps/htslib/htslib-1.3.2/tabix -p vcf chr1_qc.vcf.gz 





SNP test v2.5 
 
Use clinical variable with most significance as covariate for analysis. (Used 
continuous cervical length for 82 patients, excluding medical intervention.) 
1) To prepare file for SNP test analysis (for this data will be using frequentist association 
test), make an excel sheet with the relevant headings and coding: 
http://www.stats.ox.ac.uk/~marchini/software/gwas/file_format.html  
Save excel file in cluster and convert to space separated file. The file headers should 
look like this: 
ID_1 ID_2 missing c1 c2 cvl ptb 
0 0 0 C C C B 
A01_1B PTB_1B 0 99.9532139 99.952438 32 0 
A01_P06_97B PTB_97B 0 99.9538758 99.9520761 27 1 
 
Convert using:  
expand --tabs =1         .txt  >    .txt 
Then use: 
dos2unix samplefile_snptest.sample 
Resulting files are saved in subfolder: 27_ptb_sample 
 
2) Run command for Frequentist Association Tests (in a separate script for each 
chromosome): 
/usr/local/bin/snptest_v2.5 -data chr1.dose.vcf.gz PTB_samplefile.sample -
genotype_field GT -o chr1_ptb_frequentist_gen_snptest_cervixlength.out -
frequentist 1 -method expected -pheno ptb -cov_names c1 c2 cvl -missing_code NA 
-lower_sample_limit 20 -hwe -log chr1_snptest.log 
Output file e.g. chr1_ptb_frequentist_gen_snptest_cervixlength.out 
Resulting files are saved in subfolder: 28_ptb_freqtest 
 
 
QC steps after SNPtest analysis 
 
1) Delete first few lines of chr files. Then rename this to chr001.txt (must have extra zero). 
For chr 1 file: 
sed '/^#/d' chr1_ptb_frequentist_gen_snptest_cervixlength.out > chr001.txt 
Delete all header lines from chr2 to chr 22 files and rename similarly.  
For chr2 file onwards: 
sed '/^#/d' chr2_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr002.txt 
Repeat for chr3 to 22: 
sed '/^#/d' chr3_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr003.txt 
sed '/^#/d' chr4_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr004.txt 





sed '/^#/d' chr6_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr006.txt 
sed '/^#/d' chr7_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr007.txt 
sed '/^#/d' chr8_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr008.txt 
sed '/^#/d' chr9_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr009.txt 
sed '/^#/d' chr10_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr010.txt 
sed '/^#/d' chr11_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr011.txt 
sed '/^#/d' chr12_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr012.txt 
sed '/^#/d' chr13_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr013.txt 
sed '/^#/d' chr14_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr014.txt 
sed '/^#/d' chr15_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr015.txt 
sed '/^#/d' chr16_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr016.txt 
sed '/^#/d' chr17_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr017.txt 
sed '/^#/d' chr18_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr018.txt 
sed '/^#/d' chr19_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr019.txt 
sed '/^#/d' chr20_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr020.txt 
sed '/^#/d' chr21_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr021.txt 
sed '/^#/d' chr22_ptb_frequentist_gen_snptest_cervixlength.out | sed '/^alternate_ids/d' > 
chr022.txt 
 
To concatenate all chr files use the following command cat chr0*.txt > 
chr1_22_finalsnp.txt submit as script:  
script_submit cat_snps.sh 
Resulting files are saved in subfolder: 29_ptb_concat 
 
2) To extract columns, submit as script: 
script_submit extractcol.sh 
Shell script extractcol.sh contains command: 
awk '{print $3, $2, $4, $45}' chr1_22_finalsnp.txt > chr1_22_snpfile.txt 
 
To rename headers, submit as script: 
script_submit rename_header.sh 




sed -e 's/chromosome/CHR/' chr1_22_snpfile.txt | sed 's/rsid/SNP/' | sed 
's/position/BP/' | sed 's/frequentist_add_pvalue/P/'  > 
chr1_22_snpfile_rename.txt 
 
To remove NA pvalues, submit as script: 
script_submit remove_na.sh 
Shell script remove_na.sh contains command: 
sed '/NA/d' chr1_22_snpfile_rename.txt > chr1_22_snpfile_update.txt 
 
Resulting files are saved in subfolder: 30_ptb_update 
 
3) Use R script to produce Manhattan plot (specify input filename and output filename in 
script): 
r_submit manhattan_qqman_ptb.r 
Script manhattan_qqman_ptb.r contains: 
## This is a R script for generating your manhattan plot! Required 
headers in your results file are CHR SNP BP P.  
## Results file can be space or tab-limited. 
library(qqman) 
results <-read.table("chr1_22_snpfile_update.txt",header=T) ##Specify 
filename containing CHR SNP BP P information. 




To modify Manhattan plot e.g. change colours etc, the following linkas have 





Resulting files are saved in subfolder: 31_ptb_manhattan 
 
Identify SNPs from Manhattan plot 
 
Based on Manhattan plot, select chromosome of interest. Use following command to 
extract all SNPs from the specified chr.  For example, for chr3 use the following 
commend in a script (snps_chr3.sh): 
awk '$1==03 {print $1, $2, $3, $4}' chr1_22_snpfile_update.txt > snps_chr3.txt 
Open up the text file in excel and sort by pvalue (filter by <=5x10^-6 or 0.000005; 
then sort smallest to largest) to identify the tophits per chromosome.  
To get rsID for one SNP: 
awk '($1 == "3") && ($2 == "134815715") { print $1, $2, $3 }' /ph-
users/shared/Eunice/HRC/HRC.r1-1.GRCh37.wgs.mac5.sites.tab > chr3_tophit.txt 
Calculate plus and minus 500kb (500000b) of the snp position and search for the 
rsIDs in this region per hit. Note these upper and lower bp values may not 
correspond to actual chr positions/rsIDs/p-values, they are only being used to give a 
range of positions that exit.  




awk '($1 == "3") && ($2 <= "135315715" && $2 >= "134315715" ) { print $1, $2, 
$3 }' /ph-users/shared/Eunice/HRC/HRC.r1-1.GRCh37.wgs.mac5.sites.tab > 
chr3_tophit.txt 
 
awk '($1 == "20") && ($2 <= "50449572" && $2 >= "49449572" ) { print $1, $2, 
$3 }' /ph-users/shared/Eunice/HRC/HRC.r1-1.GRCh37.wgs.mac5.sites.tab > 
chr20_tophit.txt 
 
To get p values for SNPs within range of interest (for single digit chr number put 0 in 
front, to match snpfile): 
awk '($1 == "03") && ($3 <= "135315715" && $3 >= "134315715" ) { print $2, $3, 
$4 }' chr1_22_snpfile_update.txt > chr3_pval_tophit.txt 
 
awk '($1 == "20") && ($3 <= "50449572" && $3 >= "49449572")  { print $2, $3, 
$4 }' chr1_22_snpfile_update.txt > chr20_pval_tophit.txt 
Resulting files are saved in subfolder: 32_ptb_topsnps 
 
Prep locus zoom file 
In Excel, open up the file containing p values for the region of interest (chr3_pval 
_tophit.txt) then paste in rsIDs column (from chr3 _tophit.txt). Highlight duplicated 
cells of the two columns containing the positions. Sort by colour (make sure you 
highlight the position column and the rsID column, so that the order is not lost). 
Delete the unique values (shift cells up).  
Highlight duplicate values again but with a different colour e.g. green to pick out any 
repeated rsIDs (order as before, then delete highlighted cells). Delete the second 
duplicates (keep the ones that have rsIDs) as appropriate, find where the remaining 
rsID belong in the order (ctr+f) and paste in. Then check order of positions matches 
across the rows. 




Submit rsID of the top hit identified. Use tab as the delimiter (also default). Upload 
locuszoomfile.txt and set marker column as rsID and p-value column as p. Flanking 
region is automatically set at 400kb. Genome build is automatically hg19/1000 
Genomes Nov 2014 EUR (latest).  
 








setwd("Documents/Max Planck 27.07.2018/") 






lp2 <- lp[,c(1:6,29,45,47:48)] 
 
comb <-merge(muglia,lp2,by.x = c("chr","pos"),by.y = c("chromosome","position")) 
comb <- comb[with(comb,order(p)),] 
head(comb) 
 
snp <- comb[1:10,] 




snp$eff <- log(snp$eff) 
snp$A2 <- sub("/.*","",snp$alleles) # effect 
snp$A1 <- sub(".*/","",snp$alleles) # reference 
snp$FLIP <- NA 
snp[which(snp$A1==snp$alleleA & snp$A2==snp$alleleB),]$FLIP <- F 








i <- 1 
for(i in 1:nrow(snp)) 
   
  metaobj <-
metagen(TE=c(snp[i,]$eff,snp[i,]$frequentist_add_beta_1),seTE=c(snp[i,]$se,snp[i,]
$frequentist_add_se_1)) 
  meta <- metaobj 
  meta <- 
data.frame(t(c(meta$TE.fixed,meta$seTE.fixed,meta$pval.fixed,meta$lower.fixed,m
eta$upper.fixed))) 
  colnames(meta) <- 
c("META_BETA","META_SE","META_P","META_CI_l","META_CI_u") 
  meta <- cbind(snp[i,],meta) 




   
res$META_OR <- exp(res$META_BETA) 
res$META_CI_l <- exp(res$META_CI_l) 
res$META_CI_u <- exp(res$META_CI_u) 
 
res$M_OR <- exp(res$eff) 
res$M_CI_l <- res$M_OR-1.96*res$se 
res$M_CI_u <- res$M_OR+1.96*res$se 
 
res$LP_OR <- exp(res$frequentist_add_beta_1) 
res$LP_CI_l <- res$LP_OR-1.96*res$frequentist_add_se_1 







# forest(metaobj)   
for(i in 1:nrow(res)) 
  mmean <- c(NA,res[i,]$M_OR,res[i,]$LP_OR,res[i,]$META_OR) 
  mcl <- c(NA,res[i,]$M_CI_l,res[i,]$LP_CI_l,res[i,]$META_CI_l) 
  mcu <- c(NA,res[i,]$M_CI_u,res[i,]$LP_CI_u,res[i,]$META_CI_u) 
  mtext <- 
data.frame(cbind(c("Muglia","Liverpool","Meta"),c(res[i,]$p,res[i,]$frequentist_add
_pvalue,res[i,]$META_P)),stringsAsFactors=F) 
  mtext$X2 <- format(as.numeric(mtext$X2),sci=T,dig=2) 
  mtext <- rbind(c("Name","p-value"),mtext) 
  msum <- c(T,F,F,T) 
  sn <- paste0(as.character(res[i,]$snp),"_",res[i,]$A2) 









Appendix J: Procedure for Manual RNA extraction 
 
 






1. Centrifuge the PAXgene Blood RNA Tube for 10 minutes at 
3000–5000 x g using a swing-out rotor. 
 
Note: Ensure that the blood sample has been incubated in the 
PAXgene 
Blood RNA Tube for a minimum of 2 hours at room temperature 
(15–25°C), in order to achieve complete lysis of blood cells. 
 
Note: The rotor must contain tube adapters for round-bottom 
tubes. If othertypes of tube adapter are used, the tubes may 
break during centrifugation. 
 
2. Remove the supernatant by decanting or pipetting. Add 4 ml 
RNase-free water to the pellet, and close the tube using a fresh 
secondary BD Hemogard closure (supplied with the kit). 
If the supernatant is decanted, take care not to disturb the 
pellet, and dry the rim of the tube with a clean paper towel. 
 
3. Vortex until the pellet is visibly dissolved, and centrifuge for 
10 minutes at 3000–5000 x g using a swing-out rotor. Remove and 
discard the entire supernatant. 
Small debris remaining in the supernatant after vortexing but 
before 
centrifugation will not affect the procedure. 
 
Note: Incomplete removal of the supernatant will inhibit lysis 
and dilute the lysate, and therefore affect the conditions for 
binding RNA to the PAXgene membrane. 
 
4. Add 350 μl Buffer BR1, and vortex until the pellet is visibly 
dissolved. 
5. Pipet the sample into a 1.5 ml microcentrifuge tube. Add 300 μl 
Buffer 
BR2 and 40 μl proteinase K. Mix by vortexing for 5 seconds, and 
incubate for 10 minutes at 55°C using a shaker–incubator at 
400–1400 rpm. After incubation, set the temperature of the 
shaker– 





Note: Do not mix Buffer BR2 and proteinase K together before 
adding them to the sample. 
 
6. Pipet the lysate directly into a PAXgene Shredder spin column 
(lilac) 
placed in a 2 ml processing tube, and centrifuge for 3 minutes at 
maximum speed (but not to exceed 20,000 x g). 
 
Note: Carefully pipet the lysate into the spin column and 
visually check that the lysate is completely transferred to the 
spin column. 
To prevent damage to columns and tubes, do not exceed 20,000 x 
g. 
Note: Some samples may flow through the PAXgene Shredder spin 
column 
without centrifugation. This is due to low viscosity of some 
samples and should not be taken as an indication of product 
failure. 
 
7. Carefully transfer the entire supernatant of the flow-through 
fraction 
to a fresh 1.5 ml microcentrifuge tube without disturbing the 
pellet in 
the processing tube. 
 
8. Add 350 μl ethanol (96–100%, purity grade p.a.). Mix by 
vortexing, 
and centrifuge briefly (1–2 seconds at 500–1000 x g) to remove 
drops from the inside of the tube lid. 
 
Note: The length of the centrifugation must not exceed 1–2 
seconds, as this may result in pelleting of nucleic acids and 
reduced yields of total RNA. 
 
9. Pipet 700 μl sample into the PAXgene RNA spin column (red) 
placed 
in a 2 ml processing tube, and centrifuge for 1 minutes at 
8000–20,000 x g. Place the spin column in a new 2 ml processing 






10. Pipet the remaining sample into the PAXgene RNA spin 
column, and 
centrifuge for 1 minutes at 8000–20,000 x g. Place the spin 
column 




Note: Carefully pipet the sample into the spin column and 
visually check that the sample is completely transferred to the 
spin column. 
 
11. Pipet 350 μl Buffer BR3 into the PAXgene RNA spin column. 
Centrifuge for 1 minute at 8000–20,000 x g. Place the spin column 
in 
a new 2 ml processing tube, and discard the old processing tube 
containing flow-through. 
 
12. Add 10 μl DNase I stock solution to 70 μl Buffer RDD in a 1.5 ml 
microcentrifuge tube. Mix by gently flicking the tube, and 
centrifuge 
briefly to collect residual liquid from the sides of the tube. 
 
If processing, for example, 10 samples, add 100 μl DNase I 
stock solution to 700 μl Buffer RDD. Use the 1.5 ml 
microcentrifuge tubes supplied with the kit. 
 
Note: DNase I is especially sensitive to physical 
denaturation. Mixing should only be carried out by gently 
flicking the tube. Do not vortex. 
 
13. Pipet the DNase I incubation mix (80 μl) directly onto the 
PAXgene 
RNA spin column membrane, and place on the benchtop (20–
30°C) 
for 15 minutes. 
 
Note: Ensure that the DNase I incubation mix is placed 
directly onto the membrane. DNase digestion will be incomplete 
if part of the mix is applied to and remains on the walls or 





14. Pipet 350 μl Buffer BR3 into the PAXgene RNA spin column, 
and 
centrifuge for 1 minute at 8000–20,000 x g. Place the spin column 
in 
a new 2 ml processing tube, and discard the old processing tube 
containing flow- through. 
 
15. Pipet 500 μl Buffer BR4 into the PAXgene RNA spin column, 
and 
centrifuge for 1 minute at 8000–20,000 x g. Place the spin column 
in 
a new 2 ml processing tube, and discard the old processing tube 
containing flow-through. 
 
16. Add another 500 μl Buffer BR4 to the PAXgene RNA spin 
column. 
Centrifuge for 3 minutes at 8000–20,000 x g. 
 
17. Discard the processing tube containing the flow-through, and 
place 
the PAXgene RNA spin column in a new 2 ml processing tube. 
Centrifuge for 1 minute at 8000–20,000 x g. 
 
18. Discard the processing tube containing the flow-through. 
Place the 
PAXgene RNA spin column in a 1.5 ml microcentrifuge tube, and 
pipet 40 μl Buffer BR5 directly onto the PAXgene RNA spin column 




It is important to wet the entire membrane with Buffer BR5 in 
order to achieve maximum elution efficiency. 
 
19. Repeat the elution step (step 18) as described, using 40 μl 
Buffer BR5 and the same microcentrifuge tube. 
 
Incubate the eluate for 5 minutes at 65°C in the shaker–incubator 







This incubation at 65°C denatures the RNA for downstream 
applications. 
Do not exceed the incubation time or temperature. 
 







Appendix K: Samples included in transcriptomic analysis with QC results.  
RNA quality and quantity extracted per samples with corresponding classification 
group. Samples used in analysis highlighted in green. No sample highlighted in red. 
Sample Quantity 
(ng) 




260/280 RIN  Phenotype Include/ 
Exclude 
N/S N/S N/S N/S P71B 2045 2.11 8.80 Term Rx EXCLU
DE 
N/S N/S N/S N/S P72B 7404 2.16 7.80 Term Rx EXCLU
DE 
P73A 6690 2.12 9 N/S N/S N/S N/S PPROM EXCLU
DE 




P75A 8909 2.12 8.40 P75B 7215 2.09 8.90 sPTB INCLUD
E 








P78A 4803 2.15 8.70 P78B 1771 2.10 8 PPROM INCLUD
E 




P80A 4073 2.18 7.90 P80B 3532 2.15 8.50 Iatrogenic PTB EXCLU
DE 
P81A 2272 2.17 8.10 N/S N/S N/S N/S PPROM + chorio EXCLU
DE 
P82A 2408 2.16 8.30 P82B 2145 2.16 8.70 PPROM INCLUD
E 
P83A 3382 2.24 8.20 P83B 4095 2.07 8.10 sPTB INCLUD
E 
P84A 825 2.14 8.40 P84B 7629 2.13 8.20 LATE sPTB INCLUD
E 
P85A 6527 2.16 8.50 P85B 5700 2.11 8.70 sPTB INCLUD
E 








P88A 6939 2.13 7.90 P88B 3101 2.09 8.10 sPTB INCLUD
E 




P90A 5130 2.15 8.50 P90B 6128 2.1 9.10 LATE sPTB INCLUD
E 




P92A 7125 2.16 8.70 P92B 3068 2.07 8.10 LATE sPTB INCLUD
E 
P93A 600 2.34 9 N/S N/S N/S N/S Term Rx EXCLU
DE 
P94A 2625 2.08 8.50 P94B 0.0 0.87 N/A Term Rx EXCLU
DE 








N/S N/S N/S N/S P97B 2310 2.17 8.70 LATE sPTB EXCLU
DE 



































P106A 0.0 0.53 N/A P106B 38 2.55 8.90 Term Rx EXCLU
DE 
N/S N/S NS N/S P107B 0.2 1.36 N/A Term Rx EXCLU
DE 
P108A 0.0 N/A N/A P108B 0.1 2.37 N/A LATE sPTB EXCLU
DE 




P110A 0.1 1.32 N/A P110B 0.4 1.32 N/A LATE sPTB EXCLU
DE 












P114A 0.2 1.61 N/A P114B 1175 2.33 8.40 LATE sPTB EXCLU
DE 




















P120A 1050 1.86 8 P120B 3278 1.99 8.50 LATE sPTB INCLUD
E 
P121A 1769 1.93 8.20 P121B 2953 2 8.60 LATE sPTB INCLUD
E 




P123A 389 1.81 7.50 N/S N/S N/S N/S sPTB EXCLU
DE 




P125A 460 1.74 7.90 P125B 2355 2.01 8 Term Rx EXCLU
DE 
P126A 1548 2.04 8 P126B 1723 1.99 8.20 PPROM - poly EXCLU
DE 
P127A 1552 2.08 7.70 P127B 5169 2.1 8.10 Term Rx EXCLU
DE 











Appendix L: R script used for random forest analysis 
 
ranger(dependent.variable.name = "phenotype", data = trans_merged[,-














































Appendix N: Variable Importance by Test 
Random Forest: 
TPM1_week16         100.000 
CDH1_week16         71.121 
unknown_5_16weeks        64.849 
BAG1_week16         61.099 
SPX_week16         60.438 
BCL2L1_week16         59.805 
YBX3_week16 5        2.718 
unknown_37_16weeks        51.713 
TSTA3_week16         45.386 
glucose_44_16weeks        43.232 
unknown_52_16weeks        42.900 
unknown_54_16weeks        42.900 
ST13_week16         41.704 
threonineunknown_55_16weeks       39.075 
unknown_53_16weeks        38.521 
GABARAPL2_week16        36.739 
ANLN_week16         36.619 
GYPA_week16         34.987 
glucose_36_16weeks        34.483 
SIAH2_week16         33.238 




phenylalanine_6_16weeks       32.423 
SLC38A5_week16        32.133 
unknown_98_16weeks        31.926 
PLVAP_week16         29.616 
glucose_39_16weeks        29.186 
CTDSPL_week16         28.575 
glucose_40_16weeks        28.308 
proline_108_16weeks        27.702 
XK_week16         27.088 
unknown_125_16weeks        26.771 
glucose_45_16weeks        26.639 
CA1_week16         24.966 
glucoseunknown_50_16weeks       24.821 
GSPT1_week16         24.095 
glucose_35_16weeks        23.725 
X2_hydroxyvalerate_28_16weeks      23.557 
BCL2L13_week16        23.475 
FAM46C_week16         22.879 
SGIP1_week16         22.557 
EPB42_week16         20.791 
GYPB_week16         20.571 
glucose_60_16weeks        20.349 
MOXD2P_diff         20.208 




glucose_43_16weeks        20.056 
glucose_59_16weeks        19.378 
USP17L12_week16        18.304 
unknown_129_20weeks        18.291 
glucose_38_16weeks        18.288 
HIST1H3H_week16        17.921 
unknown_41_16weeks        17.736 
MIR4255_diff         17.124 
glucose_49_16weeks        16.854 
CD79A_week16         16.824 
ProGlu_115_20weeks        16.794 
RSU1_week16         16.707 
TNFRSF17_week16        16.701 
myoinositol_56_16weeks        15.610 
APEX1_week16         15.244 
phenylalanine_8_16weeks       15.098 
glycylproline_114_20weeks       14.965 
glucose_58_16weeks        14.524 
unknown_51_16weeks        13.995 
Isoleucine_138_20weeks        13.967 
glucose_47_16weeks        13.873 
mobile_lipids_18_16weeks       12.600 
glucose_19_16weeks        12.482 




glucose_66_16weeks        12.149 
TUBB1_week16         12.135 
lipidunknown_32_16weeks       12.079 
glucaratemyoinositol_30_16weeks      11.987 
glucose_64_16weeks        11.915 
CHRNE_week16         11.626 
glucose_61_16weeks        11.499 
ABALON_week16        11.462 
unknown_10_16weeks        11.352 
CDH1_diff          11.204 
KEL_diff          11.040 
man_20_20weeks         10.902 
DYRK3_week16         10.792 
SNORD41_week16        10.720 
DDB1_week16         10.716 
OR2W3_week16         10.632 
SPTB_diff          10.614 
acetoacetate_111_16weeks       10.507 
citrate_103_16weeks        10.473 
SELENBP1_week16        10.421 
ANXA2_week16         10.345 
glucaratemyoinositol_30_20weeks      10.332 
man_20_16weeks         10.085 





all variables have equal importance 
 
SVM Gaussian kernel: 
all variables have equal importance 
 
Kmeans 
mobile_lipids_131_20weeks       100.000 
mobile_lipids_131_16weeks       78.502 
Lactate_130_20weeks        39.099 
Lactate_130_16weeks        37.416 
mobile_lipids_132_20weeks       23.241 
mobile_lipids2_hydroxyisovalerate_145_20weeks    19.616 
argininePhosophocholine_82_20weeks      18.935 
mobile_lipids_132_16weeks       18.414 
mobile_lipids2_hydroxyisovalerate_145_16weeks    16.054 
argininePhosophocholine_82_16weeks      13.234 
 
LDA 
All variables have equal importance 
 
Genetic Expression Programming: 
SPTB_diff        100.000 






desaminotyrosine_12_16weeks     100.000 
 
